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Abstract
The SIP3 receptor is a member of the cell surface G-protein-coupled receptor superfamily 
(GPCR). SIP-mediated activation of the SIP3 receptor elicits an array of biological effects 
including angiogenesis, the process of new blood vessel formation, and may have an important 
role in atherosclerosis. After sustained exposure to agonist, many GPCRs undergo 
desensitisation, defined as the waning of receptor responsiveness in the face of persistent 
stimulation. The relative ability or inability of a GPCR to undergo classic agonist-mediated 
receptor phosphorylation and subsequent internalisation away from the cell surface is an 
important marker of GPCR desensitisation. This study has characterised, for the first time, the 
phosphorylation and internalisation of the human SIP3 receptor.
Whole cell phosphorylation studies on hamster lung CCL-39 fibroblasts stably expressing 
human SIP3 receptors showed that SIP3 is phosphorylated in response to SIP in a time and 
concentration-dependent manner. In contrast activation of multiple 2"'* messenger-activated 
kinases was without effect on SIP3 phosphorylation under the same conditions. It is well known 
that the C-terminal region of GPCRs often holds the primary site of interaction for receptor 
phosphorylation and interaction with p-arrestin. Engineering constructs that truncate the 
receptor by removing significant and potential sites of phosphorylation allowed the identification 
of a region bounded by residues Leu^^  ^ to Val^^  ^ as containing the sites of receptor 
phosphorylation. As GPCRs aie known to be phosphorylated by GRKs a panel of GRKs were 
investigated, of these GRK2 appeared to phosphorylate the SIP3 receptor in viUo suggesting that 
GRK2 or a similar kinase is present during SIP3 phosphorylation.
SIP3 receptor internalisation is not detectable in CCL-39 cells as determined by 
biotinylation assays. Also, sucrose density gradient experiments cound not detect a wholesale 
shift of receptor between lipid raft and non-lipid raft compartments after SIP exposure. 
Although, studies of SIP3 interaction with P-arrestin are currently preliminary, initial findings 
from this reseaixh suggest that both receptor and arrestin co-locaiise after agonist stimulation. 
This hints at the possibility that internalisation may be obstructed by something other than 
interaction with arrestin and provokes a receptor-complex paradigm that involves both receptor, 
arrestin and another protein which is cell-type specific in order to allow internalisation. 
Experiments in HEK293 cells demonstrated that in this system, WT and phosphorylation 
resistant SIP3 receptors cound both internalise over identical time courses following agonist 
exposure. This suggests that SIP3 sensitivity to internalisation is regulated specifically 
depending on celltype and does not require receptor phosphorylation. This has implications in
IT
embryogenesis and also angiogenesis where cell giowth and proliferation are vital to 
development of organs and vessels.
The impact of unique regulatoiy elements on functional desensitisation SIP3 was 
determined by measuring Ca^  ^ mobilisation, a classical G-protein-mediated response. The 
kinetics of WT and phosphorylation-resistant SIP3 receptor desensitisation were 
indistinguishable. This indicates that phosphorylation is not important in observing 
desensitisation of SlPs-G-protein coupling. Rather, given the lack of any effect of disrupting 
phosphorylation on receptor internalisation and desensitisation, this study poses the suggestion 
that phosphorylation of the C terminal domain regulates another aspect of SIP3 function.
An interaction of an as yet unknown protein and the SH3 interaction motif within the C- 
terminal tail of the SIP3 receptor may occur. While yeast two hybrid results remain elusive, 
GST-fusion studies which were implemented to ascertain the functionality of the RXXPXXP 
motif revealed that Fyn kinase can interact with the SH3 domain binding motif of SIP3 . It is 
likely that a kinase similar to, or indeed Fyn, prevents internalisation in some cells by its absence 
which allows finely tuned regulation of the SIP3 receptor to confer downstream signalling of 
multiple pathways.
Together, the data suggest that the SIP3 receptor is uniquely regulated by agonist- 
stimulated phosphorylation within an 18 amino acid stretch within its C-terminal domain. Given 
that deletion of phosphorylation fails to alter sensitivity to internalisation or rapid desensitisation 
kinetics, this domain may play an alternative novel role in SIP3 function. This is supported by 
the presence of a consensus class I SH3 domain interaction motif and the ability of the C- 
terminal domain to specifically bind the SH3 domain from Fyn, but not those from Src, fodrin or 
PI-3-kinase. In addition, because the interaction was not modulated by prior phosphorylation of 
the receptor, it is suggested that specific SH3 domain-containing proteins may be constitutively 
associated with the receptor in certain cell types. The potential for such an interaction to block 
the ability of agonist-bound receptor to engage with clathrin-coated pits might explain the 
resistance of SIP3 to undergo internalisation in some cell types, exemplified by CCL39 cells, but 
not in others, e.g. HEK293 cells. The development of SIP-responsive chimeric SIP 1-SIP3 
receptors in which the phospho-acceptor regions have been swapped can now provide one 
approach with which to test the potential functional importance of RXXPXXP-SH3 domain 
interaction within the context of a full-length GPCR in intact cells.
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CHAPTER 1 
Introduction
1.1 Signal Transduction in Cells
For maintenance and development, all cells must communicate with each other to pass 
vital information through the organism to which they belong [Marchese et a l,  2003]. In all cells 
the majority of signal transduction is initiated at the plasma membrane, which defines the cell’s 
surface [Singer and Nicolson, 1972]. The cell surface has been likened to a communications 
network [Marinissen and Gutkind, 2001].
The regulation of the sphingosine 1-phosphate 3 receptor (SIP3] [Rutherford et a l,  2005] 
has been studied to identify aspects of SIP3 signalling that may determine which biological 
responses are stimulated downstream of SIP3 receptor-ligand interaction. This thesis will begin 
with a synopsis of the general characteristics of G-protein-coupled receptors (GPCRs), 
mechanisms of action, to put the SIP3 receptor in context with similar receptors as well as recent 
discoveries in SIP3 receptor research.
1.1.1 G-Protein-Coupled Receptors
Transmembrane signal transduction in response to drugs, hormones and neurotransmitters 
is largely mediated by G protein-coupled receptors [Lefkowitz, 2004]. Estimates of the number 
of GPCRs in the human genome vary widely. A recent estimate using the Interpro protein 
family database [http://www.ebi.ac.uk/interpro/index.html] yielded 1405 results for a search on 
human GPCRs. One author suggests there are around 800 human GPCRs [Fredriksson et a l,
2003]. This represents the largest known family of integral membrane proteins and is responsible 
for the transduction of a diverse array of extracellular signals, including light, Ca^ ,^ odorants, 
amino acids, nucleotides, peptides, fatty acid derivatives and various polypeptide ligands [Gether 
and Kobilka, 1998; Gether, 2000; Howard et a l,  2001]. Contemporary pharmacological 
research manipulates GPCRs as they are abundant in variety in normal and patho-physiological 
processes. Over 50% of GPCRs are being researched by pharmaceutical companies as potential 
drug targets [Stadel et a l,  1997; Howard et a l,  2001], with 52% of all medicines available today 
acting on GPCRs [Oliveira et a l,  2004].
1.1.2 Structurai Features of GPCRs
Several common structural elements are shared by GPCRs. The most common elements 
are the seven distinct regions of hydrophobic residues, which traverse the cellular membrane. 
These transmembrane (TM) regions, each comprise approximately 20-27 amino-acids. By 
extrapolation from the structure of rhodopsin, TM regions are predicted to form a-helical 
domains of unequal length and can extend beyond the lipid bilayer [Unger et al, 1997], (Figure 
1. 1).
GPCRs have an amino (N)-terminal region located exterior to the cell and an intracellular 
carboxyl (C)-terminal tail These are connected by tliree extracellular and three intracellular 
loops comprised largely of hydrophilic residues [Ulloa-Aguirre et ah, 1999; Gether, 2000; 
Howard et a l,  2001]. The sequences of the loops and tails of different GPCRs tend to be far 
more divergent than TM domains.
The size of the N-terminal region also varies and can contain between ten and five hundred 
residues, whilst the loop sections can consist of as few as five amino acids to gieater than two 
hundred residues and the C-terminal tail between twelve and four hundred residues. This 
suggests that a gieat amount of ligand binding specificity is dependent on the precise 
conformation of a receptor in terms of its amino acid charges and location.
1.1.3 GPCR Classification
Over 800 GPCR-encoding sequences have been identified in the human genome 
[Fredriksson et a l,  2003]. GPCRs can be categorised bs chemosensory, “csGPCRs”, i.e. those 
that respond to exogenous stimuli such as pheromones and odours, and “endoGPCRs”, which are 
activated by endogenous molecules. There are as many as 367 endoGPCRs in the human genome 
and most of these have identified ligands [Vassilatis and Hohmann, 2003].
The term orphan receptor, “oGPCR”, is given to a GPCR with an as yet unidentified 
ligand. As oGPCRs represent potential novel targets for therapy there is great interest in de- 
orphanisation [Stadel et a l,  1997; Brezillon et a l,  2003] Roth et a l,  2003]. Tliis is because as 
many as 50% of marketed drugs target GPCRs yet only 10% of GPCRs are known drug targets 
[Roth et al, 2003] and more than 75% of identified GPCRs are oGPCRs [Karnik et a l,  2003].
Observations taken from phylogenetic analyses, classify each GPCR as a member of one 
of four main classes:
Class A comprises the rhodopsin-like receptors and contains the most endoGPCRs (284), 
which are activated by peptides (e.g. bradykinin, chemokines, orexin) and small molecules 
including lipids (e.g. SIP, LPA and cannabinoid receptors) and neurotransmitters (e.g. 
acetylcholine, dopamine and serotonin receptors), with the remaining receptors of the family 
being orphans. The sub-families of family A rhodopsin-like receptors are the largest and the 
most studied.
Class B consists of fifty secretin/glycagon like receptors, of these, sixteen are activated by 
peptides and thirty-four are orphan receptors.
Class C GPCRs are similar to metabotropic glutamate receptors and number seventeen in 
total, of which six are orphans.
Class F/S GPCRs are the smallest family with eleven members and no orphans.
There is also a NO family group which includes five genes that cannot be assigned to any 
of the above four class [Vassilatis and Hohmann, 2003].
Recently, to distinguish human GPCRs the initial class system has been revised by the 
GRAFS classification [Fredriksson et a l,  2003]. Unlike the class A-E classification it does not 
include receptors fiom several species, only the human genome. The GRAFS classification is 
divided as below:
Family G for Glutamate-like receptors with 15 members which can be likened to class C.
Family R (represents class A) for Rhodopsin-like receptors, which is further divided into 4 
main groups, a-5 , with 13 branches.
1) The g-groun consists of 5 main branches; prostanoid (15 members), amine (39 
members), opsin (9 members), melatonin (3 members) and melanocortin-endoglin-cannabinoid- 
adenosin receptors (22 members).
2) The (3-group has no main branches but includes 36 receptors that bind peptides
e.g., neuropeptide Y.
3) The y-gi'oup has 3 branches; somatostatin-opiod-galanin receptors (15 members),
melanin-concentrating hormone receptors (2 members) and chemokine receptors (42 members).
4) The b-uroup consists of 4 branches; the MAS-related receptors (8 members), the
glycoprotein-receptors (8 members), the purine receptors (42 members) and the olfactory 
receptors (460 members).
Family A for Adhesion-like receptors (24 members) with either three or four branches.
Family F for Frizzle-like receptors (24 members).
Family S consisting of Secretin-like receptors (15 members) with 4 subgroups that each 
bind large peptides [Kamik et a l,  2003].
1.1.4 Structure of GPCRs
For this thesis, details of the GPCR subfamily of SIP receptors will be discussed. SIP 
receptors are members of GPCR class A which contains a number of conserved motifs, although 
overall homology between family members is quite low. There are several proline residues 
present in TM domains IV, V, VI and VII, and these provide the a-helices with kinks, to act as a 
pivot that is important to allow each receptor to bind efficiently to its ligand. TMs I, IV and VII 
contain only one hydrophobic residue and are therefore more hydrophilic than TMs II, III, V and 
VI, which contain several ionic and/or neutral residues. Hydrogen bonds and salt bridges 
between residues of the same TM and other TMs are vital for maintaining a tightly packed TM 
core [Pebay-Peyroula et a l , 1997].
Located at the intracellular end of TMIII is the conserved D/ERY motif which appears to 
be important in receptor activation [Ulloa-Aguirre et a l,  1999; Howard et a l,  2001]. The sole 
residue which is always conserved amongst Class A members is the arginine in this motifs 
amino acid sequence.
Many class A receptors possess two cysteine residues, one present within the second 
extracellular loop, the other located at the top of TMIII. A disulphide bridge exists between 
these two residues and serves to subdivide this extracellular loop into two smaller loops and may 
play a role in constraining the TM bundle.
Class A receptors have extracellular amino-terminal tails of varying sizes, which often 
contain N-linked glycosylation motifs (N-X-T/S). Presently, this post-translational modification 
has an unestablished role, but it may be involved in the trafficking of many GPCRs to the cell 
surface and be implicated in the stabilisation of protein conformation, protection of proteins from 
proteases and modulation of protein function [George et a l,  1986; Davidson et a l,  1995; 
Davidson et a l,  1996; Ulloa-Aguirre et a l,  1999].
The intracellular C-terminal tail is also highly variable in length (12-359 amino acids), and 
typically it is rich in serine and threonine residues, the sites of phosphorylation by intracellular 
kinases. The C-terminal tail also contains one or more cysteine residues, these are 
palmitoylation sites which allow tethering of the tail to the cytoplasmic face of the plasma 
membrane to create a fourth intracellular loop [Wess, 1998; Ulloa-AguiiTe et a l, 1999; 
Ferguson, 2001], more details will be given about this later in the chapter.
The ligand binding site of Class A GPCRs is dependent on the type of ligand. If the ligand 
is small like a biogenic amine, purine, eicasanoid or lipid it is believed to bind within the TM 
crevice; whilst larger peptide and protein ligands appear to interact with residues of the 
extracellular loop and tail regions of the receptor.
1.1.5 Ligand Binding and Receptor Activation
Receptor signalling and ligand binding are distinctly dissociable functions involving 
specific interactions of precise domains of the GPCR with the ligand. Regions of the receptor 
responsible for binding and activation are dependent on the GPCR sub-family as well as 
structure and ligand size.
Many theories have been created to isolate specific receptor characteristics, these include 
the ternary complex model, the extended ternary complex model and the cubic ternary complex 
model [Kenakin, 2004]. Affinity and efficacy are properties possessed by GPCR ligands. 
Affinity describes the ligands ability to bind to a receptor, whereas efficacy depicts the extent of 
change in receptor activation induced by the ligand. Radioligand binding is a technique that cm
be used to determine the affinity of a ligand for its receptor. This allows a calculation of the 
apparent dissociation constant (Kd) of that ligand for that receptor. Positive efficacy occurs when 
the ligand induces a functional response after binding, this is the behaviour of an agonist. 
Relative efficacy gives a description of the maximal response induced by that agonist expressed 
as a percentage of that achieved by a full agonist (in this case SIP for SIP3R). An agonist that 
exhibits a relative efficacy of less than 100% is termed a partial agonist.
Functional assays and receptor internalisation provide a way to measure the consequences 
of a ligand binding to a receptor and can be used to determine the potency of a ligand. Agonist 
potency is given as the EC50 value, a value of the agonist concentration required to elicit 50% of 
the maximal response specific for each system.
There are ligands that can prevent activation of receptors by agonists, by binding to these 
receptors and not initiating a stimulus. These ligands have zero efficacy and are termed 
antagonists. Contemporaiy research has reclassified many antagonists as inverse agonists, which 
reflects a receptors ability to display activity in the absence of agonist stimulation (usually 
referred to as constitutive activity). An inverse agonist possesses negative efficacy and is able to 
reduce receptor constitutive activity [Milligan, 1995; De Ligt et a l,  2000; Jensen and Spalding, 
2004].
Original dogma identified GPCRs as generally existing in equilibrium between an inactive 
(R) and active (R*) conformation, possibly the most accepted model for describing agonist 
activation of GPCRs is the Ternary Complex Model, which accounts for the cooperative 
interactions among receptor, G-protein and agonist. This model has been reviewed and revised 
several times in the last decade and is currently referred to as the Extended Ternary Complex 
Model, (Figure 1.2).
GPCRs are allosteric proteins that adopt inactive (R) and active (R ) conformations in 
equilibrium. Preferred agonist ligand binding to the R* state promotes an isomérisation step that 
stabilises the receptor in a relaxed state and shifts the equilibrium toward the active R* 
conformation, leading to the activation of intracellular heterotrimeric G proteins. The receptors 
can then mediate a variety of intracellular responses to regulate cellular fimction. There is a 
degree of vaiiability amongst GPCRs concerning the equilibrium between R and R* 
conformations. In the basal state of most GPCRs, the majority of receptors are in the inactive (R) 
state [Milligan and Bond, 1997] R* is promoted by agonists or occurs spontaneously, leading to 
constitutive activity of the receptor. Conversely, inverse agonists promote R and decrease 
constitutive activity.
True antagonists ligands with no preference for the R and R* receptor conformation are 
difficult to differentiate from inverse agonists, where only a small proportion of R* GPCRs can 
be preferentially convened to an R state by an inverse agonist. On the other hand, a substantial 
fraction of R* state receptors are found with other GPCRs, such as the histamine H2 
receptor(cimetidine, ranitidine) and antagonists (burinaide) [Smit et a l,  1996].
A select group of GPCRs, including the Kaposi’s sarcoma-associated herpes virus and the 
cnidarian Renilla koellikeri, aminergic-like receptor Renl exhibit full constitutive activity and 
may not require or possess an endogenous ligand [Arvanitakis et a l,  1997; Rosenkilde et al, 
2001; Bouchard et al, 2003]. After the discovery of constitutive activity, the existence of 
another pharmacological entity, referred to as "protean*' agonists (after Proteus, the Greek god 
who could change shape), was assumed on theoretical grounds [Kenakin, 2004]. The rationale 
was that the reversal from agonism to inverse agonism (i.e., protean agonism] would occur when 
an agonist produces an active conformation of lower efficacy than the constitutively active 
conformation. It was predicted from the existence of constitutive activity that the same ligand of 
this class could act either as an agonist or an inverse agonist at the same GPCR, depending on the 
level of constitutive activity.
1.2 Heterotrimeric G-Proteins
G-proteins are composed of three subunits, termed a, p, and y [Downes and Gautam, 
1999; Willard and Crouch, 2000], (Figure 1.3). Characteristically, GPCRs bind G-proteins that 
act as mediators of receptor stimulated effector activation.
After a receptor is activated, bound GDP, situated in the guanine nucleotide-binding site of 
the GTPase domain of the G« subunit is released and exchanged for GTP, as a result of higher 
intracellular GTP concentrations. GTP binding facilitates the dissociation of the a-subunit from 
the py dimer, which then allows both the G« subunit qnd the Gpy dimer to activate effectors 
[Hamm, 1998; Downes and Gautam, 1999]. G-protein deactivation is rate-limiting for cell 
response termination and occurs when intrinsic GTPase activity of G« subunit hydrolyses the 
GTP to GDP and then the G« subunit reassociates with the Gpy dimer [Hamm, 1998; Downes and 
Gautam, 1999].
1.2.1 G« subunit
The a-subunit contains two domains; a domain involved in binding and hydrolysing GTP 
that is structurally identical to the large superfamily of GTPases, and a unique helical domain 
that buries the GTP into the core of the protein [Hamm, 1998]. The family of G-proteins have 
been subdivided into four categories based upon the a-subunit composition (Figure 1.4); God,
which was originally shown to result in adenylate cyclase inhibition; G«s, which stimulates 
adenylate cyclase; G„q, which activates phospholipase C (PLC) and Gai2/i3 implicated in the 
activation of small G-proteins, such as Rac and Rlio, 2001 [Downes and Gautam, 1999; Ulloa- 
Aguirre et a t, 1999; Offermanns, 2001; Radhika and Dhanasekaran, 2001].
1.2.2 Gny subunit
The p-subunit (35-36kDa) consists of an N-terminal helix followed by a seven membered 
P-propeller structure based on its seven WD-40 repeats. The y-subunit (6-lOkDa) interacts with 
the p-subunit through the N-terminal coiled coil and then all along the base of the p-subunit, 
forming a functional unit under physiological conditions that is not dissociable except upon 
dénaturation [Hamm, 1998]. Currently, there are 6 p-subunits and 12 y-subunits which are gene 
encoded.
The py subunits also play a significant role in signal transduction by regulating the activity 
of several effectors such as the adenylyl cyclase types I, II and IV, isoforms 1-3 of phospholipase 
Cp (PLCp) [Camps et a l,  1992], as well as the activity of the muscarinic-gated iC channels 
[Hamm, 1998; Ulloa-Aguirre e ta l,  1999; Radhika and Dhanasekaran, 2001].
1.2.3 Structural Features of G-proteins
The simplicity of the GTP hydrolysis cycle provides a switch mechanism that controls 
numerous cellular functions through many classes of GTPases, for example Ras-like small 
GTPases regulate cell proliferation/differentiation, cytoskeleton organization and intracellular 
membrane trafficking [Li and Zhang, 2004].
The G-protein level also provides a location where desensitisation can occur. RGS 
proteins (regulators of G-protein signalling) can increase the rate of GTP hydrolysis bound to Gi 
and Gq a-subunits which attenuates signalling via Gi- and Gq- regulated signalling pathways 
[Dohlman and Thomer, 1997; Hepler, 1999; Ferguson, 2001].
1.2.4 Modifications of G-Proteins
G-proteins are also sensitive to a number of covalent modifications. Most G* subunits 
undergo N-myristoylation and/or palmitoylation [Willard and Crouch, 2000; Chen and Manning, 
2001]. In addition, Gy subunits are subject to prénylation [Chen and Manning, 2001]. Each of 
these lipid modifications has been implicated in membrane targeting and to the interactions of 
these subunits with each other and other proteins [Hamm, 1998; Chen and Manning, 2001]. 
Some Ga subunit and a Gy subunit undergo phosphorylation, important in signal amplitude and 
duration [Chen and Manning, 2001].
A valuable experimental tool is the selective susceptibility to endotoxins of certain G« 
subunit members. For example, G«s subunits are adenosine 5’ diphosphate (ADP)-ribosylated in 
the presence of cholera toxin, which catalyses the transfer of ADP-ribose to an arginine residue 
present in the G^ subunit. This modifcation stabilises the GTP bound form of the a  subunit of 
Gs, and through inhibition of the intrinsic GTPase activity of the Gos subunit it is in a 
permanently activated state. [Hamm, 1998; Willard and Crouch, 2000; Chen and Manning, 
2001]. Similarly, Gai proteins undergo ADP-ribosylation in the presence of pertussis toxin (PTx) 
[Hamm, 1998; Willard and Crouch, 2000; Chen and Manning, 2001]. This occurs at a cysteine 
residue close to the C-terminus and is thought to uncouple the G-protein from its receptor 
[Willard and Crouch, 2000].
1.2.5 Small G-proteins
Small G-protein activation can be triggered when Gi2/i3-coupled receptors are activated. 
Small GTP-binding proteins are monomeric G-proteins with a molecular weight of 20-40kDa 
[Takai et a l ,  2001]. Each small G-protein contributes to a superfamily of more than 100 
members found in eukaryote systems ranging from yeast to human and is made of five 
subfamilies: - Ras, Rho, Rab, Arf and Ran [Bourne et a l,  1990; Hall, 1990; Takai et a l,  1992]. 
Six members belong Ras family which regulates gene expression [Takai et a l,  1992]. 
Rho/Rac/Cdc42 regulate cytoskeletal reorganisation and gene expression [Takai et a l,  1992; 
Evers et al, 2000; S ah et a l,  2000; Fukata et a l,  2001]. Intracellular vessicle trafficking is 
regulated by Rab and Arf. During G l, S and G2 phases nucleocytoplasmic transport is regulated 
by Ran [Takai e ta l,  1992].
Small G-proteins share consensus amino acid sequences responsible for specific 
interaction with GDP and GTP, for GTPase activity for bound GTP hydrolysis to GDP and Pi 
and a region for downstream effector interaction [Bourne, 1991; Takai et a l,  1992; Ikeda et a l,
2004]. C terminal sequences of Ras, Rho/Rac/Cdc42 and Rab undergo posttranslational lipid 
modifications, which include famesyl, geranylgeranyl, methyl and palmitoyl moieties and 
proteolysis [Takai et a l,  1992; Glomset and Farnsworth, 1994; Casey and Seabra, 1996]. Two 
interconvertible forms of small G-proteins exist GDP-bound inactive and GTP-bound active 
[Benard et al, 1999]. After stimulation by an upstream signal, GDP dissociates from the GDP- 
bound form followed by GTP binding. A conformational change of the downstream effector- 
binding region allows interaction with downstream effectors, enabling their function to be 
altered. The GTP-bound form is then converted back to the inactive GDP-bound form via the
intrinsic GTPase activity of the small G-protein, which ends in the release of the bound 
downstream effectors [Benard e ta l,  1999].
GDP/GTP exchange is governed by a rate limiting step which dissociates GDP from the 
GDP-bound form [Benard et a l, 1999]. Through regulation by an upstream signal, guanine 
nucleotide exchange proteins (GEFs) can increase the dissociation rate. GEFs interact with the 
GDP-bound form and release bound GDP to form a binaiy complex of small G-proteins and 
GEF. GEF is then replaced by GTP, which results in the formation of the active GTP-bound 
form [Takai et a l , 1992; Benard et a l , 1999; Takai et a l , 2001]. Many GEFs, such as Rab3GEF 
and son of sevenless (Sos), a Ras GEF, are specific for each member or subfamily of small G- 
proteins [Boguski and McCormick, 1993; Buday and Downward, 1993; Wada^/ al, 1997].
Wider substrate specificity is exhibited by some GEFs, as exemplified by dbl, a GEF 
active on Rlio/Rac/Cdc42 proteins, [Yaku et al, 1994; Hart et a l,  1998]. Rho/Rac/Cdc42 and 
Rab GDP/GTP exchanges are also regulated by the GDP dissociation inhibitors (GDIs), Rho 
GDI and Rab GDI respectively [Araki et al, 1990; Ueda^/a/., 1990; Fukui e ta l,  1997]. These 
molecules cause inhibition of the basal and GEF-stimulated dissociation of GDP from the GDP- 
bound form and maintain the small G-protein in the inactive GDP-bound form. A wider 
substrate specificity is exhibited by Rho GDI and Rab GDI than that exhibited by GEFs and 
GTPase-activating proteins (GAPs). Rho GDI and RabGDI are active on all Rho/Rac/Cdc42 and 
Rabs accordingly [Takai et a l, 2001]. Activation of Rho/Rac/Cdc42 and Rab is susceptible to 
positive and negative regulators.
1.3 GPCR Desensitisatioii
Regulation of GPCR signal tiansduction must be properly controlled in order to prevent 
overstimulation and achieve signal termination to render the receptor responsive to subsequent 
stimuli. The definition of GPCR desensitisation is stated as the process whereby receptor 
signalling responses plateau and then diminish despite the continuous presence of agonist 
[Palmer, 1996; Ferguson, 2001].
The GPCR desensitisation mechanism involves many different processes (Figure 1.17). 
Rapid, homologous desensitisation is believed to involve uncoupling of a receptor from its 
associated G-proteins within a few minutes of agonist exposure and seems to involve receptor 
phosphorylation [Palmer et a l, 1995; Jockers et a l,  1996; Bouvier e ta l,  1998; Appleyard e ta l,  
1999; X im e ta l ,  1999; Small e ta l ,  2001].
Receptor internalisation (sequestration), away from the cell surface may facilitate receptor 
dephosphorylation and subsequent resensitisation after agonist removal as well as reducing the 
number of cell surface receptors available. [Koenig and Edwardson, 1997; Mukherjee et al,
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1997; Cavalli et a l , 2001 ; Ferguson, 2001]. Internalisation of receptors can also be required for 
intracellular signalling, as exemplified by the dopamine D3 receptor [Sorkin et a l,  1993]. 
Agonist exposure after several hours may stimulate down-regulation of receptor where there is a 
decrease in the total number of receptors expressed [Clark, 1986; Bouvier e ta l,  1989; Ferguson, 
2001 ; Tsao et al, 2001]. An increase in gene expression is required to compensate for the loss of 
receptor protein expressed [Tsao et a l,  2001].
1.3.1 The Role of Phosphoiwlation in GPCR Desensitisation
The desensitisation of GPCRs is diverse from attenuation (P2AR) to complete inhibition 
(visual/olfactory systems) [Zhang et al, 1997; Sakmar, 1998; Ferguson, 2001]. For many 
GPCRs, the capability to undergo agonist-induced receptor phosphorylation is integral to the 
subsequent rate and extent of receptor desensitisation [Palmer, 1996; Clark et al, 1999; 
Ferguson, 2001]. Desensitisation of GPCRs was shown in several receptors to be regulated by 
phosphorylation by G-protein receptor kinases, arrestins and second messenger-dependent 
kinases [Yuanefu/., 1994; Jockers e ta l,  1996; Tang era/., 1998; Appleyard e ta l,  1999; Oakley 
et a l,  1999; Ferguson, 2001]. The p2-adrenergic receptor is the classic example of rapid GPCR 
desensitisation [Moffett et a l,  1993; Jockers et a l,  1996; Menard et a l,  1997; Luttrell et al,  
1999; McLean et al, 1999].
A number of GPCRs seem to share similar regulatory mechanisms, including the m2- 
muscarinic, rhodopsin, and thrombin receptors [Ferguson, 2001]. Here, the predominant form of 
the agonist-induced P2AR desensitisation is caused by altered conformation of the agonist- 
occupied receptor that facilities receptor phosphorylation by G-protein receptor kinases (GRKs) 
[Jockers et al., 1996; Menard et a l,  1997; Ferguson, 2001; Pierce and Lefkowitz, 2001]. After 
phosphorylation of the P2AR, p-arrestin a scaffold protein binds to the phosphorylated receptor 
and uncouples P2AR from the heterotrimeric G-proteins [Tohgo et a l , 2003]. Accompanying the 
desensitisation of the P2AR, p-arrestin also functions as an adaptor for clathrin, by mediating 
receptor internalisation via clathrin-coated vesicles [Menard e ta l ,  1997; Gaidarov etal., 1999b; 
Luttrell e ta l,  1999; Miller and Lefkowitz, 2001; Takei and Haucke, 2001].
1.3.2 Second Messenger-Dependent Kinases
Receptor phosphoiylation arises from the activation of second messenger-dependent 
kinases, independently of agonist occupation. Subsequently, ‘heterologous” receptor 
desensitisation occuis as the requirement of agonist occupancy is negated [Ferguson, 2001]. For 
the P2AR, phosphorylation of a consensus site within its third intracellular loop by PKA causes 
partial uncoupling of the receptor from Gs (about 40-60%) [Yuan e ta l,  1994], this mechanism is
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usually triggered by very low occupancy of receptor (2-5nM adrenaline) as it requires minute 
increases in cAMP to fully activate PKA, occurring rapidly, with a T m of 1-2 min [January e ta l,
1997]. In contrast, GRK-mediated phosphorylation has an EC50 approaching the Kd for agonist 
binding (50-200nM adrenaline) [Clark e ta l ,  1988; Hausdorffefa/., 1989; Jmiuary e ta l,  1997]. 
Hence, as agonist concentration increases, P2AR desensitisation shifts from being almost 
exclusively PKA-mediated towards a progressively larger GRK-mediated mechanism.
Furthermore, GRK-mediated phosphorylation has a time course which usually occurs 
within seconds [Clark e ta l,  1999; Ferguson, 2001]. The relatively slower time-course of second 
messenger-mediated receptor phosphoiylation can be attributed to the time required for second 
messenger kinase activation whereas phosphorylation mediated by GRKs only requires the 
necessary conformation change of the receptor. Notably, P2AR phosphorylation by PKA also 
switches the receptor from Ga to Gi coupling [Daaka et a l , 1997a].
Together with PKA, a number of other second messenger-dependent kinases are involved 
in desensitisation of GPCRs. PKC as an example, has been shown to phosphorylate and
desensitise a number of Q- and Gq-coupled GPCRs, which includes aib-adrenoceptor and the
type lA  angiotensin II receptor [Diviani, 1997; Liang era/., 1998; Tang era/., 1998].
1.3.3 The G-Protein Receptor Kinase Family
GRKs 1-7 are the seven members of the G-protein receptor kinase family [Ferguson, 2001 ; 
Pierce and Lefkowitz, 2001; Penela et a l,  2003]. The main characteristics of each GRK are: a 
central common catalytic domain, an N-terminal domain that controls substrate recognition and 
contains a conserved RGS domain, and a C-terminal domain responsible for targeting GRKs to 
the plasma membrane. The GRK family can be subdivided into three groups:
1) GRKl (rhodopsin kinase) and GRK7 (cone opsin kinase)
2) GRK2 (P-adrenergic kinase 1, pARKl) and
GRK3 (p-adrenergic kinase 2, pARK2)
3) GRK4, GRK5 and GRK6.
Famesylation occurs at CAAX motifs within the carboxyl termini of GRKl and GRK7. 
GRKl is also shown to be regulated by phosphatidylinositol 4,5-bisphosphate binding to a region 
that exhibits homologous sequence to a pleckstrin homology (PH) domain contained within the 
carboxyl-terminal domains of GRK2 and GRK3 [Pitcher gr a/., 1992; Touharaar a/., 1994]. The 
carboxyl-terminal domain of GRK5 contains a length of 46 basic amino acids that mediates 
plasma membrane-phospholipid interactions. GRK5 activity decreases in the presence of PKC
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whereas GRK2 activity is increased [Chaung et a l,  1995; Chaung et a l,  1996; Winstel, 1996] 
Chaung et al, 1996; Winstel et al, 1996].
Association of calmodulin to the N-terminal of GRK5 decreases the ability of the kinase to 
bind the receptor and phospholipids and decreases the activity of GRK5 by promoting the 
autophosphorylation of serine and threonine residues which are distinct from those involved in 
kinase activation [Pronin and Benovic, 1997; Pronin et a l, 1997; lacovelli e ta l ,  1999a; lacovelli 
et a l, 1999b]. Regulation of plasma membrane localisation of GRK4 and GRK6 is maintained 
by the palmitoylation of cysteine residues within the C-termini of GRK4 and GRK6 [Stoffel et 
al,  1994; Stoffel, 1998].
1.3.4 GRK Targeting and Regulation
Selective phosphorylation by GRKs is achieved at serine and threonine residues within the 
third intracellular loop (m2 mAChR and a2a AR) or the C-terminal tail (rhodopsin and p2AR) of 
agonist-occupied GPCRs [Ferguson, 2001]. GPCRs also isomerise to an activated conformation 
in the absence of agonist which affords GRKs the potential to contribute to basal GPCR 
phosphorylation [Pie et al, 1994; Rim and Opriann, 1995]. Conformational change in GPCRs 
triggered by interaction with agonist exposes two domains which are physically and functionally 
distinct. One dommn contains a sequence that is phosphorylated by GRK and the second domain 
acts as a GRK activator [Chen et al, 1993; lacovelli et al, 1999a], as exemplified by the sites 
within the m2-muscarinic receptor phosphorylated by GRK2 and the domains able to activate 
this kinase which were found to be located in different intracellular regions of the receptor 
[Nakata er a/., 1994; lacovelli cr a/., 1999a].
A number of mechanisms have been discovered for targeting GRKs to their membrane- 
bound receptor substrates. GRK2 and GRK3 appear to be largely cytosolic enzymes. When a 
GPCR is stimulated by an agonist it causes the receptor to interact with a heterotrimeric G 
protein leading to dissociation of cc and Pydimer subunits. The PYsubunit complex, which is 
prenylated with a geranylgeranyl group at the C terminus of the ï  is membrane-bound. Free GPv 
and membrane phosphatidylinositol bisphosphate (PIP2) appear to bind to a C-terminal domain 
of GRK2 or GRK3, the pleckstrin homology domain [Boivin and Lecomte, 1997]. Interaction of 
ligands with the pleckstrin homology domain translocates or targets the kinase to the membrane- 
bound, agonist-occupied receptor, where it is available to interact with its substrate. Different GP 
Y isoform combinations have preferential affinity for either GRK2 or GRK3, which may permit 
specificity in GRK-receptor interactions [Daaka cm/., 1997b; Shenoy and Lefkowitz, 2003a].
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1.3.5 The role of GRKs in GPCR Desensitisation
There is a surfeit of evidence that suggests that GPCR desensitisation is associated with 
GRK phosphoiylation [Lefkowitz, 1998]. Coexpression of GRKs with GPCRs in cells resulted 
in augmented desensitisation of receptors including the aib-adrenergic [Diviani, 1997], a2- 
adrenergic [Jewell-Motz and Liggett, 1996], (31-adrenergic [Freedman et a l,  1995], (32- 
adrenergic [Pippig et a l,  1993], angiotensin I I ia  (A T ia )  [Opperman e ta l ,  1996], A3 adenosine 
[Palmer et a l,  1995], m2 muscarinic [Schlador and Nathanson, 1997], histamine H2 [Shayo et 
al, 2001] and m3 muscarinic receptors [Willets et a l,  2001].
1.3.6 Other kinases which Dhosphoiwlate GPCRs
There are also other kinases apart from GRKs and/or second messenger kinases that use 
GPCRs as substrates for phosphoiylation. Tyrosine phosphorylation of agonist-occupied p- 
opioid receptors [Pak et a l,  1999] has been suggested to be an important signal for receptor 
downregulation. Tyrosine kinase inliibitors blocked bradykinin-mediated prostaglandin E2 
production for the bradykinin B2 receptor, demonstrating that tyrosine kinase phosphorylation of 
the receptor is critical for its signal transduction [Jong et a l, 1993]. Research has identified that 
casein kinase l a  can phosphorylate the m3 muscarinic receptor on the third intracellular loop 
[Tobin, 2002], although mutant receptors where the potential casein kinase l a  phosphorylation 
sites were absent still underwent agonist-mediated desensitisation [Budd et al, 2000]. The 
phosphorylation of TRH receptor on its C-terminal tail by casein kinase II [Hanyaloglu et al, 
2001] was considered to be important for receptor internalisation but not desensitisation.
1.3.7 The role of Ari^stins in Desensitisation
Stability of receptor/arrestin complexes may be regulated by the GRK-mediated 
phosphorylation of clusters of serine and threonine residues within receptor C-tails [Oakley et 
al, 1999; Miller and Lefkowitz, 2001; Lefkowitz and Whalen, 2004]. Arrestins act as adaptor 
proteins that preferentially bind agonist-activated and GRK-phosphorylated GPCRs, with which 
they form a complex that results in receptor uncoupling from G-proteins. As well as forming 
complexes they can target the receptor for internalisation via clathrin-coated vesicles and 
arrestins can also mediate the activation of alternative signalling pathways [Gaidarov et a l,  
1999a; Gaidarov e ta l,  1999b; Luttrell e ta l,  1999; Ferguson, 2001; Miller and Lefkowitz, 2001; 
Pierce and Lefkowitz, 2001]. Arrestins are a family made up of two groups. One group contains 
visual arrestin (S-arrestin) which is found within rod outer segments and is localised primarily to 
the retina [Smith et a l, 1994] and cone arrestin (C- or X-arrestin) which is highly expressed 
within neuronal tissues and the spleen where they regulate signalling of many different GPCRs
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[Attramadal et a l,  1992; Pierce and Lefkowitz, 2001]. The other group contains p-arrestin 1 and 
p-arrestin 2 (also called arrestin 3). Crystal structure analysis and mutagenesis studies of visual 
arrestin have identified 3 functional domains (a secondary receptor-binding domain, a receptor 
activation domain and a phosphate sensor domain) and two regulatory domains, located at the 
amino terminal and carboxyl-terminal [Gurevich et al, 1995; Granzin et a l,  1998; Ferguson, 
2001]. Clathrin- and p-adaptin-binding domains are located at the C-terminal region and are 
conserved among non visual arrestins [Krupnick, 1994; Laporte et a l,  2000]. Within the N- 
terminal domain of p-arrestin 1 and p-arrestin 2, but not the visual arrestins, there is a proline- 
rich region [Luttrell et a l,  1999].
1.3.8 Stnictural features of Arrestins
Visual arrestin and the p-arrestins now possess alternative splice variants. Like visual 
arrestin, the p-arrestins express at least two alternative spliced forms. The variant form of p~ 
arrestin 1 has an eight amino acid insertion between residues 333 and 334 [Parruti et a l,  1993] 
and the alternate p-arrestin 2 has an eleven amino acid insert between residues 362 and 363 
[Steme-Marr et a l,  1993]. No differences in activity of the p-arrestin splice variants have been 
reported.
AiTestins preferentially bind to phosphorylated, ligand-activated receptors suggests that 
there is a domain(s) that makes specific contacts with GPCRs in the active state. Initial 
investigations to locate the activation-recognition region suggested that it was present in the N- 
terminal half of the protein (residues 1-191) as a truncated visual ai restin containing retained its 
ability to bind light-activated state of rhodopsin [Gurevich and Benovic, 1992]. Moreover, it had 
been previously shown that the p44 visual arrestin mutant binds with high affinity to rhodopsin 
[Paiczewski, 1994; Palczewski 1994].
Mutagenesis studies have mapped the phosphorylation-recognition site to a discrete region 
within the N-terminus. Arrestin truncated at residue 185 bound to phosphorylated light-activated 
rhodopsin and phosphorylated dark rhodopsin, while arrestin truncated at residue 158 exhibited a 
reduction in its ability to detect the phosphorylated form of the receptor, thus focusing the 
location of the phosphorylation-recognition region to between residues 158 and 185 [Gurevich et 
al,  1993].
Mutagenesis of individual residues within region 158-185 of arrestin identified several 
basic residues, namely Arg^^\ Aig^^  ^ and Lys^^ ,^ which werde crucial for phosphate binding 
[Gurevich et a l,  1995]. Futhermore, Arg^ ^  ^ was suggested to function as a phosphorylation- 
sensitive trigger, since mutation of this residue to a neutral or acidic amino acid resulted in
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constitutive binding of arrestin to non-phosphoiylated light-activated rhodopsin [Gurevich et a l, 
1995]. The N-terminal segment of the p-arrestins also retained the ability to recognise agonist- 
activated receptors, indicating that the activation-recognition region of all arrestins was 
contained within the N-terminal half [Gurevich et a l , 1995].
1.4 GPCR Internalisation
Internalisation of agonist-activated receptors is an important aspect of GPCR regulation. 
Studies have demonstrated that many GPCRs translocate from the cell surface to intracellular 
membrane compartments upon exposure to agonist (Figure 1.17).
Originally discovered in bullfrog erythrocytes, GPCR internalisation was seen as a loss of 
cell surface p2ARs corresponding to an increase in intracellular p2ARs [Chuang and Costa, 
1979].
GPCRs are classified into Class A and Class B based on the distinct pattern of their 
interaction with p-arrestin [Luttrell and Lefkowitz, 2002] and the resulting rate of recovery from 
desensitization following agonist removal. Class A GPCRs, for example, p2AR, rapidly 
dissociate from p-arrestin upon internalisation. These receptors are trafficked to an acidified 
endosomal compartment, wherein the ligand is dissociated and the receptor dephosphorylated by 
a GPCR-specific protein phosphatase PP2A isoform, and are subsequently recycled to the PM. 
Class B GPCRs, for example, the angiotensin II ATI a, form stable receptor-p-arrestin 
complexes. These receptors accumulate in endocytic vesicles and are can be targeted for 
degradation or slowly recycled to the membrane via routes that are currently unknown [Luttrell 
and Lefkowitz, 2002].
1.4.1 The role of Phosphoi-vlation in GPCR Internalisation
Evidence has accumulated that phosphorylation might be important for the internalisation 
of other GPCRs. A Ser/Thr-rich sequence was suggested to be a crucial factor in the 
sequestration of the m l, m2, and m3 muscarinic receptors [Moro et a l,  1993]. Mutation within 
the third intracellular loop of the m2 muscarinic receptor reduced the rate of internalisation 
[Moro et al, 1993]. Further evidence to support the role of phosphorylation in internalisation 
was highlighted in studies with the thrombin receptor [Shapiro et a l,  1996]. Truncation or 
mutation of the Ser/Thr residues in tire C-terminus of the thrombin receptor reduced both 
agonist-induced phosphorylation and sequestration. In addition, agonist-induced phosphorylation 
of the angiotensin ATIA receptor is localised to a serine/threonine-rich region of its cytoplasmic 
tail [Smith cm/., 1998].
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The direct role of phosphoiylation of the P2AR in its sequestration was eventually 
demonstrated using a phosphorylation- and internalisation-defective mutant, p2AR-Y^^^A 
[Ferguson et a l, 1995]. Overexpression of GRK 2 enhanced both the phosphorylation and 
internalisation of the receptor mutant, hi addition, the phosphorylation and internalisation of the 
wild-type P2AR in HEK293 cells was reduced by overexpression of a dominant negative GRK 2 
mutant [Ferguson et a l,  1995]. GRK 2 phosphorylation has been shown to mediate 
internalisation of other GPCRs including the ATia [Smith et a l,  1998], endothelin A [Bremnes et 
al,  2000], D2 dopamine [Itokawacm/., 1996].
1.4.2 The role of Arrestins in Clathrin-Mediated GPCR Internalisation
GPCRs endure agonist-induced endocytosis and recycling back to the plasma membrane 
[Ferguson, 2001; Pierce and Lefkowitz, 2001; Takei and Haucke, 2001] (Figure 1.17). 
Classically, the p2AR and many other GPCRs, such as the angiotensin ATiaR, the endothelin 
ETl A receptor and the D2 dopamine receptor undergo endocytosis involving GRK- and airestin- 
dependent recruitment of GPCRs to plasma-membrane clathrin coated pits and subsequent 
invagination and pinching off to form intracellular clathrin coated vesicles [Brodin et a l, 2000; 
Ferguson, 2001; Pierce and Lefkowitz, 2001; Takei and Haucke, 2001]. Clathrin comprises three 
light and three heavy chains that form a triskelion, a structure with three legs [Brodin et a l, 
2000; Takei and Haucke, 2001]. Assembly of the triskelions into a basket-like convex 
framework of hexagons and pentagons forms the coated pits on the cytoplasmic surface of the 
plasma membrances [Schmid, 1997; Brodin et al,  2000; Takei and Haucke, 2001].
An adaptor protein (AP) called AP2 is one of the main components of the coats formed 
during membrane endocytosis. The AP2 complex conprises of four subunits: two large lOOkDa 
subunits (a-adaptin, which binds to clathrin, dynamin and Eps 15 and p2-adaptin, essential for 
clathrin coat formation), one medium size 50kDa subunit (p2, which recognises tyrosine-based 
internalisation signals) and a small 17kDa subunit (o2) [Brodin et al, 2000; Ferguson, 2001; 
Takei and Haucke, 2001].
Clathrin has a p-arrestin binding domain localised to residues 89-100 of the amino- 
terminal globular region in the terminal domain (TD) of the clathrin heavy chain at the distal end 
of each clathrin triskelion [Goodman et a l , 1997]. Specific arginine residues (Arg^ '^^  and Arg^^ )^ 
in the p-arrestin 2 C terminus have been identified that mediate p-arrestin binding to AP-2 and, 
in viti'o, these domains in p-airestin 1 and p-aiTestin 2 interact equally well with AP-2 
independently of clathrin binding [Laporte et a l,  2000]. In addition, whereas p2AR/ p-arrestin 
complexes lacking the p-aiTestin 2 clathrin binding motif redistributed to coated pits, receptor/ p-
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arrestin complexes lacking the p2-adaptin binding site did not [Laporte et a l,  2000]. Interaction 
of beta-arrestin with p2-adaptin represents a selective endocytic trigger for several members of 
the GPCR family [Laporte et a l , 2002].
p-arrestin interactions with the AP-2 complex, rather than the clathrin, are necessary for 
the initial targeting of receptors to coated pits [Laporte et a l , 2000], p-arrestins bind to both the 
clathrin heavy chain and the p2-adaptin subunit of AP2 [Brodin et a l ,  2000; Ferguson, 2001]. 
The coat also contains a monomeric adaptor protein, API80, which interacts with AP2 and may 
regulate vesicle size [Brodin et a l,  2000]. The formation of clathrin-coated pits is assisted by 
synaptotagmin, an AP2 binding protein that facilities vesicle recycling by promoting coated pit 
nucléation [Brodin et al, 2000; Ferguson, 2001; Takei and Haucke, 2001] and has been recently 
implicated as an intermediary in M4 muscarinic receptor internalisation [Madziva et a l,  2005].
When clathrin-coated vesicles are pinching off is largely dependent upon the action of 
dynamin a lai'ge GTPase and is ATP-dependent [Brodin et al, 2000; Takei and Haucke, 2001 
[Zhang et a l,  1996]. When a dominant negative form of dynamin, K44A, which lacks GTPase 
activity was overexpressed it blocked both p2AR and ATlaR internalisation [Zhang et a l,  1996; 
Gagnon et al, 1998; Brodin et a l,  2000; Ferguson, 2001; Tsao et a l,  2001]. Self-assembly of 
dynamin into a helical structure that wraps around the necks of forming vesicles facilitates their 
pinching off from the membrane [Brodin et a l,  2000; Takei and Haucke, 2001]. Amphyphysin, 
the accessory protein acts as a binding partner for clathrin, AP-2 and dynamin and has been 
shown to recruit dynamin to clathrin-coated pits [Volchuk et a l , 1998; Brodin et a l,  2000; Takei 
and Haucke, 2001]. Endocytosis connects the actin cytoskelton via amphiphysin and syndapins 
which interact with dynamin [Brodin et a l,  2000; Takei and Haucke, 2001].
Several accessory proteins are involved in clathrin-mediated endocytosis. These include: 
endophilin, a lysophosphatidic acid acyl transferase involved in pit maturation and vesicle 
fission, and epsin and Epsl5, both of which are interacting partners for the a-adaptin subunit of 
AP2, synaptojanin, an inositol phosphatase that regulates PÎP2 metabolism and the stability of 
clathrin-AP2 coats; [Mukherjee era/., 1997; Simpson era/., 1999; Brodin era/., 2000; Cavalli er 
al,  2001; Ferguson, 2001; Takei and Haucke, 2001]. Dynamin and clathrin among other 
endocytosis components, have been shown to be regulated especially as a result of the p-arrestin- 
mediated activation of ERK [Ahn et al,  1999; Miller et al, 2000; Ferguson, 2001; Miller and 
Lefkowitz, 2001; Pierce and Lefkowitz, 2001]. Recently several components of the ERK 
pathway have been found to form complexes with p-arrestins and are then recruited to GPCRs in 
an agonist-dependent manner [Luttrell et a l,  1999; DeFea et a l,  2000; Miller and Lefkowitz,
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2001]. Additional characteristics of p-arrestins have been shown to exist in the molecular 
adapter proteins since p-arrestin was discovered to recruit the non-receptor tyrosine kinase Src to 
activated p2ARs, making arrestins components of the ERK pathway [Luttrell et al,  1999].
Src molecules associated with p-arrestin and activated pzARs were found to be 
dephosphorylated on Tyr530 and therefore catalytically active [Luttrell et a l,  1999; Miller and 
Lefkowitz, 2001]. When activated Src is recruited to an agonist-occupied receptor it leads to 
phosphorylation of the adaptor protein She, formation of Shc-Grb2 complexes and mediates the 
phosphorylation of dynamin and clathrin, as well as ERK activation [Luttrell et a l ,  1999; Miller 
and Lefkowitz, 2001].
1.4.3 Trafficking Through Endocvtic Organelles
Subsequent to internalisation, receptors are transported to peripheral early endosomes 
[Mukherjee et a l , 1997; Cavalli et a l , 2001 ; Ferguson, 2001]. Rab5, the small GTPase is one of 
the key regulators of this process and cycles between GTP- and GDP-bound form, and GTP 
hydrolysis depends on Rabex-5, a specific GEF [Cavalli e ta l ,  2001; Ferguson, 2001; Takei and 
Haucke, 2001]. Rab5 often contributes to endocytic vesicle formation, the trafficking of vesicles 
to early endosomes and the fusion of endocytic vesicles with early endosomes [Cavalli et al, 
2001; Ferguson, 2001]. On arrival at early endosomes, recycling receptors such as the PzAR and 
the transferrin receptors are returned to the cell surface, at least in part via recycling endosomes 
[Ferguson, 2001; Pierce and Lefkowitz, 2001].
Rab4, another small GTPase, is also involved in the recycling pathway where it regulates 
the budding and/or recycling of receptor-bearing recycling vesicles [Seachrist et al, 2000; 
Cavalli et al,  2001; Ferguson, 2001]. In contrast to recycling receptors, some endocytosed are 
receptors targeted to lysosomes for degradation [Gruenberg and Maxfield, 1995]. Transport 
from early to late endosomes is mediated through intermediates called multivesicular bodies 
(MVBs) or endosomal carrier vesicles (ECVs). In mammalian cells, ECVs/MVBs, once formed 
on early endosomes, move towards late endosomes on microtubules and then dock onto and fuse 
with late endosomes [Gruenberg and Maxfield, 1995; Cavalli et a l,  2001]. At present the 
potential for possible cross-talk between late endosomes/lysosomes and signalling pathways is 
yet to be researched. Recent studies identified a novel 14 kDa protein that interacts with the 
MAPK scaffold protein MPI on late endosomes/lysosomes but its function remains uncleai' 
[Cavalli et al,  2001]. Protein ubiquitination has also been implicated at multiple steps of the 
endocytic pathway from internalisation to the maturation of endosomes and lysosomal delivery 
[Cavalli et a l,  2001; Ferguson, 2001; Shenoy and Lefkowitz, 2003b]. It has been shown that a
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p2AR mutant lacking lysine residues, which was not ubiquitinated, was internalised normally but 
encountered ineffective degradation [Shenoy e ta l,  2001].
1.4.4 Alternative GPCRs Pathways of Internalisation
Internalisation that is mediated by clathrin represents the most common mechanism for 
GPCR internalisation. However, receptors can also internalise via pathways that are independent 
of both clathrin and p-arrestin [Mukherjee et a l,  1997; Anderson, 1998; Cavalli et a l,  2001; 
Ferguson, 2001]. One possible route of entiy involves cell surface microdomains containing 
cholesterol and glycosphingolipids (rafts), (Figure 1.16) which are believed to play an important 
role in the internalisation of the IL-2 receptor [Mukheijee et al, 1997; Anderson, 1998; Cavalli 
et al, 2001; Ferguson, 2001]. Caveolae are flask-shaped invaginations smaller than clathrin- 
coated pitswhich are formed by lipid rafts associated with caveolin [Anderson, 1998]. Caveolae 
have been reported in a myriad of cell types, including smooth muscle cells, fibroblasts, 
adipocytes, endothelial cells and many epithelial cells [Mineo et a l,  1996; Parton, 1996; 
Anderson, 1998; Oh et a l,  1998; Kogo, 2000]. Much less is known about the molecular 
mechanism involved in internalisation via caveolae, both the agonist-occupied pzAR and the 
bradykinin p2 receptors were shown to be localised in caveolae as determined by electron 
microscopy studies [De Weerd and Leeb-Lundberg, 1997; Haasemann et a l,  1998; Okamoto et 
al,  2000b; Ferguson, 2001]. Angiotensin type 1 and m2 muscarinic acetylcholine receptors also 
undergo agonist-dependent sequestration in this microdomain, as observed by the recovery of 
receptor proteins in caveolin-rich fractions [Feron et a l,  1997]. Cell type is crucial for many 
receptors in determining the favoured pathway of receptor internalisation. The pzAR internalises 
in some cell types via clathrin-coated pits but internalises via caveolae in other cell types, such as 
A431 cells [Raposo e ta l,  1989; Kallal and Benovic, 2000; Ferguson, 2001]. Also the endothelin 
ETl A receptor has been reported to internalise via both pathways in a cell-type dependent 
manner [Okamoto et a l , 2000b]. The route of internalisation can also determine the intracellular 
trafficking of the receptor [Okamoto et al, 2000b].
1.4.5 Receptor Determinants for Endocytosis
Multiple receptor domains appear to contribute to the internalisation properties of GPCRs. 
For many GPCRs the second and third intracellular loop domains are functionally important in 
GPCR internalisation. For the m2 muscarinic receptor, the determinants for internalisation are 
found within a serine/threonine rich domain of the receptor’s third intracellular loop [Moro et a l , 
1993]. Presumably, these residues are the sites of GRK phosphorylation that are critical for 
inducing receptor endocytosis [Tsuga et a l,  1994]. As well as the third intracellular loop, the
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conserved DRYXXV/IXXPL sequence of the second intracellular loop domain is also involved 
in the internalisation of some GPCRs including the ml muscarinic and GnRH receptors.
Researchers have scrutinized the role of GPCR C-terminal tails and putative GRK 
phosphorylation sites in regulating agonist-stimulated GPCR internalisation. Despite 
internalisation of the pzAR being (3-arrestin-dependent, neither the truncation of the |3zAR  
carboxyl tail nor the mutation of potential GRK phosphorylation sites was found to inhibit (3zAR 
internalisation [Hausdorff et a l,  1989]. Alternatively, truncation of the C-tail or mutation of 
putative GRK sites of the ATiaR blocked its internalisation [Zhang et a l ,  1996; Smith et al, 
1998].
1.4.6 The role of Internalisation in receptor Desensitisation and Resensitisation
Originally, GPCR internalisation was thought to be the principal mediator of receptor 
desensitisation due to the physical separation of receptor and effectors [Sibley and Lefkowitz, 
1985]. However, additional studies demonstrated that receptor endocytosis is not as rapid as 
receptor desensitisation and the majority of sequestered receptors are phosphorylated meaning 
they do not need to be desensitised. Furthermore, hypertonic sucrose and concanavalin A  
treatments that inhibit GPCR internalisation were shown not to affect pz-AR desensitisation 
[Pippig et a l,  1995]. Many studies have reported on analysis of tmncated C-tail receptors and 
phosphorylation-deficient mutants, that desensitisation and internalisation are distinct processes. 
This is observed for receptors including the H2 histamine receptors [Fukushima et a l,  1997].
Recent studies have highlighted the importance of internalisation in the recovery from 
desensitisation (a process also known as resensitisation), even if GPCR internalisation may not 
play a critical role in agonist-induced desensitisation. The mechanisms of GPCR resensitisation 
are considered to involve the internalisation of agonist-activated receptors into endosomal 
compartments which contain a GPCR-specific phosphatase. Endosomal acidification promotes 
the association of the receptor with the GPCR phosphatase and dephosphorylation of the 
receptor. Dephosphorylated GPCRs are subsequently recycled back to the cell surface where 
they can be activated by agonist once more [Wenk and De Camilli, 2004].
The role of internalisation in resensitisation was first observed in studies of the pzAR. It 
was subsequently proposed that déphosphorylation of internalised receptors in the endosomes 
followed by recycling back to the cell surface was responsible for restoring pzAR function 
[Pippig et a l, 1995]. The critical importance of both phosphatase activity and receptor recycling 
in pzAR resensitisation was demonstrated by the ability of calyculin A  an inhibitor of protein 
phosphatases, and monesin, an inhibitor of intracellular trafficking, to block receptor
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resensitisation [Pippig et a l,  1995]. Sequestration has been reported to be critical for the 
resensitisation of many other GPCRs including the endothelin A receptors [Bremnes et a l,
2000].
1.4.7 Receptor Down-Resulation
Down-regulation often occurs after prolonged agonist treatment and is manifested as a 
decrease in receptor density. Short term desensitization results from a rapid (in minutes) and 
reversible uncoupling of the receptor-G protein complex, followed by sequestration and/or 
internalization of receptors from the cell surface (Figure 1.17). Receptors are not degraded as 
removal of agonist rapidly restores receptor function. Conversely, down-regulation, displays a 
much longer time-course (hours to days) and is characterized by a decrease in receptor density as 
determined by radioligand binding. Removal of agonist will only slowly reverse down- 
regulation, because in most cases, new receptor synthesis is required. Downregulation occurs as 
a consequence of both increased lysosomal degradation of pre-existing receptors and reduced 
mRNA and protein synthesis. The mechanism of receptor down-regulation is not well 
understood, but may include an accelerated rate of removal of receptors, a decrease in the rate of 
appearance of receptors, or both [Heck and Bylund, 1998]. Blocking pzAR endocytosis with 
chemical treatments or by expressing a dominant negative mutant of dynamin could not prevent 
receptor downregulation indicating that this process may occur at the plasma membrane [Jockers 
e ta l ,  1999].
Other studies have shown that sequestration is involved with PzAR downregulation. 
Immunocytochemical techniques were used to label epitope-tagged PzARs, agonist treatment 
induced redistribution of the receptors in punctate accumulations within the cells. While the 
majority of internalised receptors were recycled back to the plasma membrane, a small fraction 
of the internalised receptors were sorted in endosomes for degradation in lysosomes [von 
Zastrow and Kobilka, 1992]. The dynamin-K44A mutant profoundly inhibited agonist-induced 
internalisation and downregulation of the pzAR in HEK293 cells, indicating that receptor 
internalisation was critical for downregulation in these cells. A dominant-negative mutant of p- 
arrestin, p-arrestin-(319-418), also inhibited both agonist-induced receptor internalisation and 
downregulation illustrating that downregulation of the PzAR is partly due to trafficking of the 
receptor via clathrin coated pits [Gagnon et a l,  1998].
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1.5 SphingoHoids
Sphingolipids are ubiquitous molecules, with more than three hundred species that exist 
in a diverse array of organisms and virtually all cell types [Levade et a l,  2001]. Members of the 
sphingolipid class of mediators include ceramide, sphingosine and sphingosine 1-phosphate. 
Spliingolipid generation is followed by regulation of ion fluxes and activation of multiple 
signalling pathways. These processes lead to smooth muscle cell proliferation, endothelial cell 
differentiation or apoptotic cell death, cell contraction, retraction or migration. Recent 
observations implicating sphingolipids in physiological processes, such as vasculogenesis, and 
frequently in pathological conditions including atherosclerosis and its complications have 
highlighted the special importance of sphingolipids in cardiovascular signalling [Levade et a l ,
2001].
Sphingolipids can be recognised by their long-chain sphingolipid backbone, generally 
sphingosine (Figure 1.5). Structurally, ceramide consists of a long-chain sphingoid base with an 
amide-linked fatty acid component of 16-24 carbons in length. There are two potential pathways 
for intracellular ceramide formation: de novo synthesis via the condensation of serine and 
palmitoyl-CoA, followed by conversion to dihydroceramide and finally to ceramide and/or the 
breakdown of sphingomyelin through sphingomyelinase. Ceramide performs the role of a 
building block for most sphingolipids [Hannun, 1994]. Different substitutions on ceramide at the 
l-hydrojQ'l position define each sphingolipid class. The synthesis, turnover and fimctions of 
sphingolipids are shown in Figure 1.6.
1.5.1 Sphingosine 1-phoshate (SlPl-activated pathways
In 1884, sphingosine was named after the mythological Greek Sphinx due to its enigmatic 
nature [Thudichum, 1884]. Sphingosine has been under investigation since as early as 1970 
when dihydrosphingosine-1-phosphate was postulated as an intermediate in the metabolism of 
Cl8-dihydrosphingosine to palmitaldehyde and ethanolamine phosphate [Hirschberg et a l,  
1970]. The first evidence of sphingosine research in reference to SIP appeared when it was 
discovered that sphingosine stimulated cellular proliferation via a protein kinase C-independent 
pathway [Zhang et a l, 1990]. This lead to the discovery of the importance of SIP in cell growth 
regulation where it was shown to increase DNA synthesis in quiescent Swiss 3T3 fibroblasts and 
to induce transient increases in intracellular free calcium [Zhang et a l,  1991]. Research has 
since identified many aspects of the bioactive, pleiotropic, phospholipid SIP, including its ability 
to act as both an extracellular signalling molecule as well as an intracellular second messenger 
[Olivera and Spiegel, 1993; Cuvillier et a l,  1996; Lee, 1998a, b; Spiegel and Milstien, 2002], 
(Figure 1.6).
23
Successive studies have shown that SIP is a potent mitogen in diverse cell types and 
elicits various biological effects like the mobilisation of intracellular calcium, the regulation of 
cytoskeleton organisation and cell growth, differentiation, survival and motility [Im et a l,  1997; 
An et al., 1999; Hong et a l, 1999; Pyne and Pyne, 2000b, a; Spiegel and Milstien, 2003; 
Maceyka et al, 2005]. SIP acts as an extracellular mediator by binding to a distinct sub-family 
of plasma membrane GPCRs.
1.5.2 Stiuctural features of SIP
The membranes of most mammalian cells contain the integral sphingolipid component 
SIP, a phosphorylated derivative of sphingosine [Spiegel and Milstien, 2000a]. The stucture of 
SIP comprises a long hydrocarbon chain on a three carbon backbone which contains a phosphate 
group (Figure 1.5). SIP is biosynthesised either de novo through pathways of intemiediate lipid 
metabolism or via stimulus-coupled liberation of the respective precursor from 
glycerophospholipids and sphingolipids and subsequent enzymatic conversions [Smith and 
Merrill, 1995; Goetzl and An, 1998; Vesper e ta l,  1999; Pyne and Pyne, 2000b, a]. De novo SIP 
synthesis initiates with condensation of a fatty acid-CoA and serine to form 3-ketosphinganine, 
which upon reduction is converted to a dihydroceramide in the ER [Goetzl and An, 1998]. The 
dihydroceramide is then sequentially converted to ceramide, sphingosine and eventually SIP 
[Goetzl and An, 1998; Vesper et al, 1999]. That very little free ceramide and no free 
sphingosine results from this de novo pathway provides evidence for the much greater 
contributions of sphingomyelin turnover to the secreted sphingosine and SIP [Goetzl and An, 
1998], (Figure 1.6).
The dynamic metabolism of sphingolipids results in the formation of a number of 
bioactive metabolites including ceramide, sphingosine, and SIP [Spiegel and Merrill Jr, 1996; 
Pyne and Pyne, 2000b, a; Saba and Hla, 2004]. Degradation of sphingomyelin in the membranes 
of lysosomes and endosomes and in the plasma membrane occuis in response to growth factors, 
pro-inflammatory cytokines and aiachidonic acid and also following cellular stress [Spiegel, 
1999; Pyne and Pyne, 2000b, a; Spiegel and Milstien, 2000a]. Once sphingomyelinase is 
activated, sphingomyelin is hydrolysed to ceramide, which is thought to be involved in cell 
growth aiTest, differentiation and apoptosis [Hannun, 1996; Kolesnick, 1998]. The conversion of 
ceramide to sphingosine is catalysed by ceramidase. It was also shown that sphingosine inhibits 
protein kinase C (PKC) and induces apoptosis [Spiegel and Milstien, 2000b, a].
Sphingosine can be phosphorylated by sphingosine kinase to produce SIP. this implicates 
SIP in cell growth and the inhibition of ceramide-mediated apoptosis [Spiegel, 1999; Spiegel 
and Milstien, 2000b, a]. SIP catabolism is catalysed either by pyridoxal phosphorylation-
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independent lyase located in the ER, which degrades SIP to phosphoetholamine and 
palmitaldehyde, or by a phosphatase which converts SIP back to sphingosine [Goetzl and An,
1998]. Dynamically, balance between all sphingolipid metabolites helps determine cell fate. 
This is commonly recognised as the “sphingolipid rheostat” model. Figures 1.5 and 1.6, [Spiegel, 
1999; Pyne and Pyne, 2000a].
The majority of extracellular SIP in the blood is derived from platelets activated either 
via stress stimuli, phorbol esters or thiombin [Igarashi and Yatomi, 1998]. Originally, it was 
believed that subsequent to production of intracellular SIP, SIP can be released into the 
extracellular space where it is present as albumin-bound SIP [Igarashi and Yatomi, 1998; Hla et 
al,  2001]. It is now appreciated that it is also carried by, and is an important biologically active 
component of, HDL, LDL etc. It is now appreciated that it is also carried by, and is an important 
biologically active component of, HDL, LDL etc. SIP released from activated platelets into the 
plasma is concentrated in the lipoprotein fraction with high density lipoprotein (HDL3) being the 
main carrier of SIP followed by low density lipoproteins (LDL) and veiy low density 
lipoproteins (VLDL) [Sachinidis et a l,  1999; Spiegel and Milstien, 2002]. Additionally, 
extracellular SIP can be derived from other cell types such as mast cells and monocytes [Spiegel 
and Merrill Jr, 1996; Hannun et a l,  2001]. Platelets, unlike other somatic cells, lack SIP lyase 
[Yatomi et a l,  1995], and the absence of this enzyme is likely to be responsible for SIP 
accumulation. The precise SIP releasing mechanisms remain to be elucidated. A recent study 
has also suggested that as well as newly released SIP, the extracellular SIP content could also be 
derived from by the extracellular metabolism of sphingomyelin since the biosynthetic enzymes, 
namely sphingomyelinase, ceramidase and sphingosine kinase have been shown to be secreted 
by cells [Tabas, 1999; Romiti et al, 2000; Hla et a l,  2001; Maceyka et a l, 2005].
A study has also demonstrated that the cystic fibrosis transmembrane regulator (CFTR), a 
member of the ATP binding cassette family of proteins, is involved in the uptake of extracellular 
SIP and other related phosphorylated lipids [Boujaoude et a l, 2001]. This uptake would 
influence the balance between extracellular and intracellulai* SIP concentrations and hence, 
affect the ability of SIP to modulate biological activity via its interaction with cell surface 
GPCRs.
1.5.3 SIP Receptors
Over the course of SIP receptor investigations, controversy arose over the significance of 
intracellular and extracellular actions of SIP. While the intracellular targets of SIP in 
mammalian cell have yet to be elucidated, intracellular SIP has been implicated in the 
mobilisation of intracellular calcium independently of IP3, activation of ERK, inhibition of
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stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) and suppression of 
apoptosis [Spiegel and Milstien, 2000b]. However, the discovery in 1998 that SIP acts on cell 
surface G-protein-coupled receptors showed that extracellular SIP can mediate a number of 
biological effects, including some previously attributed to intracellular SIP [Lee, 1998b; Payne 
e ta l,  2002].
The extracellular effects of SIP are due to its binding to specific members of the so- 
called “Endothelial Differentiation Gene” (EDG) family of GPCRs, which have been renamed to 
account for the division between its members into SIP and lysophosphatidic acid (LPA) 
receptors [Chun et a l,  2002], see Table 1.1. The EDG receptors are a subfamily of GPCRs 
consisting of 8 members, EDGl-8, now referred to as SlPi-s and LPA1-3 . SIP1.5 are highly 
selective for SIP and to a lesser extent LPA [Pyne and Pyne, 2000b, a; Hla et a l,  2001]. 
Although they share low affinity for SIP, LPA1.3 have greatest affinity for LPA, a bioactive 
phospholipid with similar biological effects and structure to SIP [Contos et al, 2000; Fukushima 
e ta l ,  2001].
The EDG family can be subdivided, according to amino acid sequence similarity, into three 
groups:
(1) SlPi, SIP2, SIP3 and SIP5 (around 50% identical);
(2) LPAi, LPAz and LPA3 (around 55% identical);
(3) SIP4 which is 35-42% identical to the other EDG receptors [Lynch and Im, 1999].
From phylogenetic analysis there are also other receptors that share some homology with
the SIP/LPA family [Hla et a l,  2001; Joost and Methner, 2002; Rosen and Liao, 2003; Parrill et 
al,  2004] as shown in Figure 1.7 and discussed in Section 1.5.9.
The LPA  group is about 35% identical to the SlPi, SIP2, SIP3 and SIP5 group. In 
addition, the LPA  group each contain an intron in the region of the gene encoding TM6 which is 
not present in the SIP  group [Contos and Chun, 1998]. The SIP /L P A  proteins also share partial 
homology with the cannabinoid receptor subfamily (<30%), indicative that SIP /L P A  proteins are 
lipid-selective receptors and also suggestive of a possible common ancestral gene [Lynch and 
Im, 1999].
SIP receptor involvement in Ca^  ^mobilisation has been recorded as far back as 1991, 
where SIP was shown to induce transient increases in intracellular free calcium [Zhang et al,  
1991]. Regulation of calcium levels by phospholipase C is depicted in Figure 1.14. SIP can 
mobilize calcium from internal sources either via an unidentified inositol 1,4,5-trisphosphate 
(/P3)-independent receptor on tire ER or by activation of SIP receptor that stimulate 
phospholipase C. Stimulation of SK also results in decreased sphingosine levels that normally
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block the store-operated calcium release-activated calcium current leading to refilling of the 
stores. [Spiegel and Milstien, 2002] (Figure 1.14).
The SIP/LPA proteins are integral membrane proteins that are glycosylated and are 
predicted to have seven transmembrane-spanning domains. However, each SIP or LPA receptor 
possesses distinguishing structural elements that have yet to be fully related to any aspects of 
ligand binding or signalling As an example, the substitution of alanine for proline in the usual 
seventh transmembrane NPXXY sequence of LPAz, which is conserved in the other SIP/LPA 
receptors and most GPCRs [Goetzl and An, 1998].
Furthermore, it has been observed that basic amino acids within SlPi, Arg^ ^® and Arg 
form ion pairs with the phosphate of SIP [Parrill et a l, 2000]. Also, the SIP receptors, SlPi, 
SIP2, SIP3, SIP4 and SIP5 all share an anionic residue corresponding to the Glu^ ^^  residue 
defined in SlPi to interact with the ammonium SIP moiety [Parrill et al, 2000]. In comparison, 
the LPA-specific receptors, LPAi, LPA% and LPA3 possess a neutral glutamine residue at the 
same position which may interact with the neutral hydroxyl gioup in LPA [Parrill et a l ,  2000].
The SIP3 C-terminal is unique amongst SIP receptors as it contains a putative class I SH3 
interaction motif domain (RASPIQP), which is important in tyrosine kinase signalling, as shown 
by investigations of the N-terminal of phosphodiesterase 4D4, [Beard et a l,  1999] and this will 
be discussed in detail in Section 1.5.15. The last three amino acids of the SIP2 C-terminal 
(TVV) correspond to a consensus PDZ domain interaction motif.
Recent findings have suggested a new role for SIP as a second messenger for platelet- 
derived growth factor (PDGF). The controversial mechanism put forward is that of signalling 
through SlPi-PDGF receptor cross-talk. Currently, there are two models proposed for this 
mechanism. One model is of sequential activation of the PDGF receptor succeeded by 
extracellular SIP production and activation of SlPi [Hobson et a l, 2001]. The integrative model 
suggests that the interaction of SI Pi with PDGF is physical, and shows that MAPK activation by 
PDGF requires SlPi but not SKI activity [Alderton et a l,  2001b; Waters et a l, 2003]. Each 
model is unsupported by the findings of the other but both do involve cross-talk between SI Pi 
and PDGF. To add to this, fresh input has been delivered to add further support to cross-talk in 
SIP receptors as SI Pi has been found to interact with VEGF to induce membrane ruffling [Endo 
et a l, 2002]. Also, SIP3 has been discovered to mediate cross-talk between SIP and PDGF, and 
Akt phosphorylation by Akl is potentiated by SIP3 [Baudhuin et a l,  2004] (Figure 1.15). 
Additionally, SIP and SKI have been found to be important components of the transforming 
growth factor p (TGFp) signalling pathway involved in up-regulation of the tissue inhibitor of
27
metalloproteinase-1 (TIMP-1) gene [Yamanaka et a l,  2004]. This transactivation of tyrosine 
kinase receptors by GPCRs shows a new level of regulation for SIP receptors and suggests new^  
directions for studies of important pathologies.
It has been suggested that one route to cross-signalling is receptor dimerization, which 
has been reported for SIP receptors in two studies [Salim et a l,  2002; Van Brooklyn et al,
2002]. Many effects requiring multiple SIP receptors may require dimerization, and possibly 
this assists in the formation of complexes with other receptor subtypes.
Respective signalling models for all five SIP receptors are shown in Figure 1 . 8  and will 
be discussed individually. General expression patterns for each receptor are shown in Table 1.2.
1.5.4 The SlPi Receptor
The SlPi receptor was the initial receptor to be cloned from the SIP family. It was 
originally identified as an early immediate gene product induced in phorbol ester-differentiated 
human umbilical vein endothelial cells (HUVECs) [Hla and Maciag, 1990]. SlPi expression is 
observed in most mammalian tissues with the highest expression found in skeletal structures 
undergoing ossification, in endothelial cells and is highly expressed in the white matter, 
hippocampus and the Purkinje cell layer of the cerebellum [Spiegel and Milstien, 2000a; 
Fukushima et a l,  2001; Chae et a l,  2004]. The SlPi receptor was the first EDG receptor 
identified with specificity for SIP, providing the impetus for the concept of SIP as an 
extracellular mediator [Lee, 1998b; Okamoto et a l,  1998; Zondag et a l,  1998]. SIP was also 
reported to act as a low-affinity receptor for LPA to induce SlPi phosphorylation [Lee, 1998a], 
although, a separate study using membranes of Sf9 cells co-expressing SI Pi and Giz failed to 
elicit any biological effects [Windh, 1999]. Other studies have not observed competition of 
[^^P]S1P binding by LPA [Van Brooklyn et a l , 1999]. Additionally, LPA did not function as an 
agonist for the murine analog of SlPi, IpBi, when transfected into RH7777 cells [Zhang et a l,
1999].
SlPi signalling is involved in cell migration, the formation of new blood vessels and 
vascular maturation [Pyne and Pyne, 2000b, a; Spiegel and Milstien, 2000a; Hla et a l,  2001]. A 
study using SlPi-expressing Sf9 cells has demonstrated that SI Pi activation by SIP results in the 
activation of a variety of G-protein family members, including Gu, Gz, Gs, Go and G% (Figure 
1 .8 ) but not Gg, Gq, Giz or G13 [Windh, 1999]. SI Pi signalling via a Gi/o-coupled mechanism has 
been demonstrated in a number of cell types, such as transfected CHO, HEL, Cos-7 and Sf9 
cells, and often results in extracellular signal-regulated kinase (ERK) activation and the 
inhibition of adenylyl cyclase (AC) activity [Okamoto et a l,  1998; Zondag et a l,  1998; Pyne 
and Pyne, 2000b]. SlPi activation also activates phosphoinositide 3-kinase (PI3K) via the
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heterotrimeric Gi protein, leading to the activation of the serine/threonine kinase Akt and 
phosphorylation of the Akt substrates, such as, endothelial nitric oxide synthase (eNOS), shown 
to be involved in endothelial cell chemotaxis [Igarashi and Michel, 2000; Igarashi, 2001; Lee et 
al,  2001; Morales-Ruiz et a l,  2001]. It has been shown that activation of sphingosine kinases 
and consequently the SIP receptors, SlPi and SIP2, by FcsRl triggering plays a crucial role in 
mast cell function and might be involved in the movement of mast cells to sites of inflammation 
[Jolly et a l,  2004].
SI Pi activation also regulates the activation state of small GTPases of the Rho family, 
specifically Rac and Rho, which are downstream of the heterotrimeric G-proteins and are 
involved in the regulation of cytoskeletal rearrangements [Hobson et a l,  2001; Lee et a l,  2001; 
Paik et a l, 2001]. It was shown that the SlPi-induced Gi- and PI3K-dependent activation of Akt 
leads to the phosphorylation of SlPi at Thr236 located within the third intracellular loop [Lee et 
al,  2001], This activates Rac, via m  unknown mechanism and the subsequent signalling 
pathways required for cortical actin assembly, lamellipodia formation and chemotaxis [Lee et al,  
2001]. In addition, HEK293 cells transfected with SlPi have also been shown to stimulate PTx- 
insensitive, Go/is-mediated Rho pathways that regulate morphogenesis, such as adherens 
junction assembly and induction of placental (P)-cadherin and epithelial (E)-cadherin expression 
[Lee, 1998b; Lee et al, 1999; Liu et a l,  2000]. hi contrast, it has recently been observed that 
SIP3 and SIP2, but not SlPi, mediate an increase in the amount of GTP-bound Rho in CHO cells 
[Takuwa et a l,  2001]. It is possible that as SlPi cannot couple to G12/13, the SlPi receptor- 
dependent activation of Rho must be through a different mechanism which has yet to be defined 
and which may also be dependent upon cell type. A recent study showed that SlPi, along with 
SIP3, regulates signalling pathways required for HUVEC morphogenesis into capillary-like 
networks [Lee et a l,  1999]. One possible mechanism of SlPi activation of Rho could be 
through a cross-talk mechanism with SIP3 . Interestingly, SI Pi has recently been shown to be 
involved in a cross-talk mechanism with the platelet-derived gro’wth factor (PDGF) receptor 
[Rakhit e ta l ,  2000; Hobson et al, 2001; Rosenfeldt n/., 2001; Spiegel e ta l,  2002; Waters et 
al,  2002; Pyne et a l,  2003] (see Figure 1.14). SI Pi is also involved in the control of 
lymphocyte egress and endothelial barrier function [Brinkmann et al, 2004].
1.5.5 The SIP2 Receptor
The SIP2 receptor is expressed widely, but is particularly enriched in the heart and lung 
but less so in the brain of the adult rat and mouse [Pyne and Pyne, 2000b, a; Fukushima et al, 
2001 ; Takuwa et a l , 2001 ; Payne et a l , 2002; Spiegel et a l , 2002]. However, the SIP2 receptor
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is more prominent in the brain during embryonic development, suggesting a role for SIP2- 
mediated signalling in neuronal development [MacLennan and Browe, 1994; Fukushima et al, 
2001]. SIP2 receptors couple to the Gi, Gq, G12 and G13 heterotrimeric G-proteins [An et al, 
1999; Ancellin and Hla, 1999; An et a l, 2000; Arikawa et a l,  2003; Meacci et a l,  2003a]. 
Research on CHO, HEL, Jurkat T and HTC4 hepatoma cell lines demonstrated that SIP2 
receptors are coupled to the stimulation of phospholipase C and Ca^  ^mobilisation via both PTx- 
sensitive and PTx-insensitive G-proteins, most likely Gi and Gq/u respectively [Okamoto et al, 
1998; An e ta l,  1999; Gondaef n/., 1999; Yjonetal, 1999], SIP2 along with SIP3 also mediates 
ERK/MAPK activation almost exclusively via Gi in CHO cells [Takuwa et a l,  2001]. In 
contrast, SIP2 was also observed to activate JNK and p38 MAPK in a PTx-insensitive manner 
[Gonda et a l,  1999]. A recent study demonstrated that SIP2 activation resulted in an increase in 
AC activity in CHO cells [Kon et al, 1999]. However, direct coupling of SIP2 to Gs was not 
observed in membranes of Sf9 cells [Windh, 1999]. It remains to be determined whether SIP2 is 
directly coupled via Gs to adenylate cyclase.
SIP2 and SIP3 also regulate the activity of small GTPases. Both SIP3 and SIP2 have 
been shown to activate Rho through a Gi2/j3-dependent mechanism, resulting in stress fibre 
formation, cell rounding, neurite and serum response element-driven transcriptional activation 
[Buhl et a l, 1995; Kozasa et a l,  1998; Pyne and Pyne, 2000b, a; Takuwa et a l, 2001]. 
Interestingly, a recent study using transfected CHO cells has shown that, whereas SI Pi and SIP3 
result in a PI3K-dependent activation of Rac, SIP2 inhibited Rac activation and subsequently 
membrane ruffling and cell migration [Okamoto et a l,  2000a]. The physiological significance of 
this observation is illustrated by the fact that SIP2 is expressed in cells in which SIP is an 
inhibitor of cell migration, such as melanoma cells and vascular smooth muscle cells [Okamoto 
et a l,  2000a]. Current research poses the question of whether SI Pi or SIP2 receptors that are 
present on mast cells are transactivated after IgE triggering and whether this is a critical event for 
mast cell activation [Jolly et a l,  2002].
Much work has been done in investigating the regulation of PLD by SIP2 in skeletal 
muscle derived C2C12 cells [Meacci et a l,  1999; Meacci et al, 2002; Bencini et a l,  2003; 
Meacci et al, 2003a; Meacci et a l,  2003b; Donati et al, 2005], where a role for PKC and 
calcium has been found m receptor-mediated activation of phospholipase D by SIP in C2C12 
cells [Meacci et al, 1999; Meacci et a l, 2002]. Additionally, down-reguiation of SIP2 during 
myogenic differentiation results in the specific uncoupling of SIP signalling to phospholipase D 
[Meacci et a l,  2003a]. SIP has effects on excitation-contraction coupling and signal 
transduction in mammalian skeletal muscle, and regulates myogenic differentiation, those
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providing a major role for SIP2 receptor [Bencini et al, 2003; Meacci et al, 2003b; Donati et 
a/., 2005],
Recently, it has been determined by observing the functions of SlPi, SIP2 and SIP3 in 
knockout mice that SIP2 knockout mice were viable but deaf. Histological analysis revealed the 
absence of spiral ganglion neurons in the cochlea of SIP2 knockout mice. This provided a new 
physiological function for the SIP receptor signaling system and provides evidence that SIP2 is 
essential for proper neuron development in the inner ear [Kono et al,  2004].
1.5.6 The SlPs Receptor
The proposed structure for SIP3 can be seen in a schematic plot, showing the 7TM 
regions and N- and C-terminal domains. Figure 1 .1 0 . The main biological roles of SIP3 are 
summarised in Figure 1.11 and a model of currently appreciated SIP3 signalling is provided in 
Figure 1.8.
In 1996, Yamaguchi discovered by cloning, the novel human GPCR SIP3 . The receptor 
was discovered by PCR using primers derived from cannabinoid type 1 receptor (CBl) 
sequences [Yamaguchi et a l, 1996]. A full length clone of SIP3 has been isolated through 
screening of a human genomic library [An et a l,  1997]. SIP3 is located at chromosome 9, in the 
human variant it consists of 378 amino acids (Figure 1.10) with a predicted mass of 42kd. An 
integral membrane protein, the SIP3 receptor shows expression in all tissues but most abundantly 
in the heart, placenta, lung, kidney and brain where the SIP2 receptor can also be found [Pyne 
and Pyne, 2000b, a; Spiegel and Milstien, 2000a; Fukushima era/., 2001; Takuwa isr a/., 2001]. 
SIP3 is highly homologous to human SI Pi (51.9% overall and 69.2% in 7-TM regions), and is a 
relatively hydrophobic membrane protein that consists of an extracellular N-terminal domain 
linked to a cytoplasmic C-terminal domain by seven transmembrane a-helices, see (Figure 1.10). 
SIP3 receptors also couple to the Gj, Gq, G12 and G13 heterotiimeric G-proteins [An e ta l ,  1998; 
Sato and Murata, 1998; An et a l, 1999; Ancellin and Hla, 1999] see (Figure 1.8). Consequently, 
it has been demonstrated in CHO cells, HER cells, Jurkat T cells and HTC4 hepatoma cells that 
SIP3 receptors are coupled to the stimulation of phospholipase C and Ca^  ^mobilisation via both 
PTx-sensitive and PTx-insensitive G-proteins, most likely Gi and Gq/n respectively [An et a l,  
1999; Gondaetn/., 1999; Kon cm/., 1999; Okamoto eta l,  2000a]. SIP3 and SIP2 also mediate 
ERK/MAPK activation almost exclusively via Gi in CHO cells [Sato, 1999; Takuwa et a l,  
2001]. SIP3 and SIP2 regulate the activity of small GTPases [Sugimoto et a l,  2003] as 
mentioned in Section 1.5.5.
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Expression of SIP3 and SIP2 produces a constitutive activation of G12 and G13 [Siehler 
and Manning, 2002], The function of Rho in SIP receptor signalling is not Mly defined 
[Sugimoto et a l,  2003]. For SIP3 and SIP2 receptors, coupling to G12/13 appears as the main 
route of Rho activation. Rho-dependent signalling is linked with cadherin/adherens expression, 
stimulation of focal adhesion kinase (FAK), and PLD. A recent study has shown that, in SIP3- 
CHO cells, increased expression of PLD 1 and PLD2 prevents actinomycin D-induced apoptosis 
by enhanced activation of the PI3K signalling pathways [Yamada et a l,  2004].
Mouse models have been generated which assess the fimctions of SIP3 in vivo. Targeted 
homozygous deletion of SIP3 was successfully performed and unlike SlPi there was no obvious 
phenotypic abnormality. The embryonic development, overall health, body weight, fertility and 
longevity upto 18 months of the KO mice did not significantly differ from normal mice. This 
suggests that the other SIP receptors, which were not significantly affected by SIP3 knock out, 
can compensate for its deletion [Ishii et a l, 2001]. Another study further supports this 
assumption, it went on to investigate the effects of double and triple receptor knockouts and 
found that in combination, although triple knockouts (SIP1-3) were most deleterious, the 
combination of SlPi and SIP2 was significantly more fatal than SlPi together with SIP3 [Kono 
e ta l,  2004]
In the case of tumour angiogenesis, the enzyme membrane type 1-matrix 
metalloproteinase (MTl-MMP) has been shown to induce migration and morphogenic 
differentiation, which involves the cooperation of the enzyme with platelet-derived bioactive 
lipids through S IP-mediated activation of SI Pi and SIP3 . This may provide an important 
molecular link between hemostasis and angiogenesis [Langlois et a l,  2004]. It has been shown 
that in SIP3-CHO cells, increased expression of PLDs prevents ActD-induced apoptosis by 
enhanced activation of the PI3K signalling pathways [Yamada et al, 2004],
One investigation of a SIP3 peptide derived from 9 amino acids of the SIP3 second 
intracellular loop has identified KRX725 as a mimic for the effects of SIP. It was found that this 
peptide could stimulate extensive angiogenesis in the form of vascular sprouting in rat aortic 
rings [Licht et a l,  2003]. This suggests that KRX-725 could act as a therapeutic agent for 
treatments of vascular disorders where angiogenesis is beneficial, for example, peripheral 
vascular disease, myocardial ischemia, tissue grafts and diabetic wound healing, with the benefit 
of being able to design KRX-725 to degrade slowly and act locally in comparison to SIP [Licht 
e ta l,  2003].
Of particular relevance to this thesis, the C-terminal domain of SIP3 contains a unique 
regulatory element which is not significantly similai* to any other known GPCR. SIP3 contains a
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proline-rich sequence that conforms to a consensus SH3 (Src homology 3) domain binding 
motif. SH3 domains are compact globular structures found in many proteins that have important 
signalling functions which will be discussed at length in Section 1.5.15.
1.5.7 The SIP4  and SlPs Receptoi’s
The SIP4 and SIP5 receptors represent the most recently identified and therefore the most 
poorly characterised SIP receptors. SIP4 exhibits the most restricted expression pattern of all 
the SIP receptors, being expressed primarily in lymphoid and haematopoietic tissues [Graeler et 
al,  1998]. as well as the lung [Fukushima et al, 2 0 0 1 ; Takuwa et al, 2 0 0 1 ]. The SIP4 receptor 
has been shown to mediate SIP-induced PLC activation, intracellulai" Ca^  ^ mobilisation and 
ERK/MAPK activation, all of which are blocked by PTx-treatment [Fukushima et a l,  2001]. 
Thus, SIP4 couples to G, and possibly G12/13 [Siehler and Manning, 2002]. SIP4 also regulates 
cell shape and motility via coupling to G, and G12/13 [Graeler et a l,  2003]. A single amino acid 
glutamic acid residue, Glu present in the TM3 of SIP receptors was shown to be important 
for the selective recognition of SIP, versus the closely related lipid LPA [Holdsworth et al., 
2004]. This study also provided the evidence that the SIP4 receptor ligmid binding pocket is 
shorter in length than the SlPi ligand binding pocket [Holdsworth et al, 2004].
The SIP4 receptor has been shown to be expressed in human monocytes and 
macrophages [Duong et a l,  2004]. Although SIP4 receptors are expressed similarly to LPA 
receptors in human monocytic cells, stimulation of the LPAi receptor was found to be the 
receptor critical for monocyte activation through LPA, mm-LDL and serum [Fueller et al,
2003]. Murine CD4^ and CD8^ T cells express SlPi and SIP4 predominantly yet T cell receptor- 
mediated activation of CD4^ T cells suppresses expression of the two SIP receptors and 
eliminates their chemotactic function in mouse splenic T cells [Graeler and Goetzl, 2002]. SIP 
has been identified as a novel inhibitor of T-cell proliferation, and PM A plus ionomycin or anti- 
CD3 plus anti-CD28 down-regulated the expression of SIP4 and up-regulated the expression of 
SIP5 in T cells 3 days after stimulation. [Jin et a l, 2003]. Phytosphingosine 1-phosphate has 
been shown to be a high aftinity ligand for the SIP4 receptor, with greater affinity for SlP4 than 
even SIP [Candelore et a l ,  2002]. The immunosuppressant FTY720 also binds and dovm 
regulates SIP4 [Graeler and Goetzl, 2004].
The SIP5 receptor is expressed in a variety of tissue type, it is highly expressed in the 
human brain, specifically in white matter, spleen [Graeler and Goetzl, 2002], corpus collosum, 
peripheral blood leukocytes and arteries, placenta, lung, aorta and fetal tissues [Im et a l,  2000; 
Fukushima era/., 2001; Im e ta l,  2001; Takuwa etn/., 2001]. In contrast to SIP4, SIP5 does not 
appear to be expressed in human monoQdes and macrophages [Duong e ta l ,  2004]. SIP5 is also
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expressed in rat neural progenitor cells [Tham et a l, 2003], and rat microglia, where the level of 
expression depends on the activation state of the cells [Harada et a l , 2004], also rat astrocytes 
have been found to express SIP5 but expression is less than the majority of the other members of 
the SIP/LPA family [Rao et a l,  2003]. SIP5 has been shown to couple to Gi/o and G12 but not Gs 
or Gq/11 [Im et al, 2000; Malek et a l,  2001] (Figure 1.8). In a recent study using CHO cells 
transfected with SIP5, SIP treatment resulted in a PTx-sensitive inhibition of forskolin-induced 
cAMP accumulation and a PTx-insensitive activation of JNK and inhibition of serum-induced 
activation of ERKl/2 [Malek et a l,  2001]. The inhibitory effect of SIP on ERKl/2 activity was 
abolished by treatment with orthovanadate, suggesting the involvement of a tyrosine phosphatase 
[Malek et al, 2001]. Intrinsic inhibition of unstimulated adenylyl cyclase or ERK activity by the 
SIP5 receptor is apparently insensitive to ligand modulation [Niedernberg et a l,  2003a]. 
Notably, it has been revealed that rat SIP5 in CHO-Kl cells displays antiproliferative effects and 
this is not seen in the human SIP5 transfected in HEK293 cells, and this may represent a a 
celltype or species-specific effect [Niedernberg et al, 2002]. The human SIP5 receptor is 
overexpressed in the lymphoproliferative disorder, large granular lymphocyte (LGL) leukaemia 
[Kothapalli, 2002].
1.5.8 The LPA Receptors
The chemical structure of the agonist lysophosphatidic acid can be seen in Figure 1.5. 
The current relation of LPA and SIP receptors is clearly represented in the phylogenetic tree in 
Figure 1.7. There are four identified LPA receptors in mammals [Anliker and Chun, 2004b]. A 
distinct gene encodes each receptor that activates downstream signaling pathways mediated by 
one or more G proteins. The first three, LPA1-3 , share sequence homology with one another, 
whereas LPA4 is divergent in sequence. LPAi represents the first LP receptor identified. LPAi is 
widely expressed outside the nervous system and is expressed prominently in testis and intestine 
[Contos et a l , 2000; Pyne and Pyne, 2000b; Fukushima et a l , 2001 ; Takuwa et a l , 2001]. LPAi 
is also prevalent in the myelinating cells of the adult nervous system where LPA promotes the 
Gi-mediated PI3K/Akt-dependent survival of myelinated Schwann cells from the peripheral 
nervous system [Weiner and Chun, 1999]. In addition, LPAi is also expressed in several 
cancers, suggesting a pathological role for receptor-mediated LPA signalling [Furui et a l , 1999]. 
LPAi couples to Gi/o, which leads to cell proliferation and also couples to G12/13 to activate Rho 
[Weiner and Chun, 1999; Igarashi and Michel, 2000; Fukushima et al, 2001; Hla et a l ,  2001]. 
LPAi contains 364 amino acids in a seven-transmembrane receptor structure, with an apparent 
molecular mass of 42 kDa. Gene expression is most marked in the ovaries but is also observed at 
lower levels in several other tissues.. In mice, a multi-exon gene structure was reported, with the
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coding region characterized by conservation of a single intron sepaiating two coding regions at 
the sixth transmembrane domain. This intronic structure is shared with LPA2 and LPA3 [Anliker 
and Chun, 2004a, b]. LPA2 is a high-affmity LPA receptor that activates the Gq pathway [Contos 
et al, 2 0 0 0 ; Fukushima et a l,  2001]. LPA2 is constitutively expressed in CD4^ T cells and 
inhibits the secretion of interleukin- 2  (IL-2) [Hla et al, 2 0 0 1 ]. LPA2 couples to G; and Gq, which 
mediates LPA-induced PLC activation and leads to intracellular Ca^  ^ increases and inositol 
phosphate production [Contos et a l, 2000; Fukushima et al, 2001; Hla et al, 2001]. LPA2 
receptor expression is strongly induced in ovarian cancer cell lines where it regulates the 
transcription of immediate-early genes and cellular proliferation [Goetzl et a l,  1999]. LPA3 is 
abundantly expressed in testis, heart and frontal regions of the cerebral cortex [Contos et al, 
2000; Contos and Chun, 2001; Fukushima et a l, 2001; Toman and Spiegel, 2002]. Studies of 
LPA3 function within mammalian and insect cell lines have demonstrated an LPA-dependent, 
PTx-insensitive increase in PLC activity and intracellular Ca^  ^ concentration, suggesting that 
LPA3 is coupled primarily to Gq [Contos and Chun, 2001; Fukushimaer al,  2001]. LPA3 differs 
from the previous two LPA receptors by not coupling to G12/13 and showing a preference for LPA 
molecules with unsaturated acyl chains. Although still expressed in many adult tissues, LPA3 
shows somewhat more restricted expression. Its signalling properties are generally similar to 
LPAi and LPA2 except for AC-related effects that vary with respect to analyzed cell lines 
[Anliker and Chun, 2004b]. Recently, the p2y9/GPR23 receptor has been identified as the fourth 
LPA receptor (LPA4), with likely evolutionary distinct ancestors [Noguchi et a l,  2003]. 
Biological roles, null mutations, and the relationship of LPA4 to the other LPA receptors have not 
been reported [Anliker and Chun, 2004b]. The biological roles of LPA receptors in different 
systems are summaiised in Figure 1 11.
1.5.9 Novel GPCRs with homology to SIP and LPA receptors
hi addition to the agonist selectivity that is shared between SIP and LPA receptors, 
several other receptors have been found that are activated by members of the lysophopholipid 
family (Figure 1.7) [Kostenis, 2004]. A recent review focused on the assignment of lipid 
mediators to GPCRs that include GPR3, GPR6 , GPR12, GPR23, GPR40, GPR41, GPR43, 
GPR63, TG1019 (also known as R527), and BG37 (also known as TGR5). These GPRs were 
recently identified as receptors for intercellular lipid messengers such as, SIP, SPC, 
dioleoylphosphatidic acid (doPA), LPA, free fatty acids, eicosatetraenoic acid, and bile acids [Im, 
2004]. The author advises caution to the likelihood of the authenticity of these GPCRs as LP 
receptors as many of the studies were not carried out methodically, therefore binding studies are 
either lacking or unsupported by parallel studies which deems them inconclusive [Im, 2004].
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The novel LP receptors include the ovarian cancer GPCRl (OGRl) receptor (also 
GPR68 receptor) that is activated by sphingosylphosphorylcholine (SPC) [Xu et a l,  2000], the 
GPR4 receptor which is a receptor that displays high affinity for SPC and low affinity for 
lysophosphatidylcholine (LPC), and shares -50% homology with OGRl [Zhu et al, 2001] and 
homology with the cannabinoid receptors CBl and CB2 [Felder and Glass, 1998]. LPC is ahigh- 
affinity ligand for G2A, a lymphocyte-expressed GPCR whose genetic ablation results in the 
development of autoimmunity. Activation of G2A by LPC has been seen to increase intracellular 
calcium concentration, induce receptor internalization, activate ERK, and modify migratory 
responses of Jurkat T lymphocytes. These findings implicated a role for LPC-G2A interaction in 
the etiology of inflammatory autoimmune disease and atherosclerosis [Kabarowski et a l,  2001]. 
PSP24, is an orphan receptor that has been proposed to bind LPA but not in mammaliam tissues 
[Kawasawa et a l, 2000]. The orphan GPCRs, GPR3, GPR6 and GPR12 were recently identified 
as SIP receptors [Uhlenbrock et a l,  2002; Ignatov et a l,  2003]. The receptor encoded by 
GPR45 is the mammalian orthologue of a putative LPA receptor îïom Xenopus laevis, expressed 
in the central nervous system and periphery [Marchese et al, 1999]. SIP and doPA have been 
identified as low affinity agonists for the orphan receptor GPR63 [Niedernberg et al,  2003b]. 
GPR65 (T cell death associated gene, TDAG8) shares evolutionary homology to OGRl and 
GPR4 yet its agonist is proposed to be psychosine (galactosyl sphingosine) [Murakami et al,
2004]. Agonist and antagonist binding for SIP and LPA receptors has been reviewed in terms of 
development of receptor-specific ligands. [Parrill et al, 2004].
1.5.10 The involvement of SlPi and SIP3 receptoi^ in angiogenesis
Among the most important of their biological roles, SlPi and SIP3 act as regulators in the 
process of angiogenesis. Angiogenesis can be defined as the formation of new blood vessels 
from pre-existing vessels. A process that constitutes an integral component in numerous 
physiological events, from embiyonic development to wound healing [Yatomi et al, 1995; 
Vogler et a l,  2003] and the menstrual cycle, each requiring new blood vessel formation to 
simultaneously supply oxygen and nutrients and remove waste products [Carmeliet and Jain,
2000]. Angiogenesis is also critical in several pathological conditions associated with blood 
vessel formation. As an example, angiogenesis in excess has been linked to solid and 
haematologic tumour progression [Dvorak, 1986], chronic inflammation as presented in 
rheumatoid arthritis and in Crohn’s disease, endometriosis and diabetic retinopathy [Griffioen 
and Molema, 2000; Summers and Nelson, 2005].
The SIP effect on blood vessel formation was attributed to it promoting migratory 
activities of angioblasts and early endothelial cells required for the expansion of vascular
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networks [Lee, 2000]. Findings suggest that migratory events critical to the de novo formation of 
blood vessels are under the influence of SIP, possibly synthesized via the action of sphingosine 
kinase 2 (SK2), with signaling mediated by SIP receptors that include SI Pi, SIP2, and SIP3 
[Argraves et a l,  2004]. These three receptors play important roles in carefully regulating several 
overlapping pathways, as findings from mouse embryonic fibroblast cells have confirmed 
[Anliker and Chun, 2004a] (Figure 1.9).
SIP has been shown to act synergistically with FGF and VEGF in promoting 
angiogenesis [Lee et a l,  1999]. Recent evidence suggests that SIP-dependent activation of 
SI Pi, along with SIP3, results in the Rho-activation of integrin Oyps and pi-containing integrins, 
leading to the formation of initial focal contacts required for cell spreading and migration [Paik 
et a l,  2001]. a^ps has also been shown to function in a synergistic manner with VEGF in the 
processes of cell migration and proliferation [Soldi et a l,  1999]. Recently, SIP3 was shown for 
the first time to interact with PDGF as well as showing a role for SIP3 in SIP-induced Akt 
activation [Baudhuine/a/., 2004] (Figure 1.15).
1.5.11 SIP1 Involvement in the Cardiovascular System
A general scheme of the roles of SIP3 in biological systems, including the car diovascular 
system is shown in Figure 1.11. SIP3 is involved in morphogenesis is the process of newly 
formed neovasculature remodelling into capillary-like networks which occurs after endothelial 
cell proliferation [Lee et a l,  1999; Griffioen and Molema, 2000; Cross and Claesson-Welsh,
2001], and which involves the folding of epithelial cell sheets into tubes and other structures. 
Morphogenesis is typically regulated via connection sites for actin filaments known as adherens 
junctions [Akhtar and Hotchin, 2001]. Cell-matrix adherens junctions allow cells to grip the 
extracellular matrix, and various forms of cell-to-cell adherens junctions exist. In non-epithelial 
tissues, cell-to-cell adherens junctions are small punctate/streak-like attachments that connect 
actin filaments in the cortical cytoplasm of adjacent cells [Evers et a l,  2000; Griffioen and 
Molema, 2000]. In epithelial sheets, cell-to-cell adherens junctions are a continuous adhesion 
belt termed the zonula adherens, that exists for each of the interacting cells in the sheet and is 
located near the cell apex [Evers et a l,  2000]. Adhesion belts in adjacent epithelial cells are 
directly opposed and the interacting PMs are held together by transmembrane linker proteins that 
are members of the family of Ca^^-dependent cell-cell adhesion molecules called cadherins 
[Evers et al, 2000].
The family of cadherins consists of around 12 members, including vascular" endothelial 
(VE)-cadherin, found in the vascular endothelium; E-cadherin, found in epithelial cells; N-
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cadherin, found in nerve, muscle and lens cells and P-cadherin, found in placenta and epidermal 
cells [Sumpio et a l, 2002].
Cells contain a contractible bundle of actin filaments adjacent to the adhesion belt and 
running parallel to the PM that are attached via a set of intracellular attachment proteins; a-, p-, 
and y-catenin, vinculin, a-actinin and plakaglobin [Griffioen and Molema, 2000; Jones et al,  
2001; Brinkmann et a l,  2004]. Cadherins and attachment proteins link actin bundles in adjacent 
cells resulting in an extensive transcellular network. Contraction of this network mediates 
morphogenesis, which can be seen in Figure 1.13.
The development of HUVECs into capillary-like networks has been observed via S IP  
treatment in HUVECs where activation of SI Pi and SIP3 receptors further activated Rac- and 
Rho-dependent adherens junction assembly and cytoskeletal rearrangement, culminating in 
morphogenesis. [Lee et a l ,  1999]. Notably, the action of SIP  contrasts with the action of VEGF, 
which is known to disrupt adherens junctions [Lee et al, 1999; Hla et al, 2001]. S IP  
stimulation of SIP  1 and SIP3 receptors expressed in HUVECs results in the activation of ttyps- 
and pi-containing integiins [Clark and Brugge, 1995; Paik et a l, 2001]. In addition to regulating 
cell spreading and migration, antagonists of ayP3 and pi-containing integrins inhibited S IP -  
induced endothelial cell morphogenesis in a three-dimensional fibrin matrix [Paik e ta l,  2001].
1.5.12 Maturation and preservation of vasculature
After formation of the neovasculature, endothelial cells deposit a new basement 
membrane and recruit surrounding vessel layers composed of mural cells, such as pericytes in 
small vessels and smooth muscle cells in large vessels [Griffioen and Molema, 2000; Saaristo et 
a l,  2000; Richard et a l,  2001]. Mural cell recruitment is largely dependent upon PDGF 
synthesis and secretion within endothelial cells [Griffioen and Molema, 2000; Cross and 
Claesson-Welsh, 2001]. Once contact is made between endothelial cell and mural cell, a latent 
form of transforming growth factor-p (TGF-p), which is produced by both endothelium and 
mural cells is activated in a plasmin-mediated process [Griffioen and Molema, 2000]. TGF- 
P activation induces changes in myofibroblasts and pericytes, leading to the formation of a 
quiescent vessel, ECM production and maintenance of growth control [Griffioen and Molema,
2000].
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) and the receptor tyrosine kinases 
Tiel and Tie2 are essential for the communication of endothelial cells with the surrounding 
mesencyme [Lin, 1997; Griffioen and Molema, 2000; Jones et a l,  2001]. The function of Tiel 
is associated with endothelial cell differentiation and establishing blood vessel integrity whilst
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Tie2 is necessary for vascular network formation and is only expressed on endothelial cells 
[Jones et a l, 2001]. Ang-1 and Ang-2 are Tie2-specific ligands that activate or antagonize Tie2 
signalling respectively [Davis et a l, 1996; Maisonpierre et a l, 1997; Jones et a l, 2001]. 
Endothelial cells failed to associate properly with underlying support cells in the vessels of 
embryos lacking Tie2 or Angl, which demonstrated that Tie2 signalling may facilitate 
recruitment of, and tight association with, adjacent periendothelial cells [Suri e ta l, 1996; Patan, 
1998]. Persistent Tie2 expression and its phosphorylation in quiescent adult endothelium implies 
a role for Tie2 in transducing a sustained survival signal [Wong et a l, 1997; Jones et a l , 2001]. 
In human glioblastomas, a cell-specific up-regulation of Tie2, Ang-1 and Ang-2 during tumour 
progression was detected in a pattern compatible with a role in tumour-induced angiogenesis 
[Stratmann et a l, 1998; Griffioen and Molema, 2000].
SI Pi knockout mice have shovm that SI Pi is essential for vascular maturation as SI Pi 
gene disruption resulted in impaired vascular maturation due to the failure of mural cells to 
migrate to arteries and capillaries to reinforce them [Liu et a l, 2000; Kono et a l, 2004]. 
Although SlPi-null embryos died in utero due to massive haemorrhage, they exhibited normal 
vasculogenesis and a substantially normal blood vessel network, yet were severely impaired in 
the recruitment of smooth muscle cells and pericytes to the vessel walls and this was attributed to 
their defective migration [Liu et a l, 2000]. Extracellular SIP can directly stimulate SlPi on 
vascular smooth muscle cells (VSMCs), facilitating their migration to vessel walls or, 
alternatively, can stimulate SlPi expressed in endothelial cells that in turn may recruit VSMCs 
[Liu et a l, 2000]. Recent studies have demonstrated that the effect of SI Pi on vascular 
maturation can be largely attributed to the cross-talk between SlPi and PDGF receptor signalling 
mentioned previously [Hobson et a l, 2001; Rosenfeldt et a l, 2001]. Cell migration toward 
PDGF, which stimulates sphingosine kinase and increases intracellular SIP, was shown to be 
dependent upon SI Pi expression in a number of cell types, including HEK293 cells, human 
aortic smooth muscle cells (ASMCs) and mouse embryonic fibroblasts (MEFs) [Hobson et a l,
2001]. It was therefore suggested that spatially and temporally localised generation of SIP by 
activation of sphingosine kinase in response to PDGF results in restricted activation of SIP that 
in turn activates Rac, resulting in an increase in cell motility [Hobson et a l, 2001]. A recent 
study has subsequently demonstrated that the PDGF-induced cytoskeletal rearrangements, 
lamellipodia extensions and cell motility are abrogated in SlPi null fibroblasts [Rosenfeldt et a l,
2001]. Also, PDGF-induced focal adhesion formation and activation of FAK, Src and SAPK2 
were disregulated in the absence of SlPi [Rosenfeldt et a l, 2001]. However, SI Pi was not 
involved in mitogenicity and survival effects induced by SIP or PDGF [Rosenfeldt et a l, 2001].
39
Hence, it was suggested that SlPi acted as an integrator linking the PDGFR to lamellipodia 
extension and cell migration. Cells then migrate towards PDGF, enhancing PDGF receptor 
signalling and therefore acting as a positive feedback mechanism [Hobson et a l, 2001; 
Rosenfeldt e ta l, 2001].
1.5.13 Functions of SlPr i^ii Inflammation and Immunology
Both SIP and LPA receptors appear to have important roles in immunology [Payne et a l, 
2004; Radefif-Huang et a l, 2004], (Figure 1.11). Results from a recent study show differential 
effects of SIP on polyclonal T-cell proliferation and cytokine secretion [Jin et a l, 2003]. Local 
administration of SIP caused inflammation coupled to a large eosinophil (EO) recruitment in rat- 
paw tissue. The inflammatory response was accompanied by an increase in SlPi, SIP2 and SIP3 
and by an enhanced expression of CCR3, which is the main chemokine receptor known to be 
involved in EO function. Human EOs constitutively express SI Pi and, to a lower extent, SIP2 
and SIP3 receptors. SIP in vitro causes cultured human EO migration and an increase in SIP 
receptor mRNA and strongly up-regulates CCR3 and RANTES (Regulated on Activation, 
Normal T cell-Expressed and Secreted) message levels. A blocking anti-CCR3 Ab inhibited 
SIP-induced chemotaxis, implying that SIP acts as a specific recruiting signal for EOs not only 
through its own receptors but also through CCR3. These results suggest that SIP is involved in 
EO chemotaxis and helps to unravel the complexity underlying EO recruitment in several 
diseases such as asthma and some malignancies [Roviezzo e ta l, 2004].
Asthma and chronic obstructive pulmonary disease (COPD), are chronic diseases 
affecting millions of people worldwide and are characterized by airway obstruction, airway 
inflammation, and alterations in structural cell function. The role of structural cells such as 
airway smooth muscle (ASM), myofibroblasts, and fibroblasts was thought to be maintenance of 
bronchial w£Ül integrity, but evidence suggests that these cells may be integral components of the 
inflammatory response as well [Panettieri, 2004]. Asthma is a complex condition where 
exposure to environmental antigens induces inflammatory reactions in the airway characterized 
by activation of mast cells and eosinophils. Mast cells are known to be the main effector cells in 
eliciting IgE-mediated allergic response. These cells secrete various substances that sustain 
inflammation and provoke airway smooth muscle (ASM) contraction. In another study, it was 
shown that SIP may regulate human airway smooth muscle cell (HASM) contractility, which is 
important in the pathobiology of asthma [Ammit et a l, 2001; Rosenfeldt et a l, 2003]. A newly 
recognized addition to the range of FcsRI-mediated signaling events is the activation of SK 
leading to the generation SIP from sphingosine. Lung secretions of SIP significantly increase
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after challenge with an allergen, thus adding SIP to the variety of mediators that are released 
during an allergic reaction [Ammit et a l, 2001]. Previous reports also agreed that FcsRI cross- 
linking was not only found to increase cellular levels of SIP, it also markedly entranced its 
secretion from rat basophilic leukemia RBL-2H3 cells. Moreover, SIP can induce the 
degranulation of RBL and bone marrow derived mast cells (BMMCs) cells as deteimined by the 
release of hexosaminidase. Treatment of BMMCs with the SK inhibitors, DL-threo- 
dihydrosphingosine and dimethylsphingosine, reduced IgE/Ag stimulated histamine release. RT- 
PCR analysis demonstrated that mast cells express SIP receptors SI Pi and SIP2 but not SIP3 , 
SIP4 or SIP5 transcripts. Further studies would determine whether IgE triggering results in 
transactivation of SlPi or SIP2 present on mast cells and whether this is a critical event for mast 
cell activation [Jolly e ta l, 2002].
SIP influences heart rate, coronary artery calibre, endothelial integrity, and lymphocyte 
recirculation through SIP1-5. Inhibition of lymphocyte recirculation by non-selective SIP 
receptor agonists produces clinical immunosuppression preventing transplant rejection and is 
associated with transient bradycardia [Sanna et a l, 2004]. Knowledge of individual receptor 
contribution has been limited by the embryonic lethality of the SlPi knock-out and the 
unavailability of selective agonists or antagonists. A potent, SlPi-receptor selective agonist, 
SEW2871, structurally unrelated to SIP, has been discovered that activates multiple signals 
triggered by SIP, including guanosine 5'-3-0-(thio)triphosphate binding, calcium flux, Akt and 
ERKl/2 phosphorylation, and stimulation of migration of SlPi- but not SlPs-expressing cells in 
vitro. The agonist also altered lymphocyte trafficking in vivo. Use of a selective agonist together 
with mice lacking SIP3 receptor revealed that agonism of SI Pi alone is sufficient to control 
lymphocyte recirculation. Moreover, SI Pi agonist plasma levels were causally associated with 
induction and maintenance of lymphopenia [Sanna et a l, 2004]. SIP3, and not SlPi, is directly 
implicated in sinus bradycardia. The sustained bradycardia induced by SIP receptor non- 
selective immunosuppressive agonists in wild-type mice is abolished in SlPs'^' mice, whereas a 
SlPi-selective agonist does not produce bradycardia Separation of receptor subtype usage for 
control of lymphocyte recirculation and heart rate may allow the identification of selective 
immunosuppressive SlPi receptor agonists with an enhanced therapeutic window. SlPi-selective 
agonists will have future uses in understanding cell functions in vitro, and vascular physiology in 
vivo [Sanna et a l , 2004].
The novel immunomodulator FTY720 is effective in experimental models of 
transplantation and autoimmunity, and is currently undergoing Phase III clinical trials for
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prevention of kidney graft rejection [Budde, 2002]. FTY720 is a structural analogue of 
sphingosine-1-phosphate (SIP) and activates all SIP receptors except SIP2 [Forrest et al., 2004]. 
FTY720 has been shown to induce endothelium-dependent arterial vasodilation in phenylephrine 
precontracted mouse aortae. Vasodilation did not occur in thoracic aortic rings from eNOS- 
deficient mice, implicating an effect dependent on activation of the eNOS/NO pathway. Thus, 
FTY720 induced NO release, Akt-dependent eNOS phosphorylation and activation in human 
endothelial cells [Tolle et a l, 2005]. For biological efficacy, FTY720 required endogenous 
phosphorylation, since addition of the SK antagonist N',N-dimethylsphingosine (DMS) 
prevented activation of eNOS in vitro and inhibited vasodilation in isolated arteries. The 
endothelial phosphoiylation of FTY720 was extremely rapid with also most complete conversion 
after 10 minutes as determined by mass spectrometry [Toile et a l, 2005]. SIP3 was identified as 
the SIP receptor responsible for arterial vasodilation by FTY720, as the effect was completely 
abolished in arteries from SlPs-deficient mice [Tolle et a l, 2005]. In summary, FTY720 is the 
first immunomodulator for prevention of organ graft rejection in clinical development that, in 
addition, positively affects the endothelium by stimulating NO production, and thus potentially 
displaying beneficial effects on transplant survival beyond classical T cell immunosuppression, 
[Tollee ta l, 2005].
1.5.14 SIP  ^involvement with HDL
Atherosclerosis is a chronic inflammatoiy disease, with lipoproteins, vascular endothelial 
cells, monocytes, macrophages, smooth muscle cells, activated T lymphocytes, and platelets all 
interacting through adhesion molecules, cytokines, chemokmes, and prothrombotic factor 
[Yuhanna et a l, 2001]. Naturally, as SI  P3 has been associated with many of these components it 
seems likely that its involvement in inflammatory diseases is of therapeutic importance. 
Recently, HDL-induced endothelial cell migration and survival were thought to mediated by the 
lipoprotein component SI P and the lipid receptors SlPi and SIP3 [Kimura et a l, 2003].
HDLs are complex molecules known to induce a multitude of intracellular signals for 
which different components of HDL have been made responsible. The lysophospholipid 
concentrations effective in inducing vasodilation are likely to be provided in vivo by plasma 
HDL. Img of HDL contains 287 ± 17 pmol SIP and 290 ± 20 pmol SPC, which represents 
0.58nM of these bioactive phospholipids together. HDL-induced endothelial cell migration and 
survival may be mediated by the lipoprotein component SIP and the lipid receptors SlPi and 
SIP3 [Kimura et a l, 2003]. It was shown that HDL stimulates release of nitric oxide (NO) in 
human endothelial cells and induces vasodilation in isolated aortae via intracellular Ca^  ^
mobilization and Akt-mediated eNOS phosphorylation [Nofer et a l, 2004]. The vasoactive
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effects of HDL could be mimicked by three lysophospholipids present in HDL; SPC, SIP, and 
lysosulfatide (LSF). All three elevated intracellular Ca^  ^ concentration and activated Akt and 
eNOS, which resulted in NO release and vasodilation [Nofer et a l, 2004]. SIP3 deficiency 
abolished the vasodilatory effects of SPC, SIP, and LSF and reduced HDL effects by 
approximately 60%. In endothelial cells from SlPs-deficientmice, Akt phosphorylation and Ca^  ^
rises in response to HDL and LPs were severely reduced. In vivo, intra-arterial administration of 
HDL or LPs lowered mean arterial blood pressure in rats. Thus, HDL has been identified as a 
carrier of bioactive LPs that regulate vascular tone via SlPs-mediated NO release. This 
mechanism may contribute to the vasoactive effect of HDL and represent a novel aspect of its 
antiatherogenic function [Nofer et a l, 2004]. In vivo the SIP3 receptor would encounter the 
whole HDL paiticle with its total load of LPs, resulting in a much higher biologically active 
concentration at the single receptor level compared with LPs in solution, and it is likely that 
several of the LPs contained in HDL would work together to achieve vasodilation [Nofer et a l, 
2004].
Angiogenesis and promotion of endothelial cell survival have been shown to depend on 
the activation of Akt. Recently, SIP was demonstrated to induce Akt activation, eNOS 
phosphorylation, and NO production in endothelial cells [Lee et al., 2001]. Both SIP and SPC 
interact with several LP receptors such as SlPi. SIP3 , and SIP5, which are all expressed in 
endothelial cells. The effects of HDL and HDL-associated LP on Akt activation, eNOS 
activation, and NO release in HUVECs were inhibited by PTX, suggesting the involvement of a 
PTX-sensitive G  protein in vitro [Nofer et a l, 2004]. In isolated aortic segments, the 
vasodilatory effects of SPC, LSF, and SIP were completely abrogated in aortae from SIP3- 
deficient animals, suggesting that this particular LP receptor completely mediates the 
vasodilatory effect of all three compounds. As the increase in [Ca^ ]^, and Akt phosphorylation 
were either completely abolished (SIP and LSF) or substantially reduced (SPC), both major 
mechanisms of eNOS activation appear to be mediated by SIP3. This is in agreement wiüi two 
other studies that have implicated SIP3 in Akt activation and NO production. The failure of SIP 
to increase [Ca^ ]^; and activate Pl-specific phospholipase C, another target of HDL-triggered 
intracellular signalling, has been reported previously for SlPs-deficient MEFs [Nofer et a l, 
2004]. Thus, it is suggested that the specific element of the vasodilatory effect of HDL that was 
lost in SlPs-deficient animals (-50%) is attributable to its SPC, SIP, and LSF content acting via 
the SIP3 receptor. Importantly, the vasoconstrictive effect was independent of SIP3 , as it was 
not different between aortae from WT and SIP3 knockout animals. The further augmentation of 
vasoconstriction by SIP in precontracted aortae from SlPf^~ or eNOS~^ ~ mice suggested that SIP
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has a dual action; it contracts arteries under basal conditions (but not via SIP3) and mediates 
vasodilation {via SIP3) in the case of increased arterial tone, with mediation by at least two 
different pathways; one impacting on endothelial cells and another on VSMCs. These effects 
may differ among different vascular beds [Nofer et a l, 2004].
In contrast to the complete loss of eNOS activation by lysophospholipids in SIP3- 
deficient animals, the vasodilatory response to HDL, although substantially inhibited (by -60%), 
was not completely abrogated. Other HDL-mediated effects, besides resulting in eNOS and/or 
Akt activation, may account for the remaining paid of HDL-induced eNOS dependent 
vasodilation. It has been shown that HDL-induced eNOS activation is critically dependent on the 
binding of HDL to the scavenger receptor, class B, type I (SR-BI), and that Src, Akt, and MAPK 
signaling via SR-BI contribute to eNOS activation [Yuhanna et a l, 2001] (Figure 1.13). 
However, it was reported that the major SR-BI protein ligand of HDL, apoAI, failed to activate 
eNOS, while an antibody against the cytoplasmic C-terminus of SR-BI inhibited the ability of 
SR-BI to stimulate eNOS [Nofer et a l , 2004]. LPs are amphipathic molecules, and their ability 
to diffuse freely between HDL and the cell surface may be limited. Therefore, the interaction of 
HDL with SR-BI could provide the appropriate proximity for SPC, SIP, and LSF to effectively 
stimulate SIP3 . However, it is important to note that the data neither exclude direct activation of 
SIP3 via LPs within the HDL complex nor indirect mechanisms of SIP production/ release, 
which could also activate SIP3 [Nofer et a l, 2004].
In contrast to studies suggesting a role for Akt in eNOS activation by HDL, it was 
recently described that HDL bound to SR-BI stimulated eNOS via an increase in intracellular 
ceramide without an increase of [Ca^ ]^; or Akt activation [Li et a l, 2005]. Interestingly, recent 
findings suggest that plasma membrane estrogen receptors activate eNOS via Akt and that they 
are biologically coupled to eNOS through Gai [Shaul and Mineo, 2004]. This has led to the 
suggestion that cross-talk exists between estrogen receptors and a GPCR that signals via Gai 
[Nofer et a l, 2004]. An excellent candidate emerging from recent data would be the SIP3 
receptor. The observation that SIP3 acts as a functional HDL receptor and that LPs mediate an 
important part of its vasodilatory effect raises exciting questions about the role of LP receptors in 
the antiatherogenic activity exerted by HDL. Several potentially antiatherogenic effects have 
been ascribed to LP receptor signaling in vitro such as preservation of endothelial cell integrity, 
induction of endothelial cell migration, and eNOS activation [van der Giet and Tolle, 2004]. 
Information on LP receptor regulation and function in human atherosclerosis and in animal 
models of the disease is sparse, nor are there many studies on the LP content of HDL in patients 
with atherosclerosis or coronary artery disease, these studies may help elucidate the role of LPs
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receptors in HDL-mediated atheroprotection and reveal new methods to prevent and treat clinical 
atherosclerosis [Nofer et a l, 2004]. Unravelling the mechanisms of lipid mediator binding to 
and release from HDL will hopefully provide novel targets for antiatherogenic therapeutics. 
Vasodilatory potency of HDL may vary considerably among the population depending on age, 
sex and concomitant disease. As currently available drugs are not efficient in raising plasma 
HDL levels, modulating the vasoactive properties of HDL might be a new way to combat 
atherosclerosis [van der Giet and Tolle, 2004].
HDL is an independent risk factor in cardiovascular disease, and raising HDL levels alone 
results in a significant risk reduction of major caidiovascular events in patients with coronary 
disease whose primary lipid abnoiTnality was a low HDL cholesterol level. However, the 
mechanisms by which HDL exerts its powerful protective effects are still not clear. Among its 
numerous potential antiatherogenic effects, HDL cholesterol levels are directly associated with 
flow-mediated vasodilation in clinical patients in vivo [O'Connell and Genest, 2001]. Recently, 
intravenous administration of reconstituted HDL was shown to acutely restore abnormal 
endothelial function in the brachial artery of hypercholesterolemic patients. Evidence is provided 
that intravenous administration of HDL acutely stimulates myocardial perfusion in vivo in the 
murine heart via eNOS activation, and the HDL component sphingosine 1-phosphate (SIP)  and 
its receptor SIP3 have been identified as functional opponents of this effect [Levkau et a l , 2004]. 
It is extremely complex to compare the effects of S IP  in vitro and in vivo, especially because 
SIP  is recognized to induce both vasoconstriction and vasodilation in different settings. To detect 
the vasodilative effect of SIP, a study raised mean arterial blood pressure initially by infusion of 
endothelin. In isolated arteries, S I P  also had opposing effects dependent on the initial arterial 
tone, whereas S IP  had a vasodilative effect on arteries precontracted with phenylephrine, its 
effect on native, noncontracted arteries was exactly the opposite. This biological behavior of SIP  
resembles the action of vasodilators such as diadenosine polyphosphates and suggests that it has 
a dual function. S IP  contracts arteries under basal conditions, whereas it dilates arteries with 
increased arterial tone. Although S IP  is a physiological component of HDL and can 
substantially reduce myocardial perfusion it does not appear from the results of this particulai" 
investigation to diminish the stimulatory effect of HDL on perfusion because no further increase 
in perfusion by HDL in SlPf^~ mice was observed [Levkau et a l , 2004].
1.5.15 SH3 domain interactions in receptor signalling
Interaction domains such as the SH2, SH3 and PDZ binding domains control a broad 
range of cellular functions, including signal transduction, cytoskeletal architecture, protein
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trafficking, gene expression, chromatin organization, organelle biogenesis, cell polarity and 
regulated proteolysis [Bladt e ta l, 2003], as has already been exemplified in Section 1.5.14.
The Src cytoplasmic tyrosine kinase in its natural state is a peripheral membrane protein 
that contains an SH3 domain, an SH2 domain, a tyrosine kinase domain and a short C-terminal 
tail. In its autoinhibited state, c-Src becomes phosphorylated by c-Src kinase at a tyrosine 
residue within the tail. From this ensues an intramolecular interaction with the SH2 domain, 
which moves the SH3 domain to associate with the SH2-kinase linker region. Shaped like this, 
the activity of the kinase domain is repressed, though the inhibition can be lifted by breaking the 
contacts via dephosphorylation of the C-terminal tail, or by binding of a high-affinity ligand to 
either the SH2 or SH3 domain. Once activated, the SH3 and SH2 domains are liberated to bind 
cytoplasmic targets with appropriate motifs, and the kinase domain is activated to phosphorylate 
such binding partners [Mayer, 2001].
As an example of the interplay between various domains the Grb2 adaptor protein, which 
possesses a central SH2 flanked by two SH3 domains, can be seen to associate with several 
motifs. The SH2 domain binds phosphorylated motifs with the sequence pTyr-X-Asn, found in 
activated tyrosine kinases and docking proteins. The N-termmal SH3 domain binds proline-rich 
motifs in the C-terminal tail of Sos, a GEF for Ras GTPase. The C-terminal SH3 domain binds a 
scaffolding protein, Gabl, wliich in turn activates the PI3-kinase, generating PI-3,4 ,5 -P3 at the 
plasma membrane. PIP3 provides a docking site for the PH domains of the serine/threonine 
kinases PKB/Akt and PDKl, which collaborate to activate signalling pathways involved in cell 
survival and cell cycle control [Bladt et a l, 2003].
It has been demonstrated that of the five known isoenzymes generated by the 
phosphodiesterase 4D gene (PDE4D), the brain specific PDE4D4 form can interact with certain 
SH3 domains expressed as GST fusion proteins. A screen of SH3 fusion proteins revealed 
selective interaction with certain Src family tyrosyl kinases SH3 domains. It has been suggested 
that this may indicate a tendency of this isoenzyme to interact with specific SH3 domain- 
containing proteins [Beard et a l, 1999]. Due to the relative importance of these interaction 
domains in signal transduction it is useful to identify potential sites of interest within the SIP3 
receptor, and examine how they exert their role in SIP signalling. As mentioned previously, the 
SIP3 receptor has an SH3 binding motif domain present within its C-terminal (Figure 1.10). The 
RASPIQP fragment was chosen for investigation of its protein-protein interactions using both the 
yeast 2 hybrid system and fusion protein methodologies. This will be discussed in further detail 
in Chapter 5.
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1.6 Yeast Double Hybrid System Analysis
Usual tools available for the analysis of protein-protein interactions in multicellular 
organisms have been restricted to biochemical methods employing physical means of detection. 
Most familiar is the use of acrylamide gels, but also affinity chromatography, affinity blotting, 
immunprecipitation and cross-linking are available. Protein-protein interactions are intrinsic to 
nearly eveiy cellular process, all DNA related processes from replication through to translation, 
to secretion, control of cell cycle, stages of metabolism, formation of enzymatic complexes and 
the manifestation of cellular macrostructures [Bartel and Fields, 1997; Milligan and White, 
2001]. Complex interactions of proteins result in the formation of cytoskeleton, nuclear scaffold 
and the mitotic spindle. Protein-protein interactions seem to play crucial roles in the formation of 
comparatively smaller structures such as nuclear pores, centiosomes and kinetochores. As well 
as a vast structui'al requirement fulfilled by protein-protein interactions, many cellular processes 
are also controlled and regulated by transient protein-protein interactions. Enzymes interact only 
transiently with their substrates. Many enzymes can modify an array of proteins that cover 
fundamental processes like cell growth, cell cycle, metabolic pathways and signal transduction. 
Extremely large complexes also mediate many of these enzymatic activities. In many signal 
transduction pathways, catalytic activities involved, such as protein kinases, may bind strongly to 
their protein susbstrates. Structural proteins required for signal transmission have been 
suggested to act as scaffolds, bridging several proteins involved at consecutive steps in a protein 
structures through which a signal is being transmitted. Alterations in these interactions 
contributes to diseases. There is cause then for manipulation of these important interactions as 
potential therapeutic strategy. The Two-Hybrid System is a molecular genetic tool which 
facilitates the study of protein-protein interactions. The protein under investigation is called the 
bait. The protein caught with the bait is the prey. This is interaction is facilitiated by using a 
cDNA library in a special vector so that the yeast translates the gene cloned as a cDNA as a 
firsion with part of a Gal4 (the ôern-galactosidase gene) protein. The intact Gal4 protein is a 
transcriptional activator which has two separate functions (a DNA-binding domain and an 
activating domain). If the bmt and prey proteins interact, then a reporter gene e.g. Gall-lacZ, is 
transcriptionally activated, and a colour reaction on specific media is observed. This can be used 
to study the interaction between two proteins which are expected to interact and/or as a means of 
cloning a gene encoding a protein which interacts with a protein for which the gene is already 
available [Bartel and Fields, 1997].
The specificity, selectivity and duration of GPCR signaling are optimized by the 
scaffolding of functional multi-protein complexes associated with receptor C-terminal tails.
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A lthou^ the C-terminal tails of GPCRs have been readily accepted for the fine-tuning of G 
protein activation, their roles as bait to find GPCR-associated proteins have only recently been 
established [Bockaert et a l, 2003]. Interestingly, many GPCR splice varimits differ in their C- 
termini, for example, e i^ t  C-terminal splice variants have been described for the 5 -HT4 receptor 
[Bockaert et a l, 2004], and four C-terminus splice variants exist for mGluRl [Fagni et a l, 
2000], and prostaglandin EP3 receptors [Hatae et a l, 2002], variants of which bind to different 
intracellular scaffolding/signaling molecules that specify their transduction signals [Bockaert et 
a/., 2003].
Many studies use the yeast two hybrid system and GST fusion assays in tandem to 
provide supporting evidence for physiological interactions of proteins, rather than artificial 
interactions due to proximity.
1.6.1 GST Fusion Studies
The study of protein interactions using GST fusion proteins was first performed between 
the human (32-adrenoceptor and the a-subunit of its cognate G protein Gs. The fusion protein was 
produced by ligating together cDNAs encoding both proteins. The results from this study 
suggested that agonist occupation of the fusion protein resulted in the activation of AC and 
elevation in potency was suggested to reflect a covalent link between the receptor and the G- 
protein, which causes more efficient coupling between partner proteins [Milligan, 2000]. GST 
fusion proteins are unique tools for explorative pharmacology as they allow investigation of 
ligand efficacy, the contribution of post translational modifications to GPCRs and G-proteins to 
agonist function and the quantitative effects of point mutations in GPCRs and G proteins on the 
affinity of their interactions and transfer of information between the proteins [Milligan, 2000]. 
The benefit of GST fusions is that the stoichiometry of expression in the two proteins is always 
1:1 and is not dependent on the cell system used. The fusion approach, if analysed at the 
appropriate interaction should ensure directly comparable agonist-binding affinity and E C 5 0  for 
G-protein activation. Tliis approach supports investigations of the relationship between ligand 
binding and receptor activation [Milligan, 2000].
A study using both the GST fusion strategy and the yeast two hybrid system identified 
endophilin 1/2/3 as novel binding partners for (BlARs. This study suggest that interaction 
between proline-rich motifs and SH3-containing proteins may represent a previously 
underappreciated aspect of G-protein coupled receptor signaling [Tang et a l, 1999]. More on 
GST fusion studies will be discussed in Chapter 5.
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1.7 The Study of GPCR Cell Surface Distribution and Agonist-Induced Internalisation 
Using Green Fluorescent Protein (GFP)
Classical approaches to studying GPCR internalisation include radioligand binding, 
physical fractionation techniques and immunoflurescence [Kallal and Benovic, 2000]. However, 
the recent application of green fluorescent protein (GFP) as a tool in the study of agonist-induced 
GPCR internalisation has proved invaluable [Drmota ef a/., 1998; McLeane/a/., 1999; Milligan, 
1999; Kallal and Benovic, 2000; Sarvazyan et a l, 2002]. The gene encoding GFP was originally 
isolated from the jellyfish Aequorea Victoria in 1992 [Prasher et a l, 1992; Inouye and Tsuji, 
1994].
GFP is an autofluorescent protein of 238 amino acids that emits green l i^ t  with an 
emission maximum of 509nm upon fluorscent excitation at 488nm derived from either standard 
fluorescence microscope light sources or fluorescein isothiocyanate (FITC) excitation and 
emission filters [Tsien, 1998]. The use of GFP in the study of receptor internalisation has been 
used for a variety of GPCRs, including the cholecystokinin CCKl receptor, (32AR, thyrotropin- 
releasing hormone TRHl receptor and the vasopressin V2 receptor [Tarasova et a l, 1997; 
Drmotae/a/., 1998; Schulein era/., 1998; McLean era/., 1999].
There are a number of advantages gained from using GFP [Milligan, 1999; Kallal and 
Benovic, 2000]. Since there are no cofactors or substrates required for fluorescence, the time 
and expense of using primary and secondary antibodies on fixed cells can be avoided. GFP- 
expressing cells can also be studied on living cells in real time so that the dynamics of protein 
trafficking can be observed. Cells expressing GFP can also be fixed, as GFP is relatively 
chemically resistant. Also, since GFP is covalently attached to the protein of interest, non­
specific fluorescence is avoided. One of the major disadvantages of using GFP is that the 
expression of GPCR-GFP chimeras in cells results in the labelling of protein biosynthetic 
compartments, such as the endoplasmic reticulum and Golgi, which can influence the 
interpretation of results [Kallal and Benovic, 2000].
Many examples of GFP-tagging of GPCRs, such as the |32AR and TRHl receptor, have 
shown that the addition of GFP has no effect on the receptors’ ability to bind ligand and that the 
ability to generate second messengers and to desensitise was unaffected [Tarasova et a l,  1997; 
Drmota et a l, 1998; Schulein et a l, 1998; McLean et a l, 1999]. However, GFP-tagging m ^  
result in altered properties of the receptor. Hence, careful experimental comparisons to untagged 
proteins should be made prior to visualisation studies using confocal microscopy.
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1.8 Aims
The aim of this PhD is to characterise the phosphorylation, internalisation and 
desensitisation of the sphingosine 1 -phosphate receptor, SIP3. Due to the distinct differences 
that exist amongst GPCRs in relation to the processes of receptor phosphorylation and 
internalisation a basis for studying the regulation of SIP3 can be taken from the most well 
characterised examples of GPCR phosphorylation and internalisation, the pzAR. Alongside this 
line of investigation a Yeast Two Hybrid Technique will be employed to examine any potential 
protein-protein interactions that may be unique to the SIP3 receptor.
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Figure 1.1: Comparison of predicted structure for bovine rhodopsin with the x-rav crystal 
structure.
A comparison of the predicted structure for bovine rhodopsin (green) with the x-ray crystal 
structure (blue). The TM regions have an rms deviation in alpha carbon coordinates (CRMS) of
3.1 A. Taken from [Vaidehi e ta l,  2002]
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Figure 1.2: GPCRs are allosteric proteins that can adopt various conformations in 
equilibrium.
Contrary to the inactive state (R), the active state can interact with G proteins to initiate response. 
These active conformations occur either spontaneously (R*), leading to constitutive activity of 
GPCRs, or tlirough ligand binding (LR*). The competition between LR* and R* for the G proteins 
leads to agonism, neutral antagonism, or inverse agonism. Taken from [Gbahou et a l, 2003].
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Figm-e 1.3: Stmcture of G-protein. showing the location of each subunit including the 
By complex.
gg = geranylgeranyl (on y-subunit) stable, 
p = palmitate (on a-subunit) labile.
SI, SII and SIII show the switch sites.
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Figure 1.4: Relationship of G-Proteiii subfamilies;
A phylogenetic tree showing the sequence homology of each member of the four Ga-protein 
subfamilies.
These include:
Gas stimulates adenylate cyclase 
Gooif stimulates adenylate cyclase 
Gan undefined 
Gai2 inhibits adenylate cyclase 
Gan regulates channels 
Gtto regulates Ca^  ^channels
Gan transducin 1, activates cGMP phosphodiesterase
Gat2 transducin 2, activates cGMP phosphodiesterase
Ga% undefined
Gais regulates phospholipase C
Gai6 regulates phospholipase C
Gai4 regulates phospholipase C
Gan regulates phospholipase Cyl
Gaq regulates phospholipase C
Gai2 activates small G-proteins, such as Rac and Rho
Gai3 activates small G-proteins, such as Rac and Rho
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Figure 1.5: SIP and LPA Stmcture
A: Signaling functions of the substrate and product of the SK reaction. SKs using ATP as the 
phosphate donor, catalyze the phosphorylation of D-e/j/Ziw-sphingosine to produce SIP. Several 
downstream targets and potential functions of both sphingosine and SIP are indicated. PKC, 
protein kinase C; ICRAC, calcium release-activated calcium current.
Image taken from [Spiegel and Milstien, 2002].
B: LPA; l-acyl-2-5'/2-glycerol-3-phosphate is a naturally occurring LP that activate diverse 
cellular actions on many cell types. It is also an intermediate in de novo biosynthesis of membrane 
phospholipids. Although all cells contain small amounts of LPA associated with membrane 
biosynthesis, some cellular sources can produce significant amounts of extracellular LPA such as 
activated platelets, which account for the LPA found in serum [Contos et a l , 2000]. LPA is shown 
here with SIP and SPC to compare structures.
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Figure 1.6: Sphingolipid synthesis* turnover and functions.
The term sphingolipid generally refers to any of an array of lipids consisting of a head group 
attached to the 1-OH of ceramide (Cer). Cer consist of a sphingoid base, usually referred to as a 
long chain base (LCB), which is JV-acylated. De novo synthesis of LCBs begins with condensation 
of the palmitoyl Co A and serine, forming 3-ketosphinganine. This product is then reduced to 
sphinganine, also known as dihydrosphingosine (dihydro-Sph; 2-amino-l, 3 -dihydroxy- 
octadecane). A 14-26 carbon fatty acid chain is then added in an amide linkage with the 2-amino 
group, forming dihydro ceramide (dihydro-Cer). A head group, such as phosphocholine or a 
carbohydrate, can now be added to the 1-OH, forming a SL, although most SLs of higher 
eukaryotes contain further modifications of the LCB. In mammalian cells, dihydro-Cer usually has 
a 4,5-trans double bond introduced, forming Cer. The corresponding LCBs are referred to as 
sphingosine (Sph, also called sphingenine) and phyto-Sph, respectively. The term ceramides 
refers to A-acylated LCB species in general, while Cer will be used to designate JV-acyl Sph. The 
most common LCBs are Sph, dihydro-Sph and phyto-Sph, although there are reports of other 
modifications, including additional double bonds, other hydroxylations, 3-O-acetyl, méthylations, 
and even 3-ketosphinganine as the LCB of some glycosphingolipids. Metabolism of SLs is a 
constitutive process, with removal of the head group yielding Cer. In mammalian cells, 
ceramidases hydrolyze the N-acyl chains, leaving the LCBs, most commonly Sph. Sph can be 
phosphorylated on the primary hydroxyl by SKs (SKI or SK2), forming SIP. SIP then can be 
cleaved by SIP lyase. dihydro-Sph and phyto-Sph can also be phosphorylated and degraded in 
this manner. Although degradation of SIP by SIP lyase is irreversible, SIP can be converted 
back to Sph by specific SIP phosphohydrolases (SPPs), and Sph can be re-acylated to Cer by Cer 
synthases. Thus, dihydro-Sph can be synthesized de novo, but Sph can only arise from 
metabolism of SLs.
Adapted from [Maceyka et a l, 2005], adapted from [Le Stunff et a l, 2002].
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Figure 1,7: Phylogenetic tree of selected human G protein-coupled receptors.
The values show branch lengths that represent the evolutionary distance between each pair of 
sequences. The sequence divergence is equal to the sum of each value of branch length. Taken 
from [Kostenis, 2004].
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Figure 1.8; Model signalling systems for the SIP receptors
Five signalling models showing the coupling pathways of the different SIP receptors.
A: SlPi couples only to Gi, making all its effects PTX-sensitive. The arrow from Akt to the 
receptor indicates phosphorylation (p) of the receptor by Akt.
B: SIP3 -
SIP3 and SIP2 couple to Gi, Gq, and G13. The thick arrows show the predominant 
pathway regulating Rac. While SIP3 activates Rac, SIP2 inhibits it.
C: SIP2 -
D: SIP 4 couples to Gi and G13. It also activates adenylate cyclase (AC) through an unknown 
mechanism.
E: SIP 5 couples to G12 and Gi It inhibits ERK and activates INK in a PTX-insensitive manner 
Image taken from [Taha et a l, 2004].
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Figui-e 1.9; A comparison of SIP and LPA receptor signalling in mouse embryonic 
fibroblasts (MEFs).
A: Intracellular signalling efiFects of SIP through SlPi_3 receptors. Whether SlPi mediates 
activation of Rac in MEFs is presently controversial. Weak activation of signalling molecules by 
distinct receptors are indicated by dashed arrows. AC, adenylyl cyclase; cAMP, cyclic adenosine 
monophosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-triphosphate; JNK, c-Jun N-terminal 
kinase; PKC, protein kinase C; PLC, phospholipase C; Rock, Rho-associated kinase.
B: LPAr and LPA2-mediated effects on signaling molecules.
Image taken from [Anliker and Chun, 2004a].
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Figui^ 1.10: Schematic plot of SIF  ^receptor
A schematic diagram of the SIP3 receptor adapted from Visuer 
http ://www. gpcr. org/7 tm/ seq/diagrams_tGRAP/EDG3 _HUMAN-rb dg.html showing the 
conformation of the receptor within the plasma membrane. Residues denoted by a white circle 
show regions that have been previously investigated by other researchers in the field. The missing 
residues are listed as follows:
A:  ^ATALPPLQPU RGNETLREHY QYUGKLAGRL KEA 
B: LTMIKM
C: PDCST
D: LVKSSSRKVA NHN
E: CRV
F: TLAS KEMRRAFFRL VCNCLVRGRG ARASPIQPAL DPSRSKSSSS NNSSHSPKVK
EDLPHTAPSS CIMDKNAALQ NGIF N
A synthetic peptide MRPYDANKR derived from residues along the second intracellular loop 
listed in B were shown to induce a pro-angiogenic signal by S IP3 [Licht et a l , 2003].
Residues denoted by F were the residues used in this research to study the effects of the C- 
terminal tail. RASPIQP represents the SH3 interacting domain motif.
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Figure 1.11: Biological roles of IvsophosDholipids in different systems
Receptor-mediated cellular responses to LPA and SIP, such as survival, proliferation, and 
migration, exhibit biological significance particularly within the nervous system, the 
cardiovascular system, the immune system, and the female reproductive system. Indicated are 
physiological and pathophysiological functions of LPA and SIP and the involved receptors. IL-2, 
interleukin-2; OCCs, ovarian cancer cells; SCs, Schwann cells; VEC, vascular endothelial cells; 
VSMCs, vascular smooth muscle cells; HDL, high density lipoprotein. Taken fi-om [Anliker and 
Chun, 2004].
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Figure 1.12; HDL-induced eNOS activation via presentation of SIP to SlPa
A model for HDL-induced eNOS activation and vasodilation by the lysophospholipid receptor 
SIP3 . PI-PLC, phosphatidylinositol-specific phospholipase C. A-I, apolipoprotein A-I; N and C, 
amino- and carboxyl terminus of the Scavenger Receptor Class B, Type I (SR-BI). Adapted from 
[Nofer et a l, 2004] to include FTY720 which requires endogenous phosphorylation to effect 
arterial vasodilation via SIP3 . FTY720 is currently in clinical trials as the first immunomo dulator 
for prevention of organ graft rejection in clinical development that, in addition, positively affects 
the endothelium by stimulating NO production, and thus potentially displaying beneficial effects 
on transplant survival beyond classical T cell immunosuppression [Tolle et a l, 2005].
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Figure 1.13; Presei’vation of vascular integrity bv FTY720-P.
In endothelial cells (EC), FTY720-P induces translocation of vascular endothelial cadherin (VE- 
cadherin) and P-catenin to the focal contact sites between the cells, thereby promoting adherens 
junction assembly. The ci-, P- and T-catenins connect to the intracellular cortical actin ring of the 
cytoskeleton and this process stabilizes the endothelium and enhances endothelial barrier function. 
Similar effects are induced by SIP, suggesting that FTY720-P may not internalize but rather 
signal its target receptors in EC; the signaling may involve SI Pi and/or SIP3 . Image taken from 
[Brinkmann et a l, 2004].
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Figure 1.14; Model for receptor tvrosine kinase transactivation of SIP receptors.
The scheme depicts cross-communication between a tyrosine kinase growth factor receptor, 
PDGFR, and SIP receptors. Binding of PDGF to PDGFR results in activation and translocation 
of SK to the plasma membrane and generation of SIP is restricted.
A; SIP then activates SIP receptors leading to recruitment and/or activation of downstream 
signalling molecules, including Src, FAK, and Rac, which are important for cell migration.
B: Other dovmstream signalling, such as phospholipase C that regulates calcium levels is 
depicted. SIP can mobilize calcium from internal sources either via an unidentified inositol 
1,4,5-trisphosphate (/Psj-independent receptor on the ER or by activation of SIP receptors that 
stimulate phospholipase C. Stimulation of SK also results in decreased sphingosine levels that 
normally block the store-operated calcium release-activated calcium current leading to refilling 
of the stores. DAG = diacylglycerol. [Spiegel and Milstien, 2002].
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Figure 1.15: Cross talk of S lP i and PPGF and also SlPi and PDGF: Integrative and 
Sequential models
A schematic diagram of different types of interactions between SIP receptors and PDGFR. The 
left panel shows a “sequential” model which has been proposed for the SlPi receptor and PDGF 
[Hobson et a l, 2001; Rosenfeldt et a l, 2001]. The middle panel illustrates the proposed 
“integrative” model put forward, also SlPi and PDGF [Alderton et a l, 2001b; Waters et a l, 
2002]. The right panel shows SlPs-mediated Akt activation and crosstalk with PDGF which can 
be compared to the crosstalk of SI Pi with PDGF.
Image taken from [Baudhuin et a l, 2004].
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Figure 1.16: Membrane domains classified by différent lipid compositions
Membrane domains classified by different lipid compositions. Diagram of membrane depicting a 
caveolar and noncaveolar raft enriched in (glyco)sphingolipids and cholesterol, and flanked by 
semiordered lipid domains that border minimally ordered (nonraft) membrane areas. Adapted 
from [Hoekstia e /a/., 2003].
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Figure 1.17: GPCR Receptor Signalling and the role of B-arrestins
The role of 6-arrestins in the desensitization, sequestration and intracellular trafficking of GPCRs.
(1) Homologous desensitization of GPCRs results from the binding of b-arrestins (b-arr) to 
agonist-occupied receptors following phosphorylation of the receptor by GRKs. b-arrestin binding 
sterically precludes coupling between the receptor and heterotrimeric G proteins, leading to 
termination of signaling by G proteins effectors. Receptor-bound b-arrestins also act as adapter 
proteins, binding to components of the clathrin endocytic machinery including clathrin, b2-adaptin 
(AP-2).
(2) Receptor sequestration reflects the dynamin (Dyn)-dependent endocytosis of GPCRs via 
clathrin-coated pits. Once internalized, GPCRs exhibit two distinct patterns of b-arrestin 
interaction. ' Class A' GPCRs, for example the b2 adrenergic receptor, rapidly dissociate from b- 
arrestin upon internalization. These receptors are trafficked to an acidified endosomal 
compartment, wherein the ligand is dissociated and the receptor dephosphorylated by a GPCR- 
specific protein phosphatase PP2A isoform, and subsequently,
(3) Recycling to the plasma membrane and down-regulation. ' Class B' receptors, for example the 
angiotensin II ATI a receptor, form stable receptor-b-arrestin complexes. These receptors 
accumulate in endocytic vesicles and are either targeted for degradation or slowly recycled to the 
membrane via as yet poorly defined routes.
Adapted from [Lefkowitz, 1998].
Adapted from Biocarta.com image.
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Table 1.1: Nomenclature of SIP Receptors. Past and Present.
Internationally agreed nomenclature [Chun et a l, 2002].
EDG Nomenclature SIP/LPA Nomenclature
E D G l S lP i
ED G 2 LPAi
ED G 3 SIP3
ED G 4 LPA2
ED G 5 SIP2
EDG 6 SIP4
ED G 7 LPA3
EDG8 SIP5
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Table 1.2: Characteristics of SIP receptors
SIP receptors and the G-proteins they couple with.
Receptor Coupled G“proteins Expression pattern
SlPi/EDG-1 G,/o Widely expressed
SIP2/EDG- 5 Gi/oGq/12/13 Widely expressed
SIP3/EDG- 3 Gi/oGq/12/13 Widely expressed
SIP4/EDG- 6 Gi/0 Lymphoid tissues
SIP5/EDG- 8 Gi/oGq/12 Brain, spleen
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CHAPTER 2 
Materials and Methods
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2.1 Materials
All reagents used were of the highest grade commercially available and obtained from the 
following suppliers;
Amersham Pharmacia Biotech, Buckinghamshire, UK
Glutathione-Sepharose beads. Rainbow High Molecular Weight Range protein markers (14300- 
220000Da)
Alexis Corporation, San Diego, CA, USA 
Dithiothreitol
Beckman Coulter, Buckinghamshire, UK
4ml Ultra-Cleai tubes
BDH Chemicals Ltd., Poole, UK
Glass coverslips
Clontech, Palo Alto, CA, USA
Caveolin-1 mouse IgGl, 5-bromo-4-chloro-3-indolyl-a-D-galactopyranoside (X-a-Gal), Y187 
library, pGBKT7 vector, pGAD GH vector, pGAD Cl, AH109, Yeast Nitrogen-Base, Lysozyme 
Calbiochem-Novabiochem (UK) Ltd., Nottingham, UK 
Forskolin, SIP
Costar, Cambridge, MA, USA
75cm^ tissue culture flasks, 60mm and 100mm tissue culture dishes, 6-, 12-, and 24-well tissue 
culture plates, cryovinls
Fisher Scientific, Loughborough, Leicestershire, UK
HEPES, sodium dodecyl sulphate (SDS), EDTA, DMSO, (w/v) ethidium bromide solution, 
glacial acetic acid, methanol, ethanol, concentrated Hydrochloric acid, sodium fluoride, sodium 
phosphate
GIBCO BRL Life Technologies, Paisley, UK
Phenol:chloroform:isoamyl alcohol (w/v). LipofectAMINE, newborn calf serum, OptiMEM, 
phosphate-free Dulbecco’s Modified Eagle’s Medium (PF-DMEM)
Interactiva, Germany, Cruachem, Glasgmv, UK 
Oligonucleotides
Melford, Chelsworth, Ipsich, Suffolk, UK 
Kanamycin
Merck, Darmstadt, Germany
Bactotryptone, agar
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Molecular Probes Europe, AA Leiden, The Netherlands
Alexa™ 594-conjugated goat anti-mouse IgG
New England Biolabs Inc., Beverley, MA, USA
Ikb DNA Ladder, lOObp DNA ladder, restriction enzymes
NENLife Science I^oducts Inc., Boston
ECL reagents, ^^P-orthophosphate, autoradiography film
Novagen, CN Bioscience Inc., La Jolla, CA, USA
Gene Juice transfection reagent
Pierce Warmer, Rockford, IL 61105, USA
EZ-Link™ Biotin-LC-hydrazide, HRP-streptavidin
Protnega, Southampton, UK
T4 DNA Ligase, Promega™ Wizaid Plus SV miniprep kit, G-418 sulphate, restriction enzymes
Qiagen, Crawly, West Sussex
QIAquick Gel extraction kit, plasmid maxi kit
Roche Molecular Biochemicals/Boehringer-Mannheim, Mannheim, Germany 
Tris, DNA molecular weight marker, restriction enzymes 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA
Anti-GFP rabbit polyclonal IgG, Anti-lKBp antibodies, anti-p-Arrestin-2, anti-p-Arrestin 1 
Schleicher & Schuell, Inc., Keene, NH, USA 
Nitrocellulose membrane
Sigma-Aldrich Comany Ltd., Poole, Dorset, UK
Triton X-100, soybean trypsin inhibitor, benzamidine, pepstatin A, IgG-free bovine serum 
albumin, fatty acid-ffee bovine serum albumin (BSA), protein A-Sepharose, protein G- 
Sepharose, sodium periodate, 30%/0.8% (w/v) acrylamide/bisacrylamide solution, HRP- 
conjugated goat anti-rabbit IgG, HRP-conjugated goat anti-mouse IgG, rabbit anti-mouse IgG 
bridging antibody, thimerosal, bromophenol blue, bichinchonic acid, sodium azide, agarose, 
deoxycholic acid, ammonium hydroxide, isobutyric acid, ampicillin, paraformaldehyde, 
N,N,N’,N’-tetramethylethylenediamine (TEMED), phenylmethylsulphonylfiuoride (PMSF), 8- 
bromo-cGMP, Ham’s F-12 medium, Dulbecco’s Modified Eagle’s Medium (DMEM), 
phosphate-buffered saline (PBS) (sterile), foetal bovine serum (FBS), trypsin, 
penicillin/streptomycin, L-glutamine, sucrose, zymolase, amino acids 
Stratagene, N. Torr^Pines Rd, La Jolla, CA 92037-1073 
Pfu Turbo DNA polymerase
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Tocris/Semat Technical (UK) Ltd, St. Albans, Herts., UK 
A23187
Upstate Ltd, Milton Keynes, UK 
Anti-GRK2/3 monoclonal antibodies
Ascites containing 9E10 monoclonal antibody specific to the myc-epitope, Glu, Gin, Lys, Leu, 
He, Ser, Glu, Glu, Asp, Leu, was prepared in-house at Duke University, Durham, NC by Dr Tim 
Palmer.
Purified recombinant bovine GRK2 and GRK5 from SB cells Immol phosphate/min/rag using 
light activated rhodopsin as a substrate, provided by Jeffrey L.Benovic, Kimmel Cancer Centre, 
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia 
PA19107. pCMV5 expression constructs encoding bovine GRK2 and GRK5 were generated 
following subcloning of the open reading frames from pBC12BEGRK2 and pBC12BEGRK5 
expression constructs donated by Prof. Benovic.
The human SIP3 cDNA in pcDNA3 was the generous gift of Dr. Alan Wise (GlaxoSmithKline, 
Stevenage, U.K.).
Sheep a  GFP antibody was the generous gift of Francis Barr.
Bacterial expression constructs encoding glutathione-/S'-transferase-Src homology 3 (SH3) 
domains [Beard et al., 1999] were the generous gift of Professor Miles Houslay (University of 
Glasgow, U.K.).
pGADT7, pGM20, pGM22 and pGM47 were the generous gift of Gerhard May ((University of 
Glasgow, U.K.).
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2.2 Cell Culture and Transfections
2.2.1 Cell Maintenance
CCL39, HEK293 and HEKLT cells were maintained in DMEM, supplemented with 
10%(v/v) FBS, penicillin (100 units/ml), streptomycin (lOOpg/ml) and ImM L-glutamine in a 
37°C humidified atmosphere containing 5% CO2 Cells stably expressing SlPi or SIP3 receptors 
were maintained in the appropriate medium supplemented with G418 in order to optimise 
receptor expression by maintaining selection pressure. Cells were routinely passaged 1:10. 
Confluent T-75 flasks were washed with PBS without calcium chloride and magnesium chloride. 
Cells were detached by the addition of 2ml of trypsin, followed by incubation at 37°C for 30 
seconds. 8mls of medium were then added to the flasks and the cells pippetted gently to allow 
resuspension. Cells were either passaged into flasks to maintain the cell line or seeded for 
experimental analysis.
2.2.2 Transient Expression of cDNA Expression Constructs
cDNA expression constructs were transiently transfected into either HEK293, HEKLT or 
CCL39 cells using a Lipofectamine-mediated transfection protocol. Cells were plated into 6- 
well dishes at the appropriate density such that they would be 70-80% confluent the following 
day. Transfection mixes of 0.24ml OptiMEM, 2p,g plasmid DNA and 4pi Lipofectamine were 
prepared in sterile microfuge tubes for each well. The tubes were then incubated at room 
temperature for 15-45min to allow transfection. During this incubation, each cell monolayer was 
washed once with 2ml/well OptiMEM prior to the addition of 0.75ml/well of OptiMEM. 
Following the 15-45 minute incubation, the Lipofectamine-DNA-OptiMEM mixes were added 
dropwise to each well and incubated for 3 hours at 37°C. The medium was then removed from 
each well and replaced with 3ml/well of normal growth medium. Cells were analysed 48-72 
hours post-transfection.
2.2.3 Stable Expression of cDNA Expression Constructs
On day one confluent CCL39s cells in a T75 flask were split with 2nd trypsin. When 
detached, 6ml DMEM minus G418 was added and resuspended by pipetting. 1ml of suspension 
was added per 10mm dish which already contained 9ml DMEM minus G418. The following day 
cells were 70-80% confluent. In a sterile microfuge tube, 30pi Lipofectamine and lOpg of either 
pcDNAS/mycSlPs or pcDNA3/mycSIP3GFP were added to 0.4ml of OptiMEM, mixed and 
incubated for 15-45min and then added to each dish containing 5.2ml of OptiMEM, to give a 
final volume of 6ml. Dishes were incubated at 37°C for 3 hours. After incubation the
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Lipofectamine-DNA medium was removed and replaced with 10ml of DMEM with G418. On 
day 4, the cells were split for selection with 0.4mg/ml G418 into 5 dishes representing a 2:5, 1:5, 
1:10, 1:20 and 1:40 cell suspension. After selection in G418, resistant colonies were isolated, 
expanded and screened for receptor expression by immunoblotting and, in the case of the GFP 
constructs, fluorescence microscopy following excitation at 488nm using an argon/krypton laser. 
2.3 Molecular Biology
2.3.1 Preparation of Antibiotic Agar Plates
LB agai* (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, with 1.5% 
(w/v) agar was prepared, autoclaved and allowed to cool before the addition of the appropriate 
antibiotic (either ampicillin at 50pg/ml or kanamycin at 30pg/ml final concentrations). The 
liquid LB was poured into 90mm Petri dishes and allowed to solidify and sweat overnight at 
room temperature. Plates were then stored at 4°C until required.
2.3.2 Preparation of competent XLl Blue E.coli
An overnight culture of XLl Blue E.coli was grown in 3ml of LB broth containing 
50pg/ml tetracycline. The next day, 250ml of LB broth was inoculated with the culture and 
grown with aeration until the cells reached log phase. The cells were then transferred into two 
250ml centrifuge tubes on ice and left for 1 hour. Log phase was defined when the optical 
density (ODeoo) reached approximately 0.35-0.375. Cells were centrifuged at 4000g at 4°C for 
20 minutes, the supernatant decanted and the cells resuspended and washed in Va starting volume 
of ice-cold O.IM magnesium chloride. Following a second 20 min centrifugation, the cells were 
resuspended in Va starting volume of ice-cold 15% (v/v) glycerol with O.IM calcium chloride. 
250ml of resuspended cells were each aliquoted into sterile microfuge tubes on dry ice/methanol, 
to induce rapid freezing, and stored at -80°C until required,
2.3.3 Transformation of Competent E. colt
Approximately 30-50ng of DNA was added to a thin-walled, plastic round-bottomed 
13ml Falcon tube on ice. 50pl of thawed competent E.coli were added and the DNA and E.coli 
mix incubated on ice for lOmin. The tubes were then incubated for 5min in a 37 °C water bath. 
0.5ml LB/tube was then added and the tubes were incubated for 45min at 37°C. 200pi from each 
transformation was then plated onto an LB agar plate supplemented with the appropriate 
selection antibiotic and incubated overnight at 37°C.
2.3.4 Mini- and Maxi-Preparation of Plasmid DNA
Transformed colonies were picked from agar plates and used to inoculate 5-10ml LB 
containing appropriate selection antibiotic, and grown overnight at 37°C with shaking at
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~200rpm for aeration. Plasmid DNA was prepared using the Promega™ Wizard Plus SV 
miniprep purification system as per the manufacturer’s instiuctions. Larger quantities of DNA 
were obtained by transferring an initial overnight culture into 500ml of LB broth containing the 
appropriate antibiotic and grown overnight. DNA purification was achieved obtained using the 
Qiagen Plasmid Maxi-kit system. The concentration of DNA obtained was determined by 
measuring the absorbance at 260nm (A260) of a 1:50 dilution of each preparation in sterile H2O, 
assuming that 1 absorbance unit was equivalent to 50pg/ml of double stranded DNA. DNA 
purity was assessed by measurement of A260/A280 ratios.
2.3.5 Digestion of Plasmid DNA
l-2pg of plasmid DNA was digested in a volume of 10-20ml using the buffer conditions 
recommended by the manufacturer with 2-4 units of the appropriate restriction enzyme. 
Digested DNA was analysed by agaiose gel electrophoresis in which samples were prepared by 
the addition of a 1:3 dilution of loading dye. Electrophoresis was applied to a 1% (w/v) gel 
containing 2.5pg/ml ethidium bromide at 75V for 20-30min in a TAB buffer (40mM Tris- 
acetate, ImM EDTA, glacial acetic acid). DNA purification from excised agarose gel chips was 
achieved using Quiagen QIA quick gel purification kit, as per manufacturer’s instructions.
2.3.6 Ligation of DNA fragments
Ligation was carried out overnight at 4° C in a reaction volume of lOfxl containing 30mM 
Tris-HCl, pH7.8, lOmM magnesium chloride, lOmM DDT, ImM ATP, with Ipl T4 DNA ligase. 
Vector and insert DNA were present at a ratio of 1:4. Ligated DNA was then transformed into 
competent E.coli as described in section 2.3.3.
2.3.7 Constmction of SlPi Receptor constructs
(i) Generation o f Human MycSlPs cDNA Expression Construct.-
Myc epitope (EQKXISEEDL) and Hise sequences were added to the C-terminus of the 
human SIP3 open reading frame by PCR using a pcDNA3 /SlP 3 cDNA as the template. Standard 
PCR reactions contained in a volume of lOOf^ l, lOOng template DNA, lOOmM dNTPs, 50pmol 
sense/antisense primers, 0.002 units Pfu turbo, lOpl 10-fold concentrated amplification buffer 
and 5% (v/v) DMSO. The reaction was initiated by a dénaturation cycle of 95°C for 5 min 
followed by 30-40 cycles of a 95°C (Imin) denaturing step, 55°C (Imin) annealing step and 
72°C (1.5min) extension step. A final cycle of 95°C (Imin), 55°C (Imin) and 12°C (lOmin) was 
added before reactions were placed at 4°C until required. The primers used were:- 
5’ -CATTGAAGCTTCCACC^rGGCAACTGCCCTC-3’ (sense) and 
5’ -CATTGTCTAGAGTTGCAGAAGATCCCATTCTG-3 ’ (antisense)
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The sense primer was designed to add a Hindlll site (bold) upstream of a consensus 
Kozak sequence (underlined) and the SIP3 initiating Met (italics). The antisense primer was 
designed to remove the SIP3 stop codon and add SiXbal site (bold). This was to allow in-frame 
fusion of the SIP3 open reading frame with the myc epitope and His6 sequences following 
subcloning of the iJmûdlI/X&nl-digested PCR product into a similarly digested pcDNA3mycHis- 
A expression vector (Invitrogen). The completed digests were resolved on 1% (w/v) agarose 
gels at 75V in TAE buffer.
(n) Generation ofMycSlPs A27 and A45 cDNA expression constructs.- 
An analogous PCR strategy was used to generate epitope-tagged SIP3 truncation mutants 
in which either 27 or 45 amino acids had been deleted from the carboxyl-terminus. The integrity 
of all open reading frames was confirmed by the use of DNA sequencing.
27 truncation:
5'AAA CCT TCT AGA GAC CTT CGG AGA GTG GCT GCT ATT GTT 3'(antisense) 
45 truncation:
5 AAA CCT TCT AGA GTC GAG CGC AGG CTG GAT GGG 3'(antisense)
(Hi) Generation ofMycSlPs-GFP cDNA expression constructs.- 
These were generated by PCR using the pcDNA3/myc-His-S IP3 receptor as a template 
for the pcDNA3/myc-His-Sl?3-GFP construct. The primers used are shown below:- 
dTCTGGCTAACTAGAGAACC (sense)
dCAT TGG GAT CCC GAT GGT GAT GGT GAT GAT G (antisense)
The sense primer was designed to anneal upstream of the HindPil site of the SIP3 
receptor. The antisense primer was designed to remove the stop codon in the myc-His tag of the 
SIP3 and replace with that of GFP following ligation of Tfmrilll/RG^M-digested PCR product 
with a similarly digested pEGFPAlal vector.
iv) Generation o f SIP3 C-terminal cDNA expression constructs :- 
This construct contains the RASPIQP SH3 domain binding motif of the human SIP3 
receptor as a 76 amino acid peptide from Lys^ ^^  to Asn^ ^®, (Figure 1.10), and was created for 
insertion into pGBKT?, to be used as bait in the yeast two hybrid system. Standar d PCR reactions 
contained in a volume of lOOpl, lOOng template DNA, lOOmM dNTPs, 50pmol sense/antisense 
primers, 0.002 units Pfu turbo, lOpl 10-fold concentrated amplification buffer and 5% (v/v) 
DMSO. The reaction was initiated by a dénaturation cycle of 95°C for 5 min followed by 30-40 
cycles of a 95°C (Imin) denaturing step, 75®C (Imin) annealing step and 72°C (1.5min)
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extension step. A final cycle of 95°C (Imin), 75°C (Imin) and 72°C (10min) was added before 
reactions were placed at 4°C until required.
The primers for these constructs are as foliows:-
5’- AAA GCT GAA TTC CGG CGG GCC TTC TTC CGT CTG GT-3’ (sense)
5’- AAA GCT CTG CAG GTT GCA GAA GAT CCC ATT CTG-3’ (antisense)
SIP3 C-terminal constructs were created following ligation of P^rl/EcoTÎI-digested PCR 
product with a similarly digested pGBKT? vector. Subcloning was applied in frame with a myc 
epitope in the vector.
v) Generation ofSlPs C-terminal cDNA binding partner constructs 
These constructs amplify the Matchmaker sequence inserts in the positive activation 
domain (AD)/library clones to verify the presence of an open reading frame (ORF) fused to the 
GAL4 AD sequence, and enable comparison of the novel sequences to those in GenBank, 
EMBL, or other databases. Standard PCR reactions contained in a volume of lOOpl, lOOng 
template DNA, lOOmM dNTPs, 50pmol sense/antisense primers, 0.002 units Pfu turbo, lOpl 10- 
fold concentrated amplification buffer and 5% (v/v) DMSO. The reaction was initiated by a 
dénaturation cycle of 95®C for 5 min followed by 30-40 cycles of a 95°C (Imin) denaturing step, 
45°C (Imin) annealing step and 72°C (1.5min) extension step. A final cycle of 95°C (Imin), 
45°C (Imin) and 72°C (lOmin) was added before reactions were placed at 4*^ C until required.
5’ -  GAT GAA GAT ACC CCA CCA- 3’
5’ -  GCG GGG TTT TTC AGT ATC- 3’
2.4 Experimental Techniques
2.4.1 Preparation of SIP
Img of commercially supplied SIP was resuspended in 0.66ml of methanol to give a final 
SIP concentration of 4mM. The tube was capped tightly and transferred to an 80°C oven. The 
SIP was then vortexed eveiy 5min until it had gone visibly into solution. The SIP solution was 
then pipetted into 25 pi aliquots in brown glass vials. The methanol solvent was then evaporated 
off using a nitrogen gas stream, and the tubes capped for storage at -80°C. Reconstitution of 
SIP was achieved by the addition of 0.25ml serum-fiee medium supplemented with 0.5mg/ml 
fatty acid-free BSA to give a working SIP stock concentration of 400pM. Following addition of 
“medium + BSA”, the vial was waimed to 37°C for 30min with occasional vortexing to 
resuspend the SIP prior to use.
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2.4.2 Preparation of Cell Extracts for Imnmnoblotting
Confluent monolayers in 6-well dishes were kept on ice and washed three times with ice- 
cold PBS. All procedures were carried out at 4°C unless indicated otherwise. Cells were 
solubilised by scraping into 250pl of immunoprécipitation buffer (50mM Hepes, pH 7.5, 5mM 
EDTA, lOmM sodium fluoride, lOmM sodium phosphate, O.lmM phenylmethylsulfonyl 
fluoride, and lOpg/ml each of soybean trypsin inhibitor, leupeptin, and pepstatin A in 1% (w/v) 
TXlOO, 0.5% (w/v) deoxycholate (DOC), 0.1% (w/v) SDS. The lysate was then transferred into 
ice-cold microfuge tubes and solubilised by a 1 hour incubation on a rotating wheel. Lysates 
were clarified by centrifugation (14000g for 15 minutes) and supernatants assayed for protein 
content.
2.4.3 BCA Assay for protein content
Bovine serum albumin (BSA) physiological standards ranging flom 0-2mg/ml were 
loaded as a final volume of lOpl into the wells of a 96 well plate to obtain a best-fit straight line 
of a plot of A492 versus protein concentration in a bicinchonic acid (BCA)-based protein assay 
(Reagent A: 5g 1% (w/v) 4,4 dicarboxy-2,2 biquinoline, disodium salt, 2% (w/v) sodium 
carbonate, 0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) 
sodium bicarbonate. Reagent B: 4% (w/v) copper sulphate, BCA Assay solution 200jrl Reagent 
B to 9.8ml Reagent A). Analysis was performed using the graph package “Prism v20”. The 
protein concentrations of 10|rl samples of each sample were calculated from the equation of the 
best-fit straight line obtained from the BSA standards.
2.4.4 SDS-PAGE and Immunoblotting
In conjunction with prestained protein markers (6.5-175 kDa), samples were solubilised 
in immunoprécipitation buffer and equalised for protein content. The appropriate quantity of 
Laemmli sample buffer (50mM Tris (pH 6.7), 10% (v/v) glycerol, 12% (w/v) SDS, 0.0001% 
(w/v) bromophenol blue, 1.6mg/ml dithiothreitol) was then added to each sample to give a total 
volume of 30pl per sample. Samples were fractionated by SDS-PAGE using a 10cm 10% (w/v) 
acrylamide resolving gel (10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pH 8.8), 
0.1%(w/v) SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) 
TEMED) and 3% aciylamide stacking gel (3% (v/v) acrylamide, 0.1% (v/v) bisacrylamide, O.IM 
Tris (pH 6.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) TEMED). 
Electrophoresis was carried out at 150V in a running buffer containing 27.4mM Tris, 0.19M 
glycine and 0.1% (w/v) SDS until the bromophenol blue dye front reached the bottom of the gel. 
The resolved proteins were then electrophoretically transferred to nitrocellulose at 400mA for
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45min in transfer buffer containing 24.7mM Tris, 0.19M glycine and 20% (v/v) methanol. 
Following transfer, the nitrocellulose was washed briefly in PBS and incubated for 1 hour in 
Blotto (5% (w/v) skimmed milk in PBS supplemented with 0.2% (v/v) Triton X-100) to block 
non-specific protein binding sites. Membranes were then incubated for 1 hour with the 
appropriate dilution of primary antibody in firesh Blotto as indicated in the appropriate figure 
legends. The membranes were then washed three times for 1 Omins with Blotto followed by two 
brief washes in PBS. Membranes were then incubated for 1 hour with HRP-conjugated 
secondary antibody in High-Detergent Blotto (10% (v/v) Blotto in PBS supplemented with 
1.02% (v/v) Triton X-100 and 0.1% (w/v) SDS). The membranes were then washed three times 
for lOmin in Blotto, followed by two washes with PBS for lOmin. Membranes were then 
incubated for Imin at room temperature with ECL reagents (1ml solution A, 1ml solution B). 
Immunostained protein was then visualised on autoradiography film.
2.4.5 Electrophoretic mobility shift assay (EMSAi for NF-kB activation
Nuclear extracts were made from cells treated with vehicle or SIP by lysing cells in 0.4 
ml Buffer A (10 mM Hepes, pH 7.9, 10 mM potassium chloride, 0.1 mM EDTA, 0.1 mM 
EGTA, ImM dithiothreitol, 0.625% (v/v) NP40, 0.5 mM PMSF and lO^g/ml each of soybean 
trypsin inhibitor and benzamidine). The samples were then spun at 48,000g for 30 seconds at 
4^C, and the supernatant removed. The pellet was resuspended in 50 pi of buffer B (20 mM 
Hepes, pH 7.9, 0.45 M sodium chloride, ImM EDTA, ImM EGTA, ImM dithiothreitol, 0.5 mM 
PMSF and lOpg/ml each of soybean trypsin inhibitor and benzamidine). Samples were agitated 
for 15 min at 4°C, centrifuged at 48,000g for 5min. and the protein content of the supernatant 
determined using a Bradford assay. The DNA probe was labelled as follows: 10 pmol of single­
stranded oligonucleotide was labelled in a final reaction volume of 20 pi comprising 5 pCi [y- 
^^PJATP, 2 pi polynucleotide kinase (Promega) and 2 pi 1 Ox-concentrated polynucleotide kinase 
reaction buffer. After incubation for 30 min at 37®C, 3.2 pi (equivalent to 16 pmol) of the 
complimentary strand and 0.5 pi 5 M sodium chloride were added and the samples incubated at 
100”C for 2 min before cooling slowly to room temperature over the course of 2-3 hr. Following 
brief microcentrifugation 5 pg aliquots from each nuclear extract were then added to the ^^ P- 
labelled double stranded DNA probe (10,000 cpm/sample) containing the consensus k B  binding 
sequence GGGGACTTTCCC to give a final reaction volume of 25 pi containing 10 mM Hepes, 
pH 7.9, 0.1 mM magnesium chloride, 0.1 mM EDTA, 0.5 mM dithiothritol, 10% (v/v) glycerol, 
50 mM sodium chloride and 0.625 pg/nd poly dIdC.
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Following a 30 min incubation at room temperature, samples were analysed by 
fractionation on a non denaturing 6 % (w/v) polyacrylamide gel containing 0.5x TBE buffer (45 
mM Tris-borate, 1 mM EDTA) followed by autoradiography.
2.4.6 Whole Cell Receptor Phosphoiwlation
Cells were plated into 6 -well dishes at a density of 1x10^ cells/well and cultured 
overnight. When confluent, cells were quiesced by a 16-24hr incubation in semm-free DMEM. 
The next day, the cells were washed twice with 3ml/well phosphate-ffee DMEM and incubated 
for 90mins at 37°C with 0.75ml of the same medium supplemented with 0.2pCi/well f^P] 
orthophosphate. After stimulation with the indicated agonists, added as a 2 X concentrated dose 
in 0 .7 5 ml, reactions were terminated by placing the cells on ice and washing the monolayers 
twice with 3ml of ice-cold PBS. All subsequent procedures were carried out at 4°C unless 
indicated otherwise. Cells were washed three times with PBS and solubilized by scraping into an 
initial 250pl of immunoprécipitation buffer. The lysate was then transferred into ice-cold 
microfuge tubes and the wells washed with another 250pl of immunoprécipitation buffer which 
was subsequently transferred to the appropriate microfuge tube. The cells were then solubilized 
and assayed for protein content as described in section 2.4. Equivalent amounts of soluble 
protein from each sample were then made up to 400pl with immunoprécipitation buffer and 
added to microfuge tubes containing lOOpl 0 .2 % (w/v) IgG-free bovine serum albumin and, in 
the case of myc-tagged constructs, 5 pi 9E10 ascites, 2 pi of a rabbit antimouse IgG bridging 
antibody and 20 pi of a 50% (v/v) suspension of protein A-Sepharose beads.
Following incubation on a rotating wheel for 1 hour, immune complexes were isolated by 
brief centrifugation, washed three times with 1 ml immunoprécipitation buffer and eluted from 
the beads by the addition of 30pl Laemmli electrophoresis sample buffer (Section 2.4.4) and 
incubation at 37°C for 1 hour, vortexing every 15 minutes. Analysis was by SDS-PAGE using 
10% (w/v) polyacrylamide resolving gels as described in Section 2.4.4 and the gels were dried 
under vacuum prior to autoradiography for between 16 and 40 hours at -80®C. Quantitation of 
phosphorylation experiments was by densitometric analysis of non-saturating autoradiographs 
using Totallab v2.0image quantitation software (Nonlinear Dynamics).
2.4.7 In Vitro Receptor Phosphoiwlation Assay with Purified GRKs
Confluent monolayers of transfected cells in 100mm dishes were washed with ice-cold 
PBS and scraped into 5ml/dish of lysis buffer (lOmM HEPES, pH 7.5, 2mM EDTA, 0.25M 
sodium chloride supplemented with O.lmM PMSF, lOpg/ml soybean trypsin inhibitor and 
lOpg/ml benzamidine). The cells were then transferred to a tight-fitting glass-on-glass Dounce
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homogeniser on ice and homogenised by 20 up-and-down strokes. Following a 15min 
incubation on ice, the membranes were pelleted by centrifugation at 14,000g for 15min. The 
supernatant was then discarded and the pellet resuspended in 5ml lysis buffer as before. The 
membranes were then re-homogenised, left on ice and centrifuged as described previously. The 
pellet was then resuspended in 5ml GRK assay buffer (25mM Hepes, pH 7.5, 2.5mM EDTA and 
7.5mM magnesium chloride supplemented with the above protease inhibitors) by 
homogenisation and re-centrifuged. The pellet was finally resuspended in 220pl GRK assay 
buffer. Each assay tube consisted of 40pl membrane suspension, 40pl kinase mix (GRK assay 
buffer supplemented with 0.25mM ATP, 0.88mM dithiothieitol, 0.15pM okadaic acid (a 
phosphatase inhibitor) and 10 pCi [y-^^P]ATP), lOpl vehicle or 50nM purified GRK, and lOpl of 
vehicle or SIP, at the concentration indicated in the figure legends. After incubation at 30°C for 
5 min, reactions were terminated by placing the tubes on ice and adding 0.5ml/tube stop solution 
(O.IM sodium phosphate, pH 7.5, lOmM EDTA). Membranes were pelleted by 
microcentrifugation (14,000g, lOmin) and the resulting pellets solubilised in 0.3ml 
immunoprécipitation buffer by rotation for 60min at 4'^ C. After removal of insoluble material by 
centrifugation, detergent extracts were equalised by protein assay prior to receptor 
immunoprécipitation with 9E10 as described in Section 2.4.6. For Rhodopsin phosphorylation 
experiments, urea-treated bovine rod outer segments (ROS) were employed. In this case, each 
assay consisted of GRK assay buffer containing 0.5 pi ROS and 2pCi [y-^ ^P] ATP. In these 
experiments, reactions were terminated by the addition of 15 pi Laemmli sample buffer prior to 
analysis of rhodopsin phosphorylation by SDS-PAGE and autoradiography.
2.4.8 Biotin Labellmg-ImmunoDrecipitation Assay Of Cell Surface Receptor Expression 
Cells were plated into 6 -well dishes at a density of 1 x 10  ^ cells/well and cultured 
overnight. Cell lines expressing SIP3 constructs were then serum-starved for 16-20 hours in 
serum-free DMEM. The next day, the cells were washed in the appropriate medium followed by 
the addition of 0.75ml/well of the same medium. Incubations were initiated by the addition of 
0.75ml medium supplemented with either vehicle or 2X concentrated dilution of drug as 
indicated in the Figure Legends. Reactions were terminated by placing the cells on ice, 
removing the medium and washing monolayers twice with ice-cold PBS supplemented with 
O.lmM calcium chloride and ImM magnesium chloride (PBS-CM). All subsequent procedures 
were performed at 4°C unless stated otherwise. The alcohol groups on the cell surface 
glycoproteins were oxidised to aldehydes by a 30min incubation with 0.75ml/well lOmM sodium 
periodate in PBS-CM. Following the removal of the periodate and washing with PBS, the
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monolayers were washed twice with 3ml O.IM sodium acetate, pH 5.5, and incubated for 30min 
in 0.75ml/well of the same buffer supplemented with ImM biotin-LC-hydrazide. This reacts 
with the newly formed alcohol groups thereby labelling all cell-surface glycoproteins with biotin. 
Labelling was terminated by removal of the biotin-LC-hydrazide solution was washing the 
monolayers three times with 3ml PBS. Cells were then solubilised for receptor 
immunoprécipitation as described for whole cell phosphorylation assay (Section 2.4.4). 
Following fractionation of immunoprecipitated receptors by SDS-PAGE, proteins were 
transferred to a nitrocellulose membrane. Non-specific protein binding sites were blocked by 
incubation in Blotto and cell-surface biotin-labelled receptors were then identified by incubation 
of the membrane with 1 mg/ml HRP-conjugated streptavidin for 60min at room temperature. 
Following three lOmin washes with Blotto and two washes with PBS, reactive proteins were 
visualised by enhanced chemiluminescence (ECL). Agonist-induced loss of cell-surface receptor 
was quantitated by densitometric scanning of non-saturating blots.
2.4.9 Identification of Membrane Localisation of mvcSlP^ Receptors using Sucrose- 
Densitv Gradient
Confluent cells fi’om two 1 0 0 mm dishes were used for each treatment. Dishes were 
treated with either vehicle or 10p.M SIP in DMEM for 3Omins followed by 2x washes in PBS. 
The cells were scraped twice in 3ml PBS and diluted to 10ml (in 50ml conical flasks) followed 
by centrifugation at 1800g for lOmin. The resulting supernatant was removed and with a blunted 
pipette tip the pellet was loaded in 0.8ml of 1% or 0.5% (v/v) TXlOO in MES Buffered Saline 
(MBS) containing 25mM 2-Morpholinoethanesulfonic acid (MES), 150mM NaCl, pH 6.5). For 
0.5% (v/v) TXlOO in MBS, a 2.5ml stock of 20% (v/v) TXlOO in 100ml MBS was ued. The 
samples were put into a 7ml Dounce homogeniser containing lOpg/ml of soy bean inhibitor and 
lOpg/ml benzamidine inhibitor and homogenised with 20 up-and-down strokes to ensure 
complete resuspension. Following homogenisation and centrifugation each pellet was placed on 
a rotating wheel at 4°C for 2Omins. All the remaining steps were completed at 4°C to preserve 
lipid raft architecture. After rotation, samples were rehomogenised and the gradient was 
constructed as follows: 0 .8 ml of sample was combined with 0 .8 ml of 80% (w/v) sucrose in a 
centrifuge tube. This was followed by the careful addition of 1.6ml of 30% (w/v) sucrose, and 
lastly a layer of 1 .6 ml of 5% (w/v) sucrose was added. Samples were centrifuged at 200000g for 
approximately 18hrs. Samples were removed the following day as 400p,l aliquots (this provides 
1 1  samples and a pellet) and transferred to microfuge tubes containing lOpg/ml of soy bean and 
10p,g/ml of benzamidine inhibitor. (In some cases the pellet needed a further 400p.1 of MBS to
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resuspend it, which was also dounce homogenised as required). A distinct opaque band was seen 
between the 5% (w/v) and 30% (w/v) sucrose, which represented lipid rafts. Special care was 
employed when taking these aliquots to ensure the gradient was not disturbed. Samples with a 
1:4 ratio of sample:sample buffer were resolved on a 12.5% (w/v) acrylamide SDS-PAGE gel. 
Gels were transferred to nitrocellulose, which was cut at the 30kDa marker to make independent 
blots of receptor and caveolin-1 (22kDa).
2.4.10 Co-Immunonredpitations of mvcSlP^ and B Arrestin-2
CCl-3 9 /mycSlF3 cells were transfected with p arrestin-2 and following serum starvation 
for 24hrs, treated with lOpM SIP for 2 hours. Reactions were terminated by placing the cells on 
ice and washing the monolayers twice with 3ml of ice-cold PBS. All subsequent procedures 
were carried out at 4°C unless indicated otherwise. Cells were solubilized by scraping into an 
initial 250pl of immunoprécipitation buffer (Section 2.4.2). The lysate was then transferred into 
ice-cold microfuge tubes. The wells were then washed in another 250pl of immunoprécipitation 
buffer which was subsequently transferred to the appropriate microfuge tube. The cells were 
then solubilized and analysed for protein content as described in Section 2.4.3 Equivalent 
amounts of soluble protein from each sample were then made up to 400pl with 
immunoprécipitation buffer and added to microfuge tubes containing lOOpl 0.2% (w/v) IgG-free 
bovine serum albumin containing, 5 pi anti-Arrestin-3 Ab, and 2 0 pl of a 50% (v/v) suspension of 
protein G-Sepharose beads for 1 hour.
Following incubation on a rotating wheel for 1 hour, immune complexes were isolated by 
brief centrifugation, washed three times with 1 ml immunoprécipitation buffer and eluted from 
the beads by the addition of 30pl Laemmli electrophoresis sample buffer and incubation at 37°C 
for 1 hour, vortexing every 15 minutes. Analysis was by SDS-PAGE using 10% (w/v) 
polyacrylamide resolving gels and then transferred to nitrocellulose membrane. Membranes 
were then incubated with ascites 9E10 monoclonal (primary antibody) followed by HRP- 
conjugated anti-mouse (secondary antibody).
2.4.11 Membrane Recruitment of B-Arrestin
Stably transfected SIP3GFP CCL39 cells were used, with the contents of 1X10cm dish 
per condition. For each condition (time course of 0, 1, 2, 5, 8 , 12 minutes) cells were treated 
with or without 20pM SIP. Cells were washed twice with 5mis of ice cold KHEM (Incomplete 
KHEM buffer: 50mM Potassium Chloride, 50mM Hepes-Potassium Hydroxide pH 7.2, lOmM 
EGTA, 1.92mM Magnesium Chloride. For complete KHEM buffer add ImM DTT, and O.lmM 
PMSF, lOpg/ml benzamidine, lOpg/ml soy bean trypsin). 0.5ml of complete KHEM was added
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to each 10cm dish and cells were scraped and removed to a microfuge tube prior to snap freezing 
in liquid nitrogen or dry ice. Once thawed on ice, the cells were homogenised by ten passes 
through a 0.2mm gauge needle. The PI fraction was centrifuged at 1300g for 3mins and the 
supernatant removed to an ultracentrifoge tube. The P2 fraction was centrifuged at lOOOOOg for 
3Omins. The supernatant was removed and the S fraction withheld. The pellet was washed once 
in 750pl KHEM, resuspended and centrifuged at lOOOOOg again. Finally, the pellet was 
resuspended in 100-200pl complete KHEM. The protein concentrations were determined by 
BCA assay (Section 2.4.3) and equal amounts of protein were aliquoted and sample buffer 
added. All samples were fractionated on a 10% SDS PAGE gel and then blotted to nitrocellulose 
membrane. Membranes were incubated in ji-Anestin-l (primary antibody), followed by HRP- 
conjugated anti-mouse (secondary antibody) as described in Section 2.4.4. Immunostained 
proteins were then visualised on photographic film.
2.5 Confocal Laser-Scanning Microscopy
For fixed cell analysis of S1 Pg-GFP-receptors, cells were grown on coverslips and treated 
with vehicle or agonist. Following two washes with 3ml/coverslip of PBS, the cells were fixed 
for 20min at room temperature in 1.5ml/coverslip of 4% (w/v) paraformaldehyde in 5% (w/v) 
sucrose/PBS (pH7.2). Cells were then washed twice with PBS and washed 3x 2ml/coverslip for 
5min in 0.4% (v/v) new bom calf serum (NBCS)/0.2% (w/v) gelatin/PBS and once with 
2ml/coverslip PBS prior to mounting on microscope slides with 7p.l/coverslip of 40% (v/v) 
glycerol in PBS.
Cells were visualised using a Zeiss Axiovert 100 laser scanning confocal microscope 
(Zeiss, Oberkochen, Germany) using a Zeiss Plan-Apo 63 x 1.4 NA oil immersion objective, 
pinhole of 20 and electronic zoom between one and four. GFP was excited using a 488nm 
argon/krypton laser and detected with 515-540nm band pass filter. The images were 
manipulated with Zeiss LSM or MetaMorph software (Universal Imaging Corporation, West 
Chester, PA).
2.6 Preparation of Yeast Two Hybrid System Media
A variety of selective media were employed throughout the Yeast Two Hybrid Screening 
Protocol. These included
Synthetic dextrose (SD) dropout media. Added to IL of distilled water; 1.7g yeast 
nitrogen base w/o amino acids, 5g ammonium sulphate, 1.3g amino acid dropout powder, 20g 
dextrose, (20g agar), pH 5.8 autoclaved (allowed to cool to 50°C before pouring plates).
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YNB -his-leii-trp-ade media. A selective minimal medium with quadruple knockout 
(QDO) of amino acids and the purine adenine. Added to IL of distilled water; 1.7g yeast 
nitrogen base w/o amino acids, 5g ammonium sulphate, 0.6g Histidine-Adenine-Tryptophan- 
Leucine dropout powder, 20g dextrose, (20g agar), pH 5.8 autoclaved (allowed to cool to 50°C 
before pouring plates). Media lacking all or multiple amino-acids were made, simply adding the 
required amino acid(s) to make triple or double knock out media, using 0.04 mg/ml Tryptophan, 
0.06mg/ml Leucine, 0.02mg/ml Adenine and 0.02mg/ml Histidine.
YPD yeast growth media (a rich medium). Added to IL of distilled water; lOg Yeast, 
20g Peptone, 20g glucose (20g agar), autoclaved (allowed to cool to 50°C before pouring plates).
2.6.1 Pre-Transformed LibraiT Screening
Each bait colony of SIP3 C-terminal/pGBKT?, transformed in AH109 (which is an 
appropriate yeast reporter strain that serves as a mating partner for Y187), was added to 50ml of 
SD medium minus tryptophan and left overnight at 30°C in a rotating incubator at 250-270rpm. 
The following day the ODgoo was recorded as 0.8. The cells were centrifuged at lOOOg for 5min 
and resuspended in a residual 5ml of medium by vortexing.
A 1ml aliquot of the Matchmaker pretransformed HeLa cDNA library culture in Y187 
(Lot number 7080576) was thawed to room temperature in a water bath and lOpl was saved for 
titering. Both the bait and library cultures were combined in a 2L flask with 45 pi of YPD A 
medium (YPD plus Adenine medium) with kanamycin and swirled to mix. The library tube was 
rinsed in a further 2 X 1ml of medium and the final volume made up to 50ml. The flask was left 
in a rotating incubator at 30°C overnight at 30-50rpm. The following day the conjugating mix 
was transferred to a 100ml centrifuge bottle and centrifuged at lOOOg for 1 Omins. The original 
flask was rinsed with 2 X 50ml YPDA medium with kanamycin. Both rinses were combined to 
resuspend the pellet and spun again for a further 1 Omins. The conjugating media was plated for 
efficiency controls using 100ml of mix in dilutions of 1;10,000, LIOOO, 1;100 and 1:10 on plates 
selective against leucine; against tiyptophan or against both leucine and tryptophan. The 
remaining conjugating medium was spread 200pl per plate on 50 large (150mm) plates, 
equivalent to -2x10"* -  2x10'^ cells per plate. 25 plates represented quadruple drop-out (QDO) 
media (-Adenine (A), -Histidine (H), -Leucine (L), -Tryptophan (W)), the other 50% represented 
triple drop-out (TDO) media (-Histidine, -Leucine, -Tryptophan). All the plates were incubated 
at 30°C, between 3-8 days for TDO plates and between 8-21 days for QDO.
Mating efficiency was calculated and a number of clones were screened. For colonies 
growing on TDO media, the suiwiving colonies were replica plated onto 10cm QDO dishes and
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incubated at 30°C for a further 3-8 days. Adenine and Histidine positive transformant colonies 
were chosen for further analysis. These colonies were streaked out on to SD medium-TLAH.
2.6.2 Yeast Two Hybrid System Analysis of a Libraiw Screening
From a master plate of yeast transformed with the target DNA binding domain-fusion 
protein (A master plate can be stored at 4°C for not more than 2 weeks) four 20-50ml cultures of 
a single large colony were inoculated in synthetic dropout (SD) medium with the appropriate 
selection for the target protein (e.g. -Trp). Cultures were giown for 36-48 hours, and each was 
transferred to a 200ml culture which was grown further overnight. During the protocol the four 
culture pools were kept separate. The following day each 200ml culture was transferred into 
400ml of YPD medium (OD should be around 0.2 in a total volume of 600ml) and grown to an 
ODgoo of about 0.7-0.75 (~ 4 hours). The resultant culture transferred into 250 ml bottles (in 
shifts) and centrifuged at lOOOg for 5min. The supernatant was removed and the pellet 
resuspended in water and centrifiiged at lOOOg for 5min. The supernatant was removed and the 
4 batches of cells were resuspended, with about 10ml of IX TE/LiAc (10 mM Tris-HCl pH 8.0, 
1 mM EDTA, 0.1 M Lithium acetate, made fresh ) per bottle. The final volume was made up to 
50 ml per tube and centrifuged at lOOOg for 5min, supernatant removed and the final volume 
brought up to 2 ml with IX TE/LiAc. Transformations were performed in 4 x 10 microfirge 
tubes containing: 200^1 yeast cells, 8p,g library DNA, 30p,l salmon sperm DNA (lOpg/ml), 7pi 
lOX TE/LiAc, 30pl DMSO, 1.2pl PEG/LiAc (40% (v/v) PEG-4000, 10 mM Tris-HCl pH 8.0, 1 
mM EDTA, 0.1 M Lithium actetate, freshly made). Vortexed and agitated to assure DNA is well 
distributed. The transformations were incubated at SO'^ C for 30min while gently shaken in a 
thermomixer, and agitiated every lOmin. Followed by incubation at 42 "^ C in a thermomixer. 
After incubation, cells were put on ice (Imin) and centrifuged at 1500g for Imin, followed by 
resuspension in 300pl IX TE. From each microfuge tube, equal amounts (133pi per plate) were 
spread onto 3 plates lacking the appropriate amino acids: a total of 4 x 30 large plates. Plate 
dilutions (1/1000, 1/10000 & 1/100000) on -Trp & -Leu plates to assay transformation 
efficiency, for each of the 4 competent yeast batches. Plates were then left at 30°C for 1-2 
weeks.
2.6.3 Preparation of X-a-Gal Plates
Indicator plates containing the chromogenic substrate X-a-Gal (5-Bromo-4-Chloro-3- 
Indolyl-a-D-galactopyranoside) were used to rapidly detect protein interactions using a GAL4- 
based library. IL of appropriate dropout agar medium was prepared and cooled to 55°, then 1ml
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of X-a-Gal (20mg/ml) was added. The plates were poured and the medium was allowed to 
harden at room temperature. Cells were plated and incubated at 30°C until blue colonies formed.
2.6.4 Preparing Replica Plates
Each colony from a selection plate was spiked using a sterile toothpick and mapped to a 
X-a-gal assay plate. The replica plate was then left at 30°C to observe indicator activity. This 
assay plate was made to mirror the contents of each original transformation plate to identify the 
positive clones. All clones that brought back a positive blue X-gal result were mapped back to 
the original transformation plate and then a spike from the original colony was grown overnight 
in culture medium (with the appropriate selection).
2.6.5 TCA Protein Extraction from Yeast
Colonies from freshly streaked plates (<3 days) were picked and added to 5ml of Drop 
Out media which was then left at 30°C overnight (or two nights depending on growth rate). 
Cultures were centrifuged at lOOOrpm and the resulting pellets were each resuspended in 1ml of 
distilled H2O and transferred to microfuge tubes. To each pellet 150pl trichloroacetate (TCA) 
buffer (1.85M NaOH, 7.4% P-mercaptoethanol in distilled water) was added and then incubated 
on ice for lOmin. After incubation, 150^1 55% (w/v) TCA was mixed with the buffered pellets 
and incubated on ice for a further lOmin. Samples were centrifuged at 4°C for 15min at 1300g. 
The supernatant was removed and briefly centrifuged to remove any remaining supernatant. 
Then 100-150pi of the precipitated proteins were resuspended in High Urea Buffer (8M Urea, 
5% (w/v) SDS, 200mM Tris-HCl pH6.8, O.lmM EDTA, 0.5mg/ml bromophenol blue, 10% (v/v) 
p-mercaptoethanol, pH6.8) and 5 pi was loaded on to a 10% SDS-PAGE gel. Protein extracts 
were resolved by electrophoresis on a 12.5% SDS-polyacrylamide gel and proteins were 
transferred to nitrocellulose membranes, which were then incubated for 2hr with anti-myc 
monoclonal antibody 9E10, followed by incubation with peroxidase-labelled anti-mouse 
antibody, expressed SIP3 fusion proteins were visualised using ECL reagents.
2.7 SIP .3 Pull-Down Assays
PGEX-2T bacterial expression constructs encoding C-terminal fusions of glutathione-S- 
transferase (GST) with the SH3 domains from human fodrin, c-Src, phosphatidylinositol-3- 
kinase (PI3K) and Fyn, and described by Beard et a l (1999), were generously donated by Prof. 
Miles Houslay (University of Glasgow). E coli cultures (BL21 strain) transformed with either 
pGEX (for GST production) or the recombinant pGEX-SH3-containing plasmid (for GST-SH3 
production), were first grown overnight at 37°C with agitation in LB containing 60 //g/ml 
ampicillin, diluted 1:10 in the same medium and incubated at 37°C for 1.5 hr. Fusion protein
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expression was induced at 37°C by adding isopropyl p-D-thiogalactoside (IPTG, final 
concentration = 0.1 mM) and growth was continued at 37 °C for 4-6 h. Bacteria were then 
harvested by centrifugation (10,000g, 15 min) and then lysed by sonication in 20 ml PBS 
containing a protease inhibitor cocktail (40 mg/ml PMSF, 156 mg/ml benzamidine, 1 mg/ml 
apoprotinin, 1 mg/ml antipain, 1 mg/ml leupeptin, 1 mg/ml pepstatin, dissolved in DMSO). The 
debris was pelleted by centrifugation for 1 min at frill speed in a benchtop centrifuge. 600 //I of 
glutathione-Sepharose 4B beads equilibrated in PBS were added and incubated end-over-end for 
1 hr at room temperature. The beads were then washed three times with 200 //I of PBS over 15 
min, and resuspended as a 50% (v/v) slurry. GST-SH3-immobilised beads were stored at 4°C. 
Protein concentration and assessment of purity was determined by SDS-PAGE and Coomasie 
Blue staining following elution of fusion protein from a lOpl aliquot of bead suspension via the 
addition of electrophoresis sample buffer and boiling for 5 min, firactionating samples in parallel 
with known amounts of BSA (0-10 jag), followed by quantification and comparison of staining 
intensity.
For the pull-down assays, quiescent confluent 10cm dishes of mycSlPs-expressing 
CCL39 cells were treated with or without agonist as indicated in the Figure Legends. All 
subsequent procedures were performed at 4°C unless indicated otherwise. Following three 
washes with PBS, cells were solubilised by scraping into Iml/dish pull-down lysis buffer (50mM 
sodium HEPES, pH 7.5, lOOmM sodium chloride, 5mM EDTA, lOmM sodium fluoride, lOmM 
sodium phosphate, 1% (v/v) Triton X-100, 0.1 mM phenylmethylsulphonyl fluoride, lOpg/ml 
soybean trypsin inhibitor and 10|ag/ml benzamidine) and rotation for Ihr. Following removal of 
insoluble material by centrifugation, soluble extracts were equalised for protein content and 
volume prior to overnight incubation with 10 jag/sample of the GST-SH3 domains indicated in 
the Figure Legends immobilised to glutathione-Sepharose. Beads were isolated by brief
centrifugation, washed three times with pull-down lysis buffer and eluted by the addition of 30 pi 
electrophoresis sample buffer and incubation at 37^C for 60min. After fractionation by SDS- 
PAGE, resolved proteins were transferred to nitrocellulose for detection of mycSlPa binding by 
immunobiotting with 9E10.
2.8 ICa^ l^i imaging and analysis
Calcium mobilisation experiments were performed on Rati a fibroblasts transiently 
transfected with the SIP3 expression constructs indicated in the Figure Legends. After overnight 
serum starvation, transfected cells on glass coverslips were loaded with the Ca^^-sensitive dye 
Fura-2 by incubation (15-20min, 37°C) under reduced light in DMEM growth medium
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containing the dye's membrane-permeable acetoxymethyl ester form (1.5pM). Loaded cells 
were illuminated with an ultra high point intensity 75-watt xenon arc lamp (Optosource, Cairn 
Research, Faversham, Kent, UK) and subsequently imaged using a Nikon Diaphot inverted 
microscope equipped with a Nikon 40x oil immersion Fluor objective lens (NA =1.3) and a 
monochromator (Optoscan, Cairn Research), which was used to alternate the excitation 
wavelength between 340/380nm and to control the excitation band pass (340nm band pass=10 
nm; 380nm band pass=8 nm). Fura-2 fluorescence emission at 510nm was monitored using a 
high resolution interline-transfer cooled digital CCD camera (Cool Snap-HQ, Roper 
Scientific/Photometrics, Tucson, AZ). MetaFluor imaging software (version 4.6.8, Universal 
Imaging Corp., Downing, PA) was used for control of the monochromator, CCD camera, and for 
processing of the cell image data The desensitisation regimen involved stimulating cells every 6 
min with 1 min pulses of O.SpM SIP, Sequential images (2x2 binning) were collected every 2 
sec, exposure to excitation light was lOOmsec/image, and all experiments were undertaken in the 
absence of extracellular Ca^  ^ in saline solution comprising: 130mM sodium chloride, 5mM 
potassium chloride, ImM magnesium chloride, 20mM Hepes, lOmM D-glucose, O.OlmM 
EGTA, pH adjusted to 7.4 using sodium hydroxide. For analysis, ratio images were presented in 
MetaFluor intensity-modulated display mode, which associates the colour hue with the excitation 
ratio value and the intensity of each hue with the source image brightness. Briefly, background 
subtracted images acquired at 340 and 380nm excitation were first used for calculating the 
340/380nm ratio of each pixel. After determination of the upper and lower thresholds, the ratio 
value of each pixel was associated with one of the 24 hues from blue (low [Ca^ J^i) to red (high
2.9 Statistical Analysis
All statistical analysis, unless stated otherwise was carried out using the Student t-test as 
described in the Graphpad software, “Prism 3.0”. Elsewhere, statistical analysis using ANOVA 
was carried out using the “Graphpad” software as indicated in the figure legends.
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CHAPTER 3 
Characterisation and Analysis of 
Human SIP3 Receptor Phosphorylation
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Characterisation and Analysis of Human SlPn Receptor Phosphoi-ylatioil
3.1 Introduction
Derived from sphingosine, the backbone of all sphingolipids, the evolutionarily 
conserved lipid mediator SIP is now recognised as a potent modulator of cell regulation 
[Hannun, 1996; Spiegel and Merrill Jr, 1996; Hannun et a l, 2001; Saba and Hla, 2004]. Many 
cell types, notably platelets and fibroblasts, release SIP [Olivera et a l, 1999; Yang et a l, 1999; 
Spiegel and Milstien, 2002]. A myriad of cellular activities initiate with SIP signalling. These 
include intracellular calcium mobihsation, regulation of the organisation of the cytoskeleton, cell 
gro’wth, differentiation, survival and motility [Spiegel and Milstien, 2002]. This signalling is due 
to both intracellular and extracellular actions of SIP [Van Brockyin et a l, 1998; Spiegel and 
Milstien, 2002],
SIP exerts extracellular effects when it binds specifically to SIP receptors of the class A 
GPCR family [Spiegel and Milstien, 2000b, 2002]. The SIP receptors are presently 5 receptors, 
SlPi (previously known as EDGl) [Hla and Maciag, 1990], SIP2 (EDG5) [Okazaki and 
Ishizaka, 1993], SIP3 (EDG3) [Yamaguchi et a l, 1996; An et a l, 1997], SIP4 (EDG6) [Graeler 
et a l, 1998] and SIP5 (EDG8) [Im et a l, 2000], which each have high affinity for SIP [Chun et 
a l, 2002]. It has been demonstrated that SIP3 activates the NF-kB pathway via a mechanism 
that relies primarily on the activation of phospholipase C by Gq/n and perhaps some contribution 
from other G proteins [Siehler et a l, 2001]. This is presumably responsible for activating the 
IkB kinase (IKK) complex and thus triggering the agonist-mediated phosphorylation and 
degradation of IxBa, |3 and s isoforms [Ghosh and Karin, 2002]. SIP3 stimulates the PTx- 
insensitive Gi2/i3-mediated activation of Rho-coupled pathways [Moolenaar, 1999]. In addition, 
binding of SIP to the SIP3 receptor subtype results in pertussis toxin (PTx)-sensitive, Gi- 
dependent activation of ERK2 and the inhibition of adenylyl cyclase [Im et a l, 1997; Ancellin 
and Hla, 1999]. SIP3 in conjunction with SI Pi regulates the signalling pathways necessary for 
human umbilical vein endothelial cell morphogenesis into capillary-like networks [Lee et a l, 
1999; Wang et a l, 1999; Kimuia et a l, 2000]. This also suggests that antagonists of SIP3 and 
SI Pi could be used to attenuate the enhanced angiogenesis that is seen in solid tumour growth, 
rheumatoid arthritis and diabetic retinopathy [Lee, 1998b]. Since SIP3 signalling is prevalent in 
processes such as angiogenesis and vasoconstriction [Ancellin and Hla, 1999; Salomone et a l,
2003], the molecular mechanisms regulating SIP3 signalling predispose the SIP3 receptor’s 
therapeutic potential.
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As mentioned earlier, sustained agonist occupancy of many GPCRs can result in the 
desensitisation of receptor function, internalisation of the receptor away from the cell surface as 
well as GPCR coupling to alternative signalling pathways. These events are initiated by the 
phosphorylation of the GPCR at serine and thieonine residues witliin the third intracellular loop 
and/or the C-terminal tail by both second messenger-dependent protein kinases and GRKs 
[Luttrell and Lefkowitz, 2002]. Upon GRK-mediated phosphorylation, the agonist-dependent 
conformational change of the receptor can promote the selective binding of arrestins to agonist- 
activated receptors [Zhang et a l, 1997]. Arrestin binding causes steric uncoupling of the 
receptor fi-om the heterotrimeric G-proteins, triggers internalisation of GPCRs by targeting them 
to clathrm-coated vesicles, and on occasion can initiate different signalling pathways, for 
example, the arrestin-mediated increase in ERK and JNK signalling found with the pzAR [DeFea 
et a l, 2000; Chen et a l, 2001; Laporte et a l, 2002].
Phosphorylation represents a vital step in both the rapid desensitisation of GPCR function 
and their subsequent mechanisms of internalisation [Bouvier et a l, 1998]. Thus, to begin to 
characterise SIP3 signal regulation it is necessary to fully characterise the phosphorylation of the 
SIP3 receptor. In this chapter, the molecular mechanisms regulating SIP3 phosphorylation have 
been characterised in detail. Also, truncation mutants of the SIP3 C-terminus were used to define 
specific regions conferring sensitivity to phosphorylation.
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3.2 Results
The lack of a selective commercial antibody against endogenous SIP3 receptors dictated 
the development of a SlPs-expressing construct incorporating a myc epitope tag, which was 
incorporated into human SIP3 cDNA (Figure 3.1). This allowed the identification and isolation 
of recombinant receptors using the anti-myc monoclonal antibody 9E10. The construct was 
stably expressed in CCL-39 hamster lung fibroblasts and multiple colonies were screened for 
stable expression of the mycSlPs receptor in CCL-39 cells. The strength of expression was 
determined by immunobiotting using the antibody 9E10 (Figure 3.2). Several colonies with 
bands denoting strong expression were expanded and colonies 8 and 23 were used for subsequent 
experimentation.
To confirm that the SIP3 receptor is expressed at the plasma membrane a biotinylation 
experiment was carried out to label cell surface glycoproteins on parental CCL39 fibroblast cells 
and mycSlPi stably expressing CCL39 cells with the mycSlPs stably expressing CCL39 cells 
(Figure 3.3). SIP3 could be specifically immunoprecipitated from transfected cell extracts and, 
like the related receptor SlPi, migrated as a broad band centred at an approximate molecular 
mass of 50kDa.
The transcription factor nuclear factor-xB (NF-kB) responds to a large number of 
environmental cues and is especially relevant to inflammation and apoptotic/anti-apoptotic 
signalling. By using HEK293 cells, it has been shown that SIP activates NF-kB in a receptor- 
dependent fashion [Siehler et a l, 2001]. SIP3 is coupled to G,, Gq, and G12/13, and affects 
activation of NF-kB, whereas SlPi, which is coupled to Gi alone, does not. To assess whether 
stably expressed mycSlPs receptor could transmit a downstream signal, activation of the NF-kB 
pathway which is mediated via a Gq/u-dependent process [Siehler et a l, 2001] was assessed 
using the degradation of the inhibitor of NFkB kinase, IkB(3 as a read-out (Figure 3.4). This 
demonstrated that SIP exposure induced a time-dependent degradation of IkB p in mycSlP3-  
expressing cells but not parental controls. Electrophoretic mobility shift assays (EMSAs) of NF- 
kB binding to target DNA indicated that in quiescent mycS 1 Ps-expressing cells, NF-KB activity 
was elevated regardless of the absence of agonist compared with parental CCL39 cells. Addition 
of SIP further enhanced NF-kB binding but no effect was observed in parental controls, which 
confirms the tagged receptors functionality.
Many GPCRs require the presence of a specific agonist to initiate G-protein coupling and 
receptor phosphorylation and thus trigger further regulatory events within the cell [Lefkowitz,
2004]. Current research has not examined the sensitivity of SIP3 to regulatory events associated
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with receptor desensitisation, such as receptor phosphorylation. To begin the characterisation of 
SIP3 phosphorylation, a whole cell phosphorylation study using serum-starved CCL~3 9 /mycSlP3 
cells was carried out in the presence of the agonist, SIP and a number of activators of second 
messenger-regulated kinases (Figure 3.5). These included PMA, a phorbol ester that activates 
conventional and novel PKC subtypes; A231567, a calcium ionophore; forskolin, a direct 
activator of adenylyl cyclase that increases PKA activity and 8 -Br-cGMP, a non-hydrolysable 
analogue of cGMP that activates protein kinase G (PKG). A 5- to 12-fold increase in SIP3 
phosphorylation was observed following exposure to SIP (range over 8  experiments). The other 
activators failed to induce SIP3 phosphorylation {versus a vehicle-treated control where SIP- 
induced SIP3 phosphorylation was set at 100%, p>0.05, n=3. Figure 3.5).
After the discovery that second messenger kinases did not affect the phosphorylation of 
SIP3 receptors it was decided to investigate the effects of SIP on SIP3 phosphorylation by 
further characterising the SIP-induced SIP3 phosphoiylation seen in Figure 3.5. This was 
achieved using a whole cell phosphorylation study on serum-starved CCL-39/mycSlP3 cells 
which verified that the SIP3 receptor was phosphorylated upon agonist stimulation, and that this 
phosphorylation was only observed in cells over-expressing SIP3 receptors and not in parental 
CCL-39 cells (Figure 3.6).
Characterisation of SIP3 phosphorylation commenced performing time course analysis of 
SIP3 phosphoiylation in the presence of lOpM  SIP. This showed that phosphorylation is a rapid 
process, with maximal SIP3 phosphorylation observed after the earliest time point examined, 1 5  
seconds, this being sustained for 30 minutes (Figure 3.7). Similar whole cell phosphorylation 
studies were subsequently carried out in the presence of a range of SIP concentrations. This 
demonstrated SIP produced a concentration-dependent increase in SIP3 phosphorylation 
(EC5o=0 .8 5 ± 0 .0 1 pM, n=3, Figure 3 .8 ). A concentration of 5 - lO pM  was subsequently chosen for 
the remaining experiments as this was shown to induce maximal SIP3 phosphorylation. SIP3 
phosphorylation was also shown to be a reversible process, with a significant decrease in SIP3 
phosphorylation observed after only 30min of agonist removal, although this was somewhat 
slower than the time course of onset since the level of phosphorylated SIP3 after agonist removal 
for 120min was still 5 5 ± 8 % (p<0 . 0 5  versus agonist-treated cells, n=3) of that observed prior to 
agonist removal (Figure 3.9).
Based on other examples of agonist-dependent GPCR phosphorylation, potential 
candidates for kinases involved in SIP-induced SIP3 phosphorylation included one or more 
members of the GRK family. To test this hypothesis, an attempt to reconstitute S IP-dependent
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s IPs phosphoiylation in vitro was made using CCL39/S1P3 cell membranes as a receptor source 
and purified preparations of GRK2 and GRK5 (Figure 3.11). GRK2 and GRK5 were used 
because they each represent a separate subfamily within the GRK family. As shown previously 
with SI Pi, it was possible to reconstitute S IP-stimulated phosphorylation of SIP3 using GRK2 
(Figure 3.10). This was specific for GRK2, as GRK5 did not sustain SIP3 phosphorylation 
despite activity observed from both kinases under these assay conditions when assessed by light- 
dependent phosphorylation of rhodospin in urea-treated rod outer segments (Figure 3.12). 
Accordingly, agonist-dependent phosphorylation of SIP3 in CCL39 cells in vitro can be 
mediated specifically by GRK2 but not by the related kinase GRK5.
To further assess SIP3 sensitivity to GRK-mediated phosphorylation in intact cells, 
GRK2 and the related kinase GRK3 were used to measure the level of potentiation of agonist- 
mediated SIP3 phosphorylation in HEK293 cells co-trmsfected with expression constructs of the 
receptor and each GRK (Figure 3.13). The switch to HEK293 cells for these investigations was a 
practical measure, the HEK293 cells were readily transfectable and thus allowed facile 
comparison of WT and mutant receptor characteristics. Both overexpression of GRK2 or GRK3 
failed to potentiate SIP3 phosphoiylation above the level of phosphorylation seen in cells 
without overexpression of GRK2 or GRK3, in intact cells, despite explicit evidence of receptor 
and GRK expression by immunobloting. This suggests that SIP3 is not a substrate for GRK2 as 
GRK2 is not capable of phosphorylating the SIP3 receptor in both intact HEK293 cells or in 
vitro CCL39 cells. Although, this result could be due to cell-type specific characteristics 
between HEK293 cells and CCL39 cells, and/or the artificial indulgence of over-expressing 
GRKs in the cell system. Each cell line should have the opposite series of GRK experiments 
(intact and in vitro) investigated to rule out GRK2 as the mediator of SIP3 phosphorylation and 
further investigations using siRNA knockdowns of GRK2 would alleviate the problems that arise 
from over-expression of receptors.
To identify whether the carboxyl-terminal domain has a role in controlling SIP3 
phosphorylation an inspection of the SIP3 open reading frame was made. The receptor’s 
carboxyl-terminus was identified as a prime candidate for the site of regulatory phosphorylation 
as it is enriched in serine and threonine residues. To evaluate the contribution of two clusters of 
multiple potential phosphorylation sites within this domain, two truncated SIP3 mutants were 
generated (Figure 3.14). The ability of the truncated receptors to undergo agonist-stimulated 
phosphorylation in situ was assessed following transient receptor expression in HEK293 cells 
(Figure 3.15). Whilst removal of 27 residues from the carboxyl-terminus markedly elevated 
basal phosphorylation and significantly potentiated the effect of SIP, deletion of 45 residues
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abolished SIP3 phosphorylation. Immunobiotting of the same cell extracts showed that these 
effects could not be attributed to parallel differences in receptor expression (Figure 3.16). 
Together, these data suggest SIP3 is phosphorylated in situ in an agonist-dependent manner in an 
eighteen amino acid sequence between Leu332 and Val352 in the receptor’s carboxyl-terminal 
domain. They also suggest that the 27 carboxyl-terminal residues may impart a tonic inhibitory 
effect on receptor phosphoiylation.
To ensure GRK2 is not merely mimicking the effects of a native SIP3 kinase in intact 
cells, SIP3 mutant sensitivity to phosphorylation by GRK2 in vitro should reflect the sensitivity 
observed in phosphorylation in whole cells. Removal of 27 residues from the C-terminal domain 
of SIP3 increased GRK2-dependent phosphorylation in vitro when compared with the WT 
receptor, these results were similar to whole cell phosphorylation experiments. In contrast to the 
abolition of SIP3 phosphorylation observed in whole cells, removal of 4 5  residues ffom the 
carboxyl-terminus also potentiated GRK2-mediated phosphorylation in vitro (Figure 3.17).
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3.3 Discussion
Receptor phosphorylation is an important regulatoiy process in GPCR signalling. Taking 
the PzAR as example, phosphorylation is considered as the critical step necessary to achieve both 
desensitisation and internalisation of the receptor. This chapter has characterised for the first 
time the phosphorylation of the SIP receptor SIP3 using a myc-tagged human SIP3 receptor and 
two C-terminal truncation mutants.
In CCL-39 hamster lung fibroblasts, there is a strong, reversible, agonist-dependent 
phosphorylation of SIP3 (Figures 3.7, 3.8 and 3.9). Agonist-dependent SIP3 phosphorylation is 
a rapid process, with a significant phosphorylation observed after only 15 seconds (Figure 3.7). 
Dose-response experiments demonstrated that SIP produced a concentration-dependent increase 
in SIP3 phosphorylation. The EC50 value (O.SS+O.OlpM, Figure 3.7) for SIP-induced SIP3 
phosphorylation related to the physiological range of SIP concentration in the blood which 
reachs low p.M concentrations upon platelet activation [Pyne and Pyne, 2000b]. Previous studies 
have shown that the Kd of SIP for the SIP3 receptor is between 23nM and 27nM [Van Brooklyn 
et a l, 1999]. The observed K d would suggest that an additional event subsequent to agonist 
binding is required, and this highlights the possibility that complexing of receptors with other 
proteins, perhaps arrestin recruitment for receptor trafficking [Shenoy and Lefkowitz, 2003b], or 
indeed dimérisation may occur to allow desensitisation and internalisation of the receptor 
[Milligan, 1998; Gether, 2000; Milligan, 2000; Brady and Limbird, 2002; Hur and Kim, 2002; 
Salim et a l, 2002; Jensen and Spalding, 2004] or another step is involved perhaps involving a 
MAPK
SIP also induced SIP3 phosphorylation in vitro using CCL-39/mycSlP3 membranes in 
the presence of purified GRK2 (Figure 3.10). In contrast no SIP3 phosphorylation was observed 
in the presence of GRK5 (Figure 3.11). This suggests that SIP-induced SIP3 phosphorylation 
may be mediated by GRK2. Assessment continued with the investigation of sensitivity of SIP3 
to GRK-mediated phosphorylation. The ability of GRK2 and the related kinase GRK3 to 
potentiate agonist-mediated SIP3 phosphorylation was tested in whole cell phosphorylation 
experiments after co-transfection of HEK293 cells with expression constructs for the SIP3 
receptor and GRK2 or GRK3. Overexpression of either GRK2 or GRK3 failed to potentiate 
SIP3 phosphorylation in intact cell phosphorylation assays despite unequivocal evidence of 
receptor and GRK expression. While agonist-occupied SIP3 is a substrate for phosphorylation 
by GRK2 in vitro, GRK2 cannot be responsible for the phosphorylation obseiTed in intact cells 
(Figure 3.13).
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To assess more precisely which region of the SIP3 receptor is phosphorylated, SIP3 
truncation mutants removing clusters of potential Ser/Thr phophorylation sites were analysed. 
Both sites are situated proximal to acidic residues making them potential targets for aciditrophic 
kinases like GRK2 (Figure 3.15). SIP-mediated SIP3 phosphorylation was abolished by the 
truncation of the last 45 amino acids and was significantly potentiated by the truncation of 27 
amino acids (Figure 3.16).
In comparison to previously described receptors of the SIP receptor family, notably the 
closely related SlPi receptor, SIP3 is not affected by two pathways of phosphorylation as 
observed with SI Pi. SIP3 phosphorylation is not activated by an agonist-independent 
mechanism regulated by the activation of PKC, however, it appears that there may be some 
similarity in the mechanism acting via GRK2 kinase, as with SI Pi an agonist-dependent 
mechanism acts via GRK2 in vitro and fi-om this study GRK2 was also shown to reconstitute 
SIP-stimulated phosphorylation of SIP3 .
Potential problems comparing in vitro or whole cell phosphorylation experiments arise, 
when working in vitro, constituents of the cytoplasm are readily available to cell surface 
receptors located on membrane fragments. These constituents include a variety of kinases which 
could add to the effects observed by administered GRKs, and which may include the native SIP3  
kinase. Equally, when taking into account the intact cell, the model system introduces 
overexpression of a specific SIP  receptor and chosen GRK, and this skew in enzyme equilibrium 
may be sufficient to alter the regulation of the receptor which is distinct from any natural 
occurring activity in the cell-lype under investigation. To alleviate discrepancies that may occur, 
mutant receptor phosphorylation allows further comparison of receptors in vitro and in intact 
cells as it highlights whether phosphorylation is dependent on specific residues within the 
receptor, regardless of which kinase is involved. Here additional evidence is provided that 
GRK2 is unlikely to be the agonist-regulated SIP3 kinase in intact cells. Evidence that provides 
confirmation that once the putative area of the receptor involved in specific kinase interaction is 
removed, phosphorylation is potentiated regardless of the presence or absence of GRK2 which 
suggests another kinase specific to SIP3 kinase is involved and not GRK2.
This agonist-independent regulation of GPCR phosphorylation is seen in the M3 
muscarinic acetylcholine receptor by casein kinase la  [Budd et a l, 2000], casein kinase II 
phosphorylation of thyrotropin-releasing hormone receptor [Hanyaloglu et a l, 2001] and 
phosphorylation of Ser348 within the bradykinin B2 receptor by an unidentified kinase [Blaukat 
et a l, 2001]. Similai' to GRK2 and 3, CKIa and CKII are both acidotropic kinases that typically
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phosphorylate clusters of Ser and/or Thr residues in a consecutive manner [Tobin, 2002]. Casein 
kinases are unlikely to be involved in SIP3 phosphorylation as there is a distinct lack of acidic 
residues in the regions upstream and downstream of SIP3 phosphorylation sites.
SIP influences heart rate, endothelial integrity, and lymphocyte recirculation through the 
SIP receptors. Inhibition of lymphocyte recirculation by non-selective SIP receptor agonists 
produces clinical immunosuppression preventing transplant rejection but is associated with 
transient bradycardia A potent, SlPi-receptor selective agonist, SEW2871, 5-( 4-phenyl-5- 
trifluoromethylthiophen-2-yl)-3-(3-trifluoromethylphenyl)(l,2,4)-oxadiazole, that is structurally 
unrelated to SIP, was found to activate multiple signals triggered by SIP, including guanosine 
5'-3-0"(thio)triphosphate binding, calcium flux, Akt and ERKl/2 phosphorylation, and 
stimulation of migration of S lP r  but not SIPs-expressing cells in vitro. The agonist also alters 
lymphocyte trafficking in vivo. And it was found that agonism of SlPi receptor alone is 
sufficient to control lymphocyte recirculation [Sanna et a l, 2004]. As the balance of receptor 
expression is found to be of specific importance in the regulation of cell behaviour it is possible 
that disruption of regular expression of SIP 1 receptors would have pathological consequences. 
Equally, if other SIP receptors which were co-expressed in the same tissue were not properly 
regulated in synergy with SlPi, this too could have harmful results. This highlights the 
importance of the differences in sequestration of both the SIP 1 and SIP3 receptors.
SEW2871 is a full agonist on S1 Pi alone on both human and murine receptors for induced 
GTPTS binding, calcium flux, kinase activation, and cell migration; yet it is not active on the 
related receptors SIP2-5  in either species [Sanna et a l, 2004]. SEW2871 is a highly hydrophobic 
agonist that lacks any solubilizing or head groups. Despite this, it is an effective full agonist of 
SI Pi suggesting that the headgroup interactions are not required for full agonism, and can be 
achieved by hydrophobic-aromatic interactions alone. SIP3, and not SlPi, is directly implicated 
in sinus bradycardia. The sustained bradycardia induced by SIP receptor non-selective 
immunosuppressive agonists in wild-type mice is abolished in SIP3-/- mice, whereas SlPi- 
selective agonist does not produce bradycardia. The demonstration in vivo that a non-selective 
SIP receptor agonist active on SIP3 induces bradycardia in wild-type mice that is abolished in 
SIP3-/- mice provides further support for the role of SIP3 in the heart [Forrest et a l, 2004; Sanna 
et a l, 2004]. This evidence supports the concept of differential regulation of receptors depending 
on celltype as both SI Pi and SIP3 are expressed on cardiac endothelium and perhaps 
myocardium, yet deletion of SIP3 alone abolishes the bradycardia induced by non-selective SIP 
receptor agonists, and an SlPi-selective agonist does not induce bradycardia [Sanna et a l, 2004]. 
With regard to the findings of this thesis, it is possible to suggest that dysfunctional regulation of
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the SIP3 receptor, by irregular expression at the PM, which could be caused by improper 
phosphorylation, internalisation or desensitisation, is likely to be the source of atypical variations 
of heart rate that result in bradycardic conditions.
The unique regulation of SIP3 phosphorylation may be useful in designing selective 
drugs. If selective drugs were designed to inhibit or promote phosphorylation, by manipulation 
of agonist interaction with specific SIP receptor subtypes, then downstream signalling and 
trafficking of receptors could be regulated via specific signalling pathways to enable the 
processes of angiogenesis, cell growth or differentiation to be accelerated or decelerated 
accordingly. Comparative studies have been undertaken to investigate arrestin-mediated 
regulation of desensitisation in p-opiod receptors [Whistler and von Zastrow, 1998]. Studies 
related to SIP signalling have developed the SIP agonist FYT720, which is in trials for use as a 
drug in transplant rejection [Rosen and Liao, 2003], and more recently a novel 
immunomodulator, KRP203, similar to FTY720 is being developed for use in organ 
transplantation [Vincenti, 2002; Shimizu et a l, 2005].
118
Figm-e 3.1; Schematic Diagram Of The Mvc-tagged Human SIP  ^Receptor 
A myc epitope (pink) and six histidine residues (green) were added to the C-terminus of the 
human SIP3 receptor using pcDNA/SlPa as a template. The sense primer incorporated a Hindlll 
site upstream of a consensus Kozak sequence and the SIP3 initiating methionine, as indicated. 
The diagram also shows that the antisense primer was designed to remove the SIP3 stop codon 
and add an Xbal site. This allowed in-ffame ligation of the SIP3 coding region with that of the 
myc-His epitope tag following ligation of the Hindlll/Xbal-digested PCR product with a 
similarly digested pcDNA3.1/myc-HisA vector.
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Figure 3.2; A screen to assess stable expression of the Mvc-Tagged Human SlPs Receptor 
CCL39 hamster fibroblasts stably expressing the myc epitope-tagged form of the SIP3 receptor 
were solubilised in electrophoresis buffer and analysed by SDS-PAGE and immunobiotting 
using the monoclonal anti-myc antibody 9E10. Multiple colonies were screened for SIP3 
expression, firom the example shown, of the 39 colonies screened, those with the strongest 
expression, colonies 1-11, 19-21, 23 and 29-31 were selected, colonies 8 and 23 were expanded 
for this experimental research, and the remaining strongly expressing colonies were fi-ozen in 
nitrogen for experimentation at a later stage. The positive control band seen in this figure 
represents SlPi receptor expression.
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Figure 3.3; Detection of cell surface S lP i and SIP3 bv biotinylation
Glycoproteins at the cell surface of parental CCL9 fibroblasts, mycSlPi- and mycSlPs- stably 
expressing cells were biotinylated as described previously in Section 2. Normalisation of soluble 
cell extracts was performed to adjust protein content and receptors were immunoprecipitated 
with anti-myc antibody 9E10. After SDS-PAGE and transfer to nitrocellulose, biotinylated 
proteins were observed by probing with HRP-streptavidin.
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Figure 3.4; Detection of I k B B  degradation to identify SIP^ expression
A: Parental and mycSlPs-expressing CCL39 cells were treated after quiescence with 5pM SIP 
for the time periods indicated prior to cell lysis and solubilisation of whole cell extracts. Protein 
content was then normalised and samples were fractionated by SDS-PAGE for immunobiotting 
with an anti-IxBp antibody.
B: Parental and mycS 1 Pg-expressing CCL39 cells were treated after quiescence with 5pM SIP 
for the time periods indicated prior to cell lysis and nuclear extract preparation for EMSA 
analysis of NF-kB activation.
Molecular weight markers not appropriate (and thus not loaded) as it is a non-denaturing gel. 
Both bands represent p50/p65 NF-KB heterodimers, as determined by supershift analysis using 
specific antibodies (Sands and Palmer, personal communication). However, presumably the 
slower migrating band must also include an additional unknown protein.
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Figure 3.5: The Effect of Second Messenger-Activated Kinase activation on
phosphoi-vlation of
CCL-39/mycSlP3 cells were serum-starved and treated for lOmin at 37°C in the absence 
(vehicle) or presence of 10p.M of the agonist, SIP and a range of second messenger activators; 
IpM phorbol 12-myristate 13-acetate (PMA), an activator of PKC; IOjllM of A23187, a calcium 
ionophore; lOpM Forskolin, an activator of adenylyl cyclase and lOOjuM 8-bromo-cGMP, an 
activator of cGMP. The cells were then solubilised for analysis of SIP3 phosphorylation by 
immunoprécipitation followed by SDS-PAGE and phosphorimaging. Typical data is shown 
from one of three experiments.
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Figure 3.6; Whole Ceil Phosphorylation of the SlPi Receptor Stable Cell Line
^^P-labelled serum starved parental CCL-39 cells or stably transfected CCL-3 9 /mycSlP3 cells 
were treated with either vehicle or 10|iM SIP at 37°C for 30min. The cells were then solubilised 
for analysis of SIP3 phosphorylation by immunoprécipitation followed by SDS-PAGE and 
autoradiography.
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Figure 3.7: Characterisation of SlPi phosphorylation over time in intact cells
^^P-labelled serum starved stably transfected CCL-3 9 /mycSlP3 cells were treated with either 
vehicle or lOpM SIP at 37°C for the times indicated. The cells were then solubilised for analysis 
of SIP3 phosphorylation by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Maximal SIP-induced SIP3 phosphorylation was set at 100% and other results were expressed 
relative to this level. Data is from n=4 expts.
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Figure 3.8; Concentration-Dependence of Phosphorylation to Inci’easing
Concentrations of SIP
^^P-labelled serum starved stably transfected CCL-3 9 /mycSlP3 cells were treated with either 
vehicle or increasing concentrations of SIP at 37°C for 30 minutes. The cells were then 
solubilised for analysis of SIP3 phosphorylation by immunoprécipitation followed by SDS- 
PAGE and autoradiography. Maximal SIP-induced SIP3 phosphorylation was set at 100% and 
other results were expressed relative to this level. These data represent the mean ± SEM of three 
similar experiments.
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Figure 3.9; The effect of SIP Removal on S If-Mediated Phosphorylation in CCL- 
39/mvcSlP3 cells
^^P-labelled serum starved stably transfected CCL-3 9 /mycSlP3 cells were treated with either 
vehicle or 5|iM of SIP at 37°C for 30min as indicated prior to removal of the medium, washing 
the cell monolayers twice with 3 ml/well of pre-warmed medium to wash out residual SIP, and 
incubation in 3 ml/well free SIP-free medium for the indicated times prior to analysis of SIP3 
phosphorylation by immunoprécipitation followed by SDS-PAGE and phosphorimaging. 
Maximal SIP-induced SIP3 phosphorylation was set at 1 0 0 % and other results were expressed 
relative to this level. These data represent the mean ± SEM of three experiments. Graph of 
quantitation from n=3. Astrixes indicate significant reduction in phosphorylation versus SIP- 
treated cells without washout.
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Figure 3.10: Reconstitution of SIP receptor phosphorylation in vitro with GRK2 
In vitro phosphoiylations were performed as described in Materials and Methods. Membranes 
from mycSlPi- and mycSlPs- expressing CCL39 cells were prepared and incubated with or 
without 5pM SIP in the absence or presence of 50nM purified recombinant GRK2 as indicated. 
Preparations of solubilised cell membrane extracts were immunoprecipitated with 9E10 to 
analyse receptor phosphorylation. Figure represents one of three experiments.
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Figure 3.11: Comparison of SIP^ PhosphoiMation bv GRK2 and GRK5 in vitro 
In vitro phosphorylations were performed as described in Materials and Methods. Membranes 
from mycSlPs- expressing CCL39 cells were prepared and incubated with or without 5pM SIP in 
the absence or presence of 50nM purified recombinant GRK2 or GRK5 as indicated. Cell 
membranes were then solubilised and immunoprecipitated with 9E10 to analyse receptor 
phosphorylation. Figure represents one of three experiments.
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Figure 3.12: Rhodopsin Phosphorylation bv GRK2 and GRK5 in vitro
In vitro rhodopsin phosphorylation assays were performed on urea-treated rod outer segments 
treated with or without light for 30min at room temperature in the presence of the indicated GRK 
isoforms as previously described in Section 2.4.6
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Figure 3.13; Lack of potentiation of SIP^ phosphorylation upon overexpression of GRK2 
and GRK3 in whole cells
^^P-prelabelled HEK293 cells transiently co-expressing mycSlPs and either GRK2 or GRK3 as 
indicated were incubated in the absence or presence of 5p,M SIP for 30min prior to solublised 
cell extract preparation and receptor immunoprécipitation with 9E10 as described previously. 
Confirmation of receptor and GRK expression was made by immunoblotting with anti-myc 9E10 
and anti-GRK2/3 monoclonal antibodies as indicated. Graphical analysis shows quantative 
analysis of data normalised to the level of agonist-stimulated WT SIP3 phosphorylation (set at 
100%, n=3). There was no statistically significant difference (p>0.05) in SIP3 phosphorylation 
between each of the conditions.
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Figure 3.14; Mutational analysis of SlP-i Receptor C-Tail Truncations
The primary sequence of the carboî^l terminal domain of SIP3 following Asn294 is shown. 
Potential phosphoacceptor sites are W eighted and the positions of the two truncations that were 
created are indicated by arrows at A45 and A27.
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Figure 3.15: Immunoblot Analysis of the MvcSlPi. MvcSlP:^A27 and MvcSlP^A45
HEK293 cells transiently expressing either the mycSlPs, MycSlPsAZ? or MycSlP3A4 5  were 
solubilised and then analysed by SDS-PAGE and immunoblotting with the anti-myc monoclonal 
antibody 9E10. None of the bands labelled are observed in vector-transfected cells, hence they must 
be due to differentially processed forms of the receptor.
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Figure 3.16: Whole cell phosphorylation of WT and mutant SIP^ receptors 
^^P-prelabelled HEK293 cells transiently expressing WT mycSlPs or mutant SIP3 receptors 
were incubated in the absence or presence of lOpM SIP for 30min as indicated prior to 
solubilised cell extract preparation and receptor immunoprécipitation with 9E10 as described 
previously. Following fractionation of the immunoprecipitates by SDS-PAGE, phosphoproteins 
were visualised by autoradiography. Graphical analysis shows quantative analysis of data 
normalised to the level of agonist-stimulated WT SIP3 phosphorylation (set at 100%, n=3). * 
indicates a significant increase (p<0.01) while ** indicates a significant decrease (p<0.05) versus 
the level of agonist-stimulated phosphorylation observed for WT SIP3 under the same conditions 
(set at 1 0 0 %).
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Figure 3.17: In vitro phosphoiwlation of WT aiid mutant SIP^ receptors with GRK2
A: Membranes from serum-starved HEK293 cells transiently expressing WT mycSlPs or mutant 
mycSlPa receptors were incubated with [y-^ -^P] ATP in the absence or presence of 5pM SIP in 
the absence or presence of 50nM purified recombinant GRK2 prior to solubilised membrane 
extract preparation and receptor immunoprécipitation with 9E10 as described previously.
B: Confirmation of receptor expression was made by immunoblotting with anti-myc 9E10.
C: Quantative analysis of data normalised to the level of agonist-stimulated WT SIP3 
phosphorylation (set at 100%, n-3). * indicates a significant decrease (p<0.05) versus the level 
of agonist-stimulated phosphorylation observed for WT SIP3 under the same conditions. 
Statistical significance was determined using the one-way Analysis of Variance (ANOVA) 
Dunnett multiple comparisons test.
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CHAPTER 4 
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of Human SIP3 Receptor 
Subcelliilar Distribution
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Characterisation and Analysis of SIP^ Subcellulai’ Distribution
4.1 Introduction
To understand how a receptor is localised at the plasma membrane is the first step in 
characterising the manner in which a receptor is internalised by a cell. Internalisation of GPCRs 
is an integral pait of receptor regulation. The majority of GPCRs require phosphoiylation as a 
precursor to their internalisation, as evidenced by P2AR and tlirombin receptors, amongst others 
[Lefkowitz, 2004]. Generally, receptor phosphorylation increases afhniiy for arrestins, which 
uncouple GPCRs from their associated G-proteins. As anestin is an adaptor protein, it also 
functions directly in receptor trafiBcking and targeting of receptors to clathrin-coated vesicles 
from where the receptor is sequestered from the membrane into the cell [Goodman et a l, 1997; 
Krueger et a l,  1997; Ostrom, 2002]. By bringing a receptor closer to an endosome-associated 
phosphatase, GPCR internalisation is believed to promote dephosphorylation [Zhang et a l , 1996; 
Koenig and Edwardson, 1997]. Dephosphorylation and recycling of receptors back to the 
plasma membrane contributes to the reversal of desensitisation [Ki'ueger et a l, 1997]. This 
process of resensitisation is required for complete recovery of cellular signalling following 
agonist withdrawal [Krueger et a l, 1997; Krupnick and Benovic, 1998]. Alternatively, the 
internalised receptor can be targeted to lysosomes for degradation [Koenig and Edwardson, 
1997; Innamorati et a l, 2001; Fuertes et a l, 2003].
As described in Chapter 3, SIP3 is phosphorylated in the presence of agonist, and the 
requir es the presence of serine and thi*eonine residues within the last 45 amino acids of the 
receptor’s C-terminal tail. As a precedent, SlPi has already been shown to be phosphorylated at 
serine and threonine residues within the C-teiminal tail and internalises maximally after two 
hours exposure to SIP [Van Brocly^ln et a l, 1998; Watterson et a l, 2002]. In this Chapter, the 
internalisation of human mycSlPs receptor stably expressed in CCL-39 hamster lung fibroblasts 
was characterised using cell surface biotinylation and confocal microscope analysis, while 
desensitisation was investigated thr ough calcium mobilisation assays in Rati a fibroblasts.
The P2AR receptor was the first GPCR where internalised receptors could be 
distinguished from cell surface populations. This was shown using astrocytoma cells 
administered with catecholamine which resulted in a decrease in stimulated adenylate cyclase 
activity and a corresponding difrerential sedimentation on sucrose gradients compared with un­
stimulated cells [Harden et a l, 1980]. Hie internalised receptors were found to be associated 
with a “light vesicle” fraction that could be separ'ated from a “heavy vesicle” plasma membrane
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fraction that was associated with tlie cell surface receptors [Harden et a l, 1980]. Previously, it 
has been reported that SlPi is targeted to plasmalemmal caveolae upon agonist stimulation 
[Igarashi and Michel, 2000]. Altliough this finding could not be reproduced by several members 
of the lab, it was useful to see how SIP3 was distributed at the plasma membrane with and 
without agonist stimulation using a similar sucrose density system. It has been shown in a recent 
study that in SlPi-expressing HEK293 cells, SIP exposure results in tlie translocation of p- 
arrestin 2 (airestin 3) towar'ds activated SlPi receptor [Hobson et a l, 2001]. It is likely that as 
the SIP3 receptor also interacts with PDGF, via a distinct mechanism (Figure 1.14), that SIP3 
once activated by SIP also results in ar*restin 3 translocation [Baudhuin et a l, 2004; Payne et a l, 
2004; Tanimoto et a l, 2004; Waters et a l, 2004].
In this Chapter the investigations of subcellular* localisation are described in succession 
from biotinylation and confocal laser microscopy studies, sedimentation sucrose density gradient 
assays to arrestin co-localisation analysis and intracellular calcium mobilisation assays.
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4.2 Results
The SIP3 receptor is phosphorylated in tlie presence of SIP, as described in the previous 
Chapter. That SIP3 is phosphorylated in the presence of SIP allowed the enquiry of whether 
SIP3 phosphorylation results in SIP3 internalisation. Stable mycSlPa expressing CCL-39 cells 
provide a suitable model to characterise SIP3 internalisation. A cell surface receptor 
biotinylation assay was performed on mycS 1P3-expressing CCL-39 cells wliich were exposed to 
10|liM  SIP over a time course of two hours. The underlying premise of the biotinylation assay is 
that it makes use of the extr eme size and abundance of biotin molecules which has a very high 
binding affinity with streptavidin (lO^^m'^), tliis conjugation is a stable interaction where 
streptavidin binds four molecules of biotin. Initially, sodium periodate oxidizes the glycoproteins 
present in die SIP3 receptor to form aldehydes which can spontaneously react with hydrazides. 
Biotin-hydrazide is used to attach biotin onto the oxidized glycoproteins. Biotinylated proteins 
can then be detected by addition of streptavidin conjugated to horseradish peroxidase for 
luminol-based detection using ECL™ reagents. This shows that SIP3 is not significantly 
internalised over time in CCL39 cells (Figure 4.1). After establishing a lack of internalisation in 
CCL39 cells the next clarification was to assert whether internalisation was dependent on agonist 
concentration. As seen with the time course experiment, these experiments demonstrate that no 
internalisation was seen at any of the concentrations used (Figure 4.2).
To allow visualisation of any SIP-induced changes in SIP3 receptor trafficking, a 
mycSlPs-GFP construct was generated and stably expressed in CCL-39 hamster lung fibroblasts 
as described in Materials and Methods Section 2.3.7 (Figure 4.3). Stable expression of the 
mycSlPg-GFP receptor was confirmed by immunoblotting using the anti-myc monoclonal 
antibody 9E10 and a monoclonal anti-GFP antibody (Figure 4.4). Both receptors were shown to 
be expressed at similar' levels as visualised by the 9E10 antibody. Incubation with the anti-GFP 
antibody selectively identified the SIP3-GFP protein The observed difference in molecular 
mass between the wild type SIP3 receptor and tire SIP3-GFP receptor (around 28kDa) was 
consistent with the addition of the GFP tag. hr previous similar studies of the SI Pi receptor, it 
was confirmed that addition of tire GFP tag does not influeirce receptor function. Tlris has also 
been shown for SlPiGFP [Watterson et a l, 2002] aird other tagged GPCRs, such as p2AR 
[Kallal and Benovic, 2000].
Based on the assumption that SI Pi and SIP3 share significant homology it was deemed 
appropriate to follow the same irrethod of experimental analysis as observed in previous work 
carried out on the SI Pi receptor [Watterson et a l, 2002] where the addition of a GFP tag to the C
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terminus of the receptor did not appear to cause obstruction to receptor internalisation. The CCL- 
3 9 /mycSlP3-GFP cell line represented a relevant model for studies of SIP3 receptor trafficking 
upon exposure to SIP. As initially observed, the CCL-39/mycS 1P3-GFP cells are present on the 
cell surface in unstimulated cells. When CCL-39/mycS 1P3-GFP cells were exposed to lOpM 
SIP over a two hour time course and studied with confocal microscopy, a two hour treatment of 
lOpM SIP does not result in a significant translocation of mycSlPs-GFP from the cell surface as 
compared to untreated mycSlPa-GFP (Figure 4.5). These data correlate with the cell surface 
biotinylation experiments, where mycSlPs-expressing cells are shown not to mtemalise over 
time or increasing concentration of agonist. Also, this would suggest that there is no gross re­
distribution of SIP3 into microdomains at the cell surface. Currently, it is unknown how SIP3 
receptors are distributed within the plasma membrane. To determine SIP3 receptor distribution 
and how it may change with agonist exposure a series of sucrose density gradient assays were 
peiformed (Figure 4.6) to identify whether SIP3 is localised to lipid rafts after exposure to 
agonist, as observed for other GPCRs [Simons and Ikonen, 1997]. The gradients observed with 
agonist stimulation did show some redistribution of SIP3 from plasma membrane fractions (- 
fraction 9 to fraction 12), to vesicle fractions (fraction 1 to fraction 8 ) upon stimulation with SIP 
which suggests that recruitment of the receptor at the surface is possibly being blocked by a 
protein adaptor complex.
If SIP3 is not localised at clathrin coated pits after agonist stimulation it is possibly 
because it is not recruited there by arrestin. Tlris could be due to a number of reasons, for 
example, steric hindrance of the receptor due to other proteiii-SIP3 receptor interactions may 
cause obstruction of arrestin binding. In order to observe what is preventing SIP3 from 
internalising in CCL-39 cells it was important to determine whetlier arrestin would complex with 
the SIP3 receptor. Preliminaiy findings from studies of co-expression of the SIP3 receptor with 
arrestin-3 in CCL-39 cells indirectly suggest that agonist-stimulation of the SIP3 receptor 
promotes downstream airestin recmitment as observed by the increase in SIP3 association after 
co-immunoprecipitation with arrestin 3 over a time course (Figure 4.7). However, due to the 
limited data collated in this experimentation further analyses are required to fully confirm this 
hypothesis.
However, further investigations with the Rati a cell type have shown that SIP3 can 
internalise upon S IP  exposure (Figure 4.8), which further supports the concept of dynamic 
regulation of the SIP3 receptor via differential internalisation. Biotinylation and confocal 
scanning laser microscopy studies of internalisation (Figure 4.1, 4.2 and 4.5) have shown that
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CCL39 cells over-expressing myc-SlPs were unable to internalise upon exposure to SIP, and 
this itself was in contrast to investigations o f internalisation for myc-SlPi in CCL39 cells 
[Watterson et al ,  2002]. These findings, taken with the internalisation observed for HEK293 
cells over-expressing myc-SlPs, suggest an as yet unobserved level o f SIP3 receptor regulation 
which has potential ramifications for downstream signalling, whereby differential internalisation 
between celltypes regulates variation in cell migration, proliferation and survival, and provides a 
novel mechanism that could be used to selectively control pathological conditions, such as 
angiogenesis.
Agonist-stimulated phosphorylation by GRKs o f many GPCRs is followed by the 
removal o f the phosphorylated receptor away from the cell surface into endosomal vesicles 
[Zhang et al ,  1997; Laporte et al ,  2002]. For example, it has been demonstrated that SI Pi is 
internalised immediately following GRK2 phosphorylation of the receptor protein [Liu et al ,  
1999; Watterson et al ,  2002]. Whether SIP3 regulation is comparable with SI P i  despite 
evidence for phosphorylation by a GRK-independent process was assessed via biotinylation 
assays which quantitated the levels o f  cell surface WT and mutant SIP3 in HEK293 cells after 
S IP  exposure. Following agonist treatment for 2 hr, a significant loss o f WT SIP3 from the cell 
surface was noticed. Furthermore, successive truncations o f the C-terminal tail o f  the receptor 
failed to significantly decrease the extent to which internalisation occurred, posing the 
hypothesis that prior phosphorylation of SIP3 is not required for internalisation to occur (Figure 
4.8).
GPCRs classically undergo rapid functional desensitisation of heterotrimeric G-protein 
signalling after they have been phosphorylated [Zhang et al ,  1997], From the evidence for 
GRK-independent phosphorylation o f SIP3 in intact cells and its ability to internalise without 
receptor phosphorylation, it was important to determine the susceptibility o f WT and mutant 
SIP3 receptors to undergo functional desensitisation in intact cells. Tlris was achieved by 
assessment o f SIP-induced changes in [Ca^ ]^i in Fura2-labelled Rati a cells transiently 
expressing WT and non-phosphorylated A45 mutant SIP3 receptors (Figure 4.9). Transfected 
cells chosen for study were identified by co-transfection with a GFP expression construct and 
recombinant protein expression was visualised by fluorescence microscopy. From initial 
experiments it was shown that as cells expressing GFP alone failed to significantly mobilise 
[Ca^*]i after agonist exposure, cells co-expressing GFP and either WT or A45 SIP3 receptors 
appeared to increase transient mobilisation o f [Ca^ ]^i after SIP challenge. Repeated challenge 
with a submaximal concentration o f SIP induced a time-dependent desensitisation o f  agonist-
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stimulated [Ca^^i mobilisation by both receptors. This emerged as a possible homologous 
desensitisation event that did not significantly deplete the intiacellular calcium pool, as the 
response to endogenous am-adrenoceptor activation by phenyleplirine was identical between 
control GFP-expressing and SlPs-expressing cells following SIP exposuie (Figure 4.10 and 
4.11).
There was no significant difference in desensitisation after SIP exposure between the WT 
receptor or the phosphoiylation-resistant A45 SIP3 (Figur e 4.11), which intimates that functional 
desensitisation of [Ca^ ]^i mobilisation in Rati a cells progresses in a receptor phosphorylation- 
and internalisation-independent manner. A potential reason for the receptor phosphorylation 
independence of functional desensitisation of [Ca^^i mobilisation in Rati a cells could be that the 
phospholipase C-p isoforms activated by SIP3 are subject to negative regulation by PKC- 
mediated phosphorylation, which has been demonstrated for several G, and Gq/u-coupled 
GPCRs, including the iV-formyl-MetLeuPhe, P2Y2 purinergic and M3 muscarinic acetylcholine 
receptors [Ali et a l, 1998; Strassheim and Williams, 2000]. However, it was noted by personal 
communication [John Pediani], that pretreatment with a maximally efifective concentration of tlie 
PKC inhibitor GF109203X failed to change WT and A45 mutant SIP3 receptor desensitisation 
kinetics, suggesting that desensitisation is PKC independent.
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4.3 Discussion
This Chapter has established through cell surface biotinylation and confocal microscopy 
studies that in CCL-39 cells the SIP3 receptor, unlike the SI Pi receptor, is not internalised upon 
agonist-stimulated phosphorylation in CCL39 cells. This behaviour appears to be cell-type 
specific as experiments on HEK293 cells have shown that SIP3 can internalise in these cells. In 
contrast to many G-protein-coupled receptors, SIP3 is not lost from the cell surface following 
sustained agonist exposure for up to two hours in CCL-39 cells.
In attempting to characterise SIP3 as a classic GPCR this research has discovered the 
observation that SIP3 possesses unique cell-type specific resistance to internalisation Examples 
abound to highlight that individual subtypes of the SIP family are expressed differently fiom one 
cell type to another depending on their specific fimctions. For example, human cardiac SIP 
receptors are differentially expressed within cardiovascular tissues. The human cai'diac SIP3 
receptor is localised predominantly in the aorta and is also found in SMCs of cardiac vessels 
whereas SI Pi is present in cardiomyocytes and cardiac vessel endothelial cells, and is usually co­
expressed vrith SIP2 and SIP3 [Mazuiais et a l, 2002]. Another study has also shown that the 
expression of SIP3 and SIP2 receptors is 4-fold higher in murine cerebral aitery compared with 
aorta [Coussin et a l , 2002], suggesting species vaiiation.
hi relation to cardiovascular disease, it is possible that dysfimctional expression of SI Pi 
and/or SIP3 would prevent the specificity of receptor internalisation required, for example, to 
balance blood vessel development or bradycardia and that tliis would ultimately create a negative 
feedback of downstream signalling that could result in angiogenesis, athlerosclerosis or 
ischemia, conditions for which both of these receptors have been implicated [Licht et a l, 2003; 
Forrest et a l, 2004; Sanna et a l, 2004]. Additionally, the finding that RGS1-4 differentially 
regulate signalling through SIP 1.3 receptors, combined with the effects of RGS proteins in AT-1 
and ETa receptor signalling suggest additional levels of specificity in regulation of SIP receptors 
[Cho et a l, 2003]. Subsequently, from the findings of cell type specificity in SIP3 regulation in 
this research, it is possible that in fibroblast cells receptors are required for longer-term 
signalling at the cell-surface, for example, in the immune system, whereas in vascular cells the 
receptors are orchestrated at a faster pace, and this fine tuning of SIP receptor turnover allows 
rapid signalling events that are necessary in the cardiovascular system. CCL39, HEK293 and 
Rati a cell lines are all fibroblast or fibroblast-like cells. When each of these celltypes 
overexpresses tlie SIP3 receptor, and is treated with agonist, SIP3 appears to show differential 
internalisation between cell types. This suggests that dynamic regulation of SIP receptors is 
dependent on celltype.
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It has been suggested for SI Pi that its expression in embryonic development in mice 
allows the SIP activated endothelial cells to become permissive to smooth muscle cells and 
pericytes to vessel walls [Allende and Proia, 2 0 0 2 ]. Further results from Allende’s group have 
indicated that the SlPi, SIP2 and SIP3 receptors have redundant or cooperative functions for die 
development of a stable and mature vascular system during embiyomc development [Kono et al., 
2004]. Redundant and cooperative frmctions of SIP receptors suggests that with regard to cell 
type, the greater level of expression of cooperative functioning SIP receptors will be preferred 
above those receptors that have redundant functions in development. Si Pi is critical for S IP- 
induced, Gi-dependent migration, but not for PDGF-BB-induced, receptor tyrosine kinase- 
dependent chemotaxis in vascular smooth muscle cells [Kluk et a i, 2003]. Together this 
supports the model of distribution of receptor subtypes in endothelial cells having specific 
impact on die activity of the cells in relation to their environment.
Similar to SlPi [Igarashi and Michel, 2000] evidence from sucrose density gradient 
supports localisation of SIP3 with caveolin-I. From studies of sucrose density gradients it has 
been observed that upon agonist exposure there is a significant change in localisation of SIP3 
witliin the plasma membrane. After stimulation with agonist, SIP3 appears to localise to with 
caveolin-1. The significance of this localisation to lipid rafts has yet to be realised. This could 
be achieved through investigations of the actions of constituents of the lipid rafts by using statins 
to disrupt cholesterol levels.
From the results of subcellular distribution investigations it appeared important to 
discover if SIP3 was able to interact at all with arrestin in receptor recruitment. Arrestins, as 
mentioned in Chapter I, assist in recruiting receptors to clathiin-coated pits in order for them to 
become internalised. If this event requires agonist exposure, it is reasonable to assume that once 
S IP  is delivered to the cell the localisation of SIP3 at the plasma membrane would predominate 
in areas rich in caveolin, such as lipid rafts, in order for SIP3 to become internalised. If however, 
as is proposed, a unique SH3  binding domain (or another interacting protein), obstructs 
interaction with arrestin, the receptor may not internalise and localisation within the plasma 
membrane would appear non-specific, i.e. no recruitment to lipid rafts. Preliminary findings 
have suggested an interaction between arrestin and the SIP3 receptor upon agonist-stimulation. 
As SIP3 does appear to co-localise with arrestin it is feasible that if internalisation does not occui' 
there must be another interacting protein that restricts internalisation. This suggests that there 
may be an arrestin-dependence but does not explain the absence of internalisation.
As there appeals to be no relation between phosphoiylation and desensitisation or 
internalization it is suggested that otlier aspects of SIP3 function are regulated by internalisation
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and phosphorylation perhaps tyrosine kinase activity or activation of JNK. Evidence of 
precedents for resistance to internalisation despite receptor phosphoiylation is provided by the 
impact of MAP kinase isoforms ERKl/2 on the internalization of DORs expressed in HEK293 
cells, hi a recent study, ô opiod receptors (DORs) were found to elicit different responses after 
ERK/MAP kinase phosphorylation was blocked [Eisinger and Schulz, 2004]. The study showed 
that DOR activation by etorphine transiently phosphorylated ERK/MAP kinases and brought 
about DOR internalization witliin 20min. In contrast, prolonged exposure of HEK293 cells to 
morphine excited persistent phosphorylation of ERK/MAP kinases, and those cells failed to 
internalize the opioid receptor. When ERK/MAP kinase phosphorylation was blocked by 2'- 
Amino-3'-methoxyflavone (PD98059), morphine gained the ability to strongly induce DOR 
endocytosis. The importance of activated MAP kinases for DOR internalization was further 
demonstrated by substances that induce phosphoiylation of ERKl/2 and concomitantly prevent 
DOR sequestration by etorphine. Receptor internalization by morphine was also facilitated by 
inhibition of protein kinase C and opioid-mediated transactivation of epideimal growth factor 
receptor (EGFR), both activating ERK/MAP kinases by opioids. The mechanism permitting 
DOR internalization by PD98059 may relate to arrestin, wliich uncouples GPCRs and thus 
triggers receptor internalization. Arrestin considerably tianslocates towaid the cell membrane 
upon DOR activation by morphine in presence of the MAP kinase blocker, but it fails in the 
absence of PD98059. The study concluded that ERK/MAP kinase activity prevents opioid 
receptor desensitization and sequestration by blocking arrestin 2 interaction with activated DORs 
[Eisinger and Schulz, 2004]. Evidence is gathering to suggest that ceramide and its metabolites 
sphingosine and SIP represent a new class of intracellular second messengers diat mediate a 
variety of cellular functions. Sphingosine and SIP have been shown to induce mitogenesis in a 
wide range of cell types. PDGF, a potent mitogen, increases cellular levels of sphingosine and 
SIP, and inliibition of the PDGF-induced increase in SIP levels markedly decreased PDGF- 
induced cellular proliferation.
Correspondingly, SIP3 may be prevented from internalisation by a kinase that blocks the 
macliinery of the multi-complex that includes the interaction between arrestin2  and the activated 
SIP3 receptor. It is possible that inhibiting PDGF receptor signalling in CCL39 cells mty 
facilitate SIP3 sequestiation by SIP in the same way that DORs internalize when EGF is 
inhibited by PD98059.
Disruption of the PDGF-BB or PDGFR-ft genes in mice resulted in defective 
ensheathment of nascent blood vessels. Dysfunctional migration of SI Pi null embryonic
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fibroblasts toward a gradient of PDGF links these two phenotypes at the final steps of vascular 
development, underscoring the importance of SI Pi and endothelial cell-pericyte communication 
in vascular matuiation and angiogenesis. This study revealed novel cross-talk between a receptor 
tyrosine kinase, PDGFR, and a GPCR, SI Pi [Usui et a l, 2004].
Binding of PDGF to its receptor activates and recruits sphingosine kinase to the leading 
edge of the cell. This localized formation of SIP spatially and temporally stimulates SI Pi, 
resulting in activation and integration of downstream signals essential for cell locomotion, such 
as FAK and Src, necessary for turnover of focal complexes, and the small guanosine 
triphosphatase Rac, important for protrusion of laniellipodia and forward movement. These 
results shed light on the proposed vital role of SI Pi in vascular maturation and angiogenesis. 
Further support for such receptor cross-communication recently emerged fi*om the demonstration 
that PDGFR is tethered to SlPi providing a platform for integrative signaling by these two types 
of receptors [Aldertonef a/., 2001b].
Alderton et al., [2001] concluded that growth factor receptor-GPCR complexes provide a 
platform for integrating signals from different receptor classes. A mechanistic model was 
provided that may account for the co-mitogenic effect of GPCR agonists with growth factors. 
More specifically, the proposed model provided a mechanism that may account for PDGF- 
stimulated cell motility being SlPi-dependent [Hobson et a l, 2001]. SIP released fiom cells (not 
HEK293 cells) in response to PDGF could act back on SlPl-PDGF receptor complexes to 
induce more efficient downstream stimulation of effector pathways in response to PDGF. This 
might be specific to certain cell types where SIP fimctions as an autocrine with PDGF [Alderton 
et a l, 2001b]. Likewise, SIP3 involvement in Akt activation has been discussed in relation to 
crosstalk with PDGF and integrative and sequential models of signalling [Baudhuin et a l, 2004] 
as mentioned previously. Figure 1.15.
In contrast, it was recently proposed that tyrosine kinase receptors, such as the insulin­
like growth factor- 1 receptor, transactivate SI Pi through Akt-dependent phosphorylation that 
does not require the sphingosine kinase pathway [Alderton et a l, 2001a]. Possibly, SIP3 could 
interact with PDGF in a comparable way to SI Pi binding IGF-1-activated Akt. It has been 
demonstrated for SIPi that residue Thi'236 on the third intracellular loop is sensitive to 
phosphorylation by Akt, essential for SIPi activation of Rac which induced lamellapodia 
formation and migration of vasculai' endothelial cells [Lee et a l, 2001]. The third intracellular 
loop of SIP3 (Figure 1.10) contains five serine residues, two of wliich have direct proximity to 
residue 236 but these do not impart the same sensitivity to Akt for SIP3 as Thi'236 does to SlPi 
[Lee et a l, 2001], Further studies are necessary to validate the generality of this concept of SIP-
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independent activation of SlPRs.
In conclusion, through mutagenesis studies SIP3 has been shown to be rapidly and 
reversibly phosphoiylated in whole cells within an area of 18 residues on die C-terminal domain 
in response to increased S IP  concentrations. However, unlike SI Pi and many other GPCRs, 
receptor phosphoiylation is not required to trigger sequestration of SIP3 away fiom the plasma 
membrane. One possible explanation is that constitutive association of a cytosolic protein or 
interaction motif within the carboxyi-tenuinal domain of SIP3 is preventing the binding of 
arrestin proteins, which promote the clustering of GRK phosphorylated GPCRs within clatlirin- 
coated pits prior to their internalisation. Functional analysis of wild type and phosphoiylation 
resistant SIP3 receptor-stimulated calcium mobilisation indicates that sensitivity to agonist- 
induced phosphorylation has no influence on the kinetics of SIP3 receptor desensitisation. Tlie 
question of whether a non-phosphorylated receptor can still bind arrestins to cause 
desensitisation is one that could be answered by mutagenesis. Point mutations of specific SIP3 
phosphoiylation sites could be devised so that investigations of arrestin translocation can be 
made.
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Figure 4.1: Detection of the Lack of SIP-Mediated Time-Dependent SIP3 Receptor 
lutemalisation iii CCL-39 cells
Serum-starved stably transfected CCL-39/mycS 1P3 cells were treated at 37"C with vehicle or 10 
pM SIP for the times indicated. The cells were examined for internalisation by cell surface 
labelling with biotin-LC-hydrazide, followed by immunoprécipitation of solubilised receptors 
with anti-myc 9E10 antibody. Biotin labelling of vehicle-treated CCL-3 9 /mycSlP3 cells was set 
at 100% and the results following agonist treatment expressed relative to the control. The data 
represents the mean ± SEM of three similar experiments.
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Figure 4.2; Detection of the Lack of SIP-Mediated Dose-Dependent SlPi Receptor 
Internalisation in CCL-39 cells
Serum-starved stably transfected CCL-39/mycS 1P3 cells were treated at 37”C with vehicle or 
increasing concentrations of SIP for two hours. The cells were examined for internalisation by 
cell surface labelling with biotin-LC-hydrazide, followed by immunoprécipitation of solubilised 
receptors with anti-myc 9E10 antibody. The data shown represents one of three similar 
experiments.
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Figure 4.3; Schematic of the mvcSlP^-GFP Receptor
Tiie human mycSlPs receptor was tagged with green fluorescent protein using a pcDNA/human 
mycSlPs template. The mycSlPs receptor was ligated into the multiple cloning site of pEGFP- 
N1 at HindllUBamBi. The addition of the GFP tag allowed visualisation of any movement of 
the cell surface SIP3 receptor following sustained agonist exposure.
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Figure 4.4; Stable Expression of mvcSlP^and mvcSlP^-GFP Receptors in CCL-39 cells
Cell extracts prepared from non-transfected CCL-39 fibroblasts or CCL-39 cells stably 
expressing either mycSlPs or mycSlPs-GFP receptor were solubilised, normalised for protein 
content and analysed by SDS-PAGE and immunoblotting with either an anti-myc monoclonal 
or anti-GFP antibody as indicated. mycSlPs and mycSlPs-GFP bands are indicated.
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Figure 4.5: Visualisation Bv Confocal Microscopy Of The Resistance To SIP-Mediated 
Internalisation Of mvcSlP^-GFP Receptoi-s expressed in CCL-39 cells.
A: Serum-starved CCL39/mycS 1P3-GFP cells were plated onto coverslips and then washed 
and fixed in paraformaldehyde prior to visualisation of receptor distribution by confocal 
microscopy. Under conditions of no agonist treatment, the mycSlPs-GFP construct was 
expressed on the cell surface.
B: Serum-starved CCL39/mycS 1 Pg-GFP cells plated onto coverslips and exposed to 20pM 
SIP for either, 15, 30, 60, 90 or 1 2 0 min at 37°C. The cells were then washed and fixed in 
paraformaldehyde prior to visualisation of receptor distribution by confocal microscopy. From 
Omin to 120min there was no variation in distribution of receptors at the cell surface, as 
observed. Thus, no significant trafficking of the mycSlPs-GFP receptor was seen after 2  hours 
in the presence of 20pM SIP.
173
B 2 0  mm
1 7 4
Figure 4.6; Sucrose Density Gradient Analysis of SIPi receptor distribution in the 
plasma membrane of CCL-39 cells
Stably expressing CCL-3WmycSlPs cells were treated with either vehicle or lOpMSlP in 
DMEM. Samples were analysed by sucrose density gradient ultracentrifugation as described 
in Section 2.6. Fraction samples were resolved on a 12.5% SDS gel. Gels were transferred to 
nitrocellulose and probed for either mycSlPs receptor or caveolin-1 (22K). Caveolin-1 and 
SIP3 were observed at samples 3 and 4 and 9-12.
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Figure 4.7; Preliminary study of mvc-SlP^ i^ceptor association with arrestin-3
MycSlPs stably transfected CCL39 cells were co-transfected with arrestin-3 and, following 
serum starvation for 24hrs, treated with lOpM SIP agonist for up to 2 hours. All subsequent 
procedures were carried out at 4^C. The cells were solubilized and analysed for protein 
content as described in Section 2.4.3. Proteins were normalised and solubilised cell membrane 
extracts were immunoprecipitated with anti-arrestin-3 to detect co-localisation. Following 
incubation for 1 hour, immune complexes were analysed by SDS-PAGE and transfered to 
nitrocellulose. Membranes were incubated with monoclonal antibody 9E10 followed by HRP- 
conjugated anti-mouse, as detailed in section 2.4.4. Since there is no negative control sample 
included (i.e. non-transfected CCL39s) it is not possible to assign what the multiple bands in 
the SIP3 lane are. Bands in the co-IP lanes are mostly from HRP-conjugated second Ab 
recognition of the IgG used to immunoprecipitate arrestin-3 (the SIP3 band is clearly present 
below the IgG heavy chain and its presence increases with time after time zero, but it is 
considerably weaker than the IgG bands).
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Figure 4.8: Effect of agonist exposure on WT and mutant receptor cell surface 
expression in HEK293 cells
A: HEK293 cells transiently expressing the indicated myc epitope-tagged SIP3 receptors were 
incubated with 5p,M SIP for two hours. Following biotinylation of cell surface glycoproteins, 
soluble cell extracts normalised for protein content were prepared for receptor 
immunoprécipitation. Following fractionation by SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane for probing with HRP-conjugated streptavidin as described in Section 
2.4.8.
B: Quantitative analysis from three such experiments at time point = 2  hr. Statistical analysis 
revealed no significant difference (p>0.05) in extent of internalisation between WT and mutant 
receptors at this time point.
C: Quantitative analysis of time-courses of WT and A45 SIP3 receptor internalisation. Data 
normalised to the level of cell surface receptor observed m unstimulated cells (set at 1 0 0 %).
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Figure 4.9: Deteimination ofS lP i receptor expression in Ratla cells
Ratla cells were transiently transfected with expression constructs encoding the indicated SIP3 
receptors or empty vector. Soluble cell extracts were then processed for immunoblotting with 
anti-myc 9E10 antibody.
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Figure 4.10; Functional Desensitisation of ICa^ l^r Mobilisation in WT and Mutant SlPi 
Receptoi*s
Calcium mobilisation experiments were performed on quiescent Ratla cells transiently 
expressing either GPP alone (Control) or in combination with WT and A45 SIP3 receptors 
were treated for Imin periods with 0.5pM SIP every 6 min as indicated (arrows). The response 
to activation of stably expressed aib-adrenoceptors following administration of 3p.M 
phenylephrine (Phe) is also indicated. These traces are from one experiment that is 
representative of four separate transfections.
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Figure 4.11: Rates of WT and Mutant SIP^ Receptor Desensitisation of FCa^ l^r 
Mobilisation
Quantitative analysis of WT and A45 SIP3 receptor desensitisation of [Ca^^i over three 
experiments. In each case, responses have been normalised to the mobilisation observed upon 
initial cellular challenge with O.SpM SIP.  Astrixes indicate significant difference (p<0.05). 
Mutant actually desensitises by slightly less at each time point examined compared to WT, even 
though it is not phosphorylated at all.
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Strategies to Identify Novel Human SIP3  Receptor-Interacting Proteins 
5.1 Introduction
After establishing for the first time that SIP3 is phosphorylated in the presence of SIP,  
that SIP3 internalisation is cell-type specific and that a kinase, unlikely to be GRK2  or similar is 
involved in phosphorylation and additionally, that arrestin may associate with the receptor at the 
onset of phosphoiylation, it would seem that the next step would be to identify the regulatory 
mechanism of SIP3 that confers SIP3 as distinct from the other S IP  receptors. The ability of the 
A45 truncated SIP3 mutant receptor to undergo agonist-induced internalisation and 
desensitisation to the same extent as the WT receptor suggests that phosphorylation of the 
carboxyl-terminal domain may regulate novel aspects of SIP3 function. The novelty of SIP3 
compared to the other S IP  receptors might be provided by the presence of a class I SH3  domain 
interaction motif (RxxPxxP) between Arg^ '^^  and Pro^^  ^ (R^^"^ASPIQP) within the receptors C- 
terminal domain. It is possible that tliis may control specific downstream interaction that makes 
it distinct from other SIP receptors.
To identify how the SH3 interaction motif plays a role in SIP3 signalling it is important 
to determine which proteins may interact with it [Jahn et a l, 1997; Simpson et a l, 1999]. To 
search for potential binding partners for the C-terrninal tail of the SIP3 receptor several 
approaches are available. Both a biochemical approach and the yeast two-hybrid system were 
used [Bartel and Fields, 1997; Jahn et a l, 1997]. Parallel studies of tire SH3 domain interaction 
motif using the GST-fiision pull-dovra assays, a protein purification strategy using a C-terminal 
SH3 domain binding motif within SIP3 as an aftinity probe, provides supporting evidence for 
potential SI Pa-interacting proteins. In the biochemical approach, GST fusion proteins 
encompassing the SH3 domain binding motif of the C-terminal tail of the SIP3 receptor were 
purified from bacteria, conjugated to glutathione Sephai'ose beads, and then incubated separately 
with cell extracts. Research has proffered candidates for SlPa-interaction, as previously, it has 
been shown tlrat fodrin, Fyn, phosphoinositide-3 kinase (PI3K) interact similarly to Src. Thus, a 
study was performed with SIP3 and this selection of proteiirs to observe potential interactions. 
Fodrin, Fyn, Src and PI3K were chosen as they each have different functions in distinct 
pathways. The Src Family of protein tyrosine kinases, of wliich Src was the first example, 
includes Fyn, Yes, Fgi, Lyn, Hck, Lck, Blk and Yrk. To date, all cells that are studied have at 
least one of these kinases which act in cellular control. Each family member is characteristised 
by a src-homology (SH) domain structure, SHI is a kinase domain, SH2 and SH3 domains, and
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SH4 which is a domain tliat has myristoylation and membrane-localisation sites. Inter-domain 
interactions regulated by phosphorylation control the activity of each kinase.
Fodrin, is a tetrameric protein (a 240 kD, p 235 kD) found in the brain, and it is an 
isoform of spectrin. Spectrin is a membrane-associated dimeric protein (240 and 2 2 0  kD) of 
erythrocytes, which forms a complex with ankrin, actin and probably other components of the 
'membrane cytoskeleton', so that there is a meshwork of proteins underlying tire plasma 
membrane, potentially restricting the lateral mobility of integral proteins. Spectrin contains the 
EF hand motif which is a very common calcium motif that consists of a twelve amino acid loop 
with a twelve amino acid a  -helix at each end. This provides octahedral coordination for the 
calcium ion. Fyn is a non-receptor type tyrosine kinase of the Src family, that is strongly 
expressed in the central nervous system (CNS), suggesting that it plays an important role in brain 
function. Fyn-deficient mutant mice have a variety of abnormal signs such as impaired long-term 
potentiation in the liippocampus, with deficits in spatial learning, abnormality in suckling 
behavior in neonatal mutants, increased tearfulness and enhanced sensitivity to audiogenic 
seizures [Kitazawa et a l, 1998], Recent findings have suggested that the disassembly of 
hemidesmosomes mediated by Fyn is a prerequisite for normal cell migration and tumor invasion 
[Mariotti et a l, 2001]. Members of the PI3K family control several cellular- responses including 
cell growth, survival, cytoskeleton remodelling and the trafficking of intracellular organelles in 
many different types of cell. In particular, PÏ3K has important functions in the immune system 
[Koyasu, 2003].
Primarily, for the high proportion of GPCRs, agonist-mediated phosphorylation and (3- 
arrestin interaction is directed at the C-terminal domain. Alterations within this region have been 
shown to influence the processes of desensitisation [Smith et a l, 1998; Pizard et a l, 1999; 
Blaukat et a l, 2001], sequestration [hmamorati et a l, 2001; Laporte et a l, 2002], and 
resensitisation [Oakley et a l, 1999; Innamorati et a l, 2001]. Many investigations make use of 
point mutations and/or receptor truncations as the most common strategies for the study of C-tail 
function. Alternatively, chimeric receptors can be generated, this approach facilitiates the 
predicted outcome as eitlier the retention of receptor function or the conferral of donor receptor 
properties to the recipient.
A study of PDE4 enzymes exemplifies the rationale behind the use of GST fusion 
proteins in identifying potential interactors for the SH3 domain bind motif [Beard et a l,  1999]. 
The PDE4D gene encodes five distinct isoenzymes. PDE4D4 and PDE4A5 shows a distinct 
levels of interaction with protein SH3 domains, including lyn, fyn and src itself as well as the
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cytoskeletal protein fodrin and abl tyrosyl kinase which implies that such an interaction occurs 
by virtue of tlie unique proline-rich N-terminal region char acteristic of the PDE4D4 isoenzyme. 
The selectivities of these two enzymes might reflect differences in the form of tlie proline-rich 
segments of their N-terminal regions. PDE4A5 is characterised by three PxxPxxR motifs, 
whereas PXXP stretches predominate in PDE4D4. This is suggested to be likely due to 
differences reflected in the range of partners these PDE4 enzymes select in various cell types and 
which may promote functional differences in the roles of these two PDE4 species [Beard et a l, 
1999].
Thus, the potential of these two enzymes to interact with SH3 domain-containing proteins 
may be related to a major functional role. It was suggested that the functional importance of any 
binding of these enzymes to SH3 domain-containing proteins may be in targeting the PDE4 
species to a specific location witliin the cell and thus conti'olling local cAMP levels [Beard et a l, 
1999]. This may be the case for the proteins that interact with the SH3 domain binding motif in 
SIP3 receptors.
Two parallel mechanistically distinct approaches have been used in the research of this 
chapter to address a role for the SIP3 RXXPXXP motif that is predicted to act as an SH3 domain 
interaction motif. Using an in vitro approach with GST-SH3 domains, it was found that the 
RxxPxxP motif is functional and exliibits a marked degree of specificity for FynSH3. 
Concomitantly, positive clones were isolated via a genetic screen to identify SIP3 C-terminal 
domain interacting proteins, although these could not be rescued from yeast and were not 
characterised any further. Finally, two chimeras were generated in an attempt to test tire 
importance of any identified interactors for receptor function in the context of an intact GPCR in 
the future.
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5.2 Results
Preliniinaiy analysis of the alignment of C-terminal residues of several SIP receptors 
identified SIP3 as having a unique SH3 interaction motif, and SIP2 a PDZ interaction motif 
(Figure 5.1). Concurrently with tlie GST fusion protein assay, the yeast two-hybrid system was 
used to search for potential binding partners for the SIP3 SH3 domain interaction motif. After 
creating a constiuct incorporating the SH3 interaction motif via oligonucleotides and PCR, the 
resulting DNA was cloned into the plasmid PGBKT7 and transformed into yeast cells to confirm 
expression. The addition of appropriate size ~8 kDa, consistent with the fusion of the SIP3 C- 
terminal domain to the GAL4-DNA binding domain can be seen. (Figure 5.2). The SIP3 SH3 
domain interaction motif within the C-terminal was fused to the GAL4 DNA binding domain and 
was used as bait to screen a human cDNA libraiy in the yeast strain Y187. Of the 6.4 x 10^  
independent colonies contained witliin the libraiy, seven clones exhibited moderate to strong 
growth on -HIS or -ADE media. Each potential interacting colony was assessed for binding to 
the SIP3CT peptide through multiple stages of screening using X-a Gal to identify the positive 
interactors by expression of blue colonies (Figure 5.3). Once positive colonies were discovered 
they were grown as cultures over 1-2 days and then rescued from plasmid. The purity of DNA 
from each colony was assessed by lunning samples on a 1 % agarose gel witli the appropriate 
DNA mai'ker (Figui'e 5.4).
Once the DNA was purified it was amplified by PCR for sequencing to be carried out 
(Figure 5.5). Unfortunately, despite rigorous screening no proteins were identified by 
sequencing. It should have been possible to rescue the clones containing tlie interactors fiom 
yeast and tiansform them into bacteria conventionally. As this did not work an attempt to PCR 
out the clone was made using primers designed to anneal to the either side of the insert within the 
vector employed to construct the libraiy, this also proved to be unsuccessful.
hi parallel to test whether SIP3 could specifically interact with SH3 domains in vitro, 
pull-down assays were performed to assess the ability of SIP3 to bind to a panel of GST fusion 
proteins containing the SH3 domains from Fyn, Src, fodrin and PI3K. Proteins were expressed 
in BL21 E.coli and immobilised on glutathione beads to assess purity (Figure 5.6). Interestingly, 
these demonstrated that SIP3 was able to bind exclusively to the SH3 domain derived from Fyn 
(Figure 5.7).
Phosporylation sites are situated downstream from the RXXPXXP motif, to test whether 
prior SIP3 phosphoiylation could either alter the association of SIP3 with Fyn-SH3 or facilitate 
interaction vrith any of the otlier SH3 domains, the ability of each of the GST-SH3 domains to
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bind SIP3 was compai'ed between extracts derived from conti’ol cells and cells treated with 5|aM 
SIP for 30min, which is sufficient to induce maximal receptor phosphorylation (Figuie 3.7). 
Under Üiese conditions, agonist pretieatment failed to alter the extent to which SIP3 could 
interact with Fyn-SH3 and it did not promote subsequent interaction with the other SH3 domains 
tested (Figure 5.8). Thus, it appears that Fyn interaction is constitutive and not agonist- 
dependent.
A rationale for making chimeric receptors was to design an approach whereby it would be 
possible to test the functional significance of any SH3 domain interaction within the context of 
an intact SIP GPCR. The simplest way to do this was to swap the C-terminal domains of SI Pi 
(which does not have a RxxPxxP motif) and SIP3 following the predicted palmitoylation sites. 
Both consti’ucts were generated and transfected into HEK293 cells to see of they encoded full 
length proteins: anti-myc immunoblots showed positive expression of each construct. Receptor 
phosphorylation assays also showed that A) they were accessible to extracellularly applied 
agonist, and thus present on the cell surface, B) capable of binding agonist, since each responded 
positively to SIP and C) appropriately regulated by phosphorlyation upon agonist binding m a 
manner similai' to the parental WT receptors SI Pi and SIP3 (Figure 5.9).
While far from conclusive it is possible to put forward a tentative model of the regulation 
of the SIP3 receptor (Figure 5.10), which encompasses all of the findings of this research and 
highlights the areas of futuie research.
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5.3 Discussion
In this chapter several steps have been made to examine the potential SH3 binding 
domain of SIP3 using the two hybird technique and GST fusion pull-down assays. The yeast 
two hybrid technique yielded seven positive clones which could not be rescued conventionally 
from yeast, sequenced or cloned by PCR. A comparison of SIP3 C terminal tail SH3 domain 
binding motif interacting proteins could not be made between results from the yeast two hybrid 
assay and the GST fusion pull down assay as a consequence.
The yeast two hybrid technique or GST pulldown approaches are each prone to 
limitations and an interaction indicated by either technique is not unequivocal proof that this 
interaction occurs in vivo. Additional strategies can be carried out to gain furtlier evidence for an 
interaction by using affinity chiomatography followed by protein identification to discover 
which proteins can bind to a known protein. Detection of proteins can be made using gel overlay 
assays which are similar to western blots, and further confirmation can be found by co- 
immunoprecipitation. Rapid advances in proteomic teclinology and improved sensitivity of mass 
spectrometry achieved during the course of tliis thesis now makes it leasable to identify proteins 
bound either to immunoprecipitated GPCRs or GST's encoding cytoplasmic GPCR domains 
following pull downs of cell extracts. For example, 15 proteins, containing synaptic multidomain 
proteins with PDZ domains, have been found to interact with the C-tail of 5 -HT2C receptors 
using a proteomic approach [Becamel et al., 2002].
As mentioned in Chapter 4, CCL-39 cells over-expressing the SIP3 receptor do not 
internalise tlie receptor after agonist stimulation. As Fyn was shown to interact with the SH3 
domain binding motif of SIP3 , one possible scenario is of interaction with Fyn or a related 
protein and the SH3 binding motif of the SIP3 receptor competitively preventing arrestin- 
receptor interaction, thus imposing a barrier as well as a conformational restriction on the 
receptor which confines the receptor to tlie plasma membrane without removal via clathrin 
coated pits. A non-GPCR precedent for lack of internalisation exists in apoER2. As described in 
Chapter 1 the TM domain and PXXP motifs of the apoER2 exclude it from canying out clathrin- 
mediated endocytosis [Sun and Soutar, 2003].
The potential role for Fyn or a similar interacting protein, although not fully elucidated in 
this research could be to function as a blockade to airestin associating with a multicomplex. This 
would support the observation in CCL39 cells where SIP3 receptors appeal- to have resistance to 
internalisation. The expression levels of Fyn in CCL39 cells has not been recorded in this lab, so 
it is possible that this is a novel regulatory mechanism in SIP3 transduction, studies of Fyn in 
relation to signal transduction and cytoskeleton remodelling have been made in the olfactory
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system and also T cell activation.
Synaptic transmission in the granule cells of the olfactory bulb of the homozygous Fyn (a 
nonreceptor type tyrosine kinase)-deficient (Jyn^lfyn^) and heterozygous Fyn-deficient (+lfyn^) 
mice was studied by using slice preparations from the olfactory bulb. The results demonstrated 
that the functions of GABAa and NMD A receptors in the olfactory system of Fyn-deficient mice 
are altered [Kitazawa et a l, 1998], which infers that tyrosine phosphorylation by Fyn kinase is 
required in synaptic transmissions between cells and receptors. Fyn has also been shovm to play 
a specific role in the mechanism and functional significance of hemidesmosome disassembly 
during normal epithelial cell migration and squamous carcinoma invasion. The findings of this 
study indicated that a fraction of the EGF receptor (EGF-R) combines with the hemidesmosomal 
integiin a6G4 in both normal and neoplastic kératinocytes. EGF-R activation causes tyrosine 
phosphorylation of the 134 cytoplasmic domain and disruption of hemidesmosomes. The Src 
family kinase inhibitors PPl and PP2 prevent tyrosine phosphorylation of 134 and disassembly of 
hemidesmosomes without interfering with the activation of EGF-R. Coimmunoprecipitation 
experiments indicate that Fyn and, to a lesser extent. Yes, another receptor tyrosine kinase, 
combine with a6134. Fyn^ "^ was shown to prevent tyrosine phosphorylation of 134 and disassembly 
of hemidesmosomes. This allows the suggestion that the EGF-R causes disassembly of 
hemidesmosomes by activating Fyn, which in turn phosphorylates the 134 cytoplasmic domain. 
Neoplastic cells expressing Fyn^ ‘^ display increased hemidesmosomes and migrate poorly in vitro 
in response to EGF. Additionally, Fyn^ '^ ' decreased the ability of squamous carcinoma cells to 
invade through Matrigel in vitro and to form lung métastasés following intravenous injection in 
nude mice. These results suggested that disruption of hemidesmosomes mediated by Fyn is a 
prerequisite for normal keratinocyte migration and squamous carcinoma invasion [Mariotti et a l, 
2001]. This has implications for tlie findings of this thesis, where interaction with Fyn has been 
suggested to occur with the SIP3 receptor C-terminal. It is tempting to suggest that whichever 
way the interaction of the SH3 domain binding motif of SIP3 affects internalisation, it is possible 
that SIP3 may assist in developing the cytoskeleton using this route. Although SIP3 appears to 
co-localise witli arrestin, arr estin interaction may not be as a recruitment to clathrin coated pits, 
but as a scaffolding protein which requires SIP3 to complex with Fyn. Investigations of this 
characteristic by controlled disruption of the constituents of lipid rafts could help to elucidate this 
potential interaction.
Tyrosine phosphorylation can modulate GABAa receptor function, and deletion of the 
fyn-kinase gene has been shown to alter GABAergic function in olfactory bulb neurons 
[Kitazawa et a l, 1998]. One study determined whether the fyn  gene deletion may have altered
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behavioui'al and functional actions of compounds that act on GABAa receptors, as this may 
suggest a role for fyn-kinase in modulating GABAa receptor function, possibly via direct 
interactions between the kinase and receptor. The results of this investigation suggested that fyn- 
kinase may alter the function of GABAa receptors, perhaps via actions on (32 and/or (33 receptor 
subunits [Boehm et al., 2004]. Data that lends itself to interpretation for the SlPs/Fyn interaction 
model where, depending on celltype, fyn may interact with the SIP3 receptor to alter its 
conformation and thus regulate internalisation. This is particularly interesting, when one 
considers the processes and the physiological locations that SIP3 and Fyn are implicated in. So 
far', due to lack of binding partner identification, research has been limited as to the function of 
fyn in immunology [Filipp and Julius, 2004].
It has been well established that SH3 binding site serve important functional roles in 
many GPCRs. For example, a recent study [Beard et a l, 1999] has shown that PJOT motifs in 
the third intracellular loop and the carboxyl-terminal tail of the P3 adrenergic receptor (p3AR) 
interact directly witli Src and aie required for ERKl/2 activation [Cao et a l, 2000b]. PXYP 
motifs in the pi adrenergic receptor interact with endophilins, SH3 domain-containing proteins, 
and are involved in receptor internalization and receptor coupling to G proteins [Tang et a l, 
1999]. In the dopamine D4 receptor, PAZP motifs have been implicated in the control of receptor 
internalization as well as coupling to adenylyl cyclase and MAP kinase [Oldenhof et a l, 1998]. 
Also the SH3 binding sites in the P2Yi nucleotide receptor carboxyl-teiminal tail interact 
directly with Src and regulate activities of Src, proline-rich tyrosine kinase 2 (Pyk2), and growth 
factor receptors [Liu et a l, 2004].
Data from Bivona et al [2003], defined a new pathway for phospholipase Cy that 
activates Ras on the Golgi apparatus by means of RasGRPl. This Src/PLC-y 1 /RasGRP 1 - 
dependent pathway is distinct from the protein tyrosine kinase receptor/Shc (present or 
absent)/Grb2/S0S pathway that activates Ras on the plasma membrane. Moreover, by activating 
both RasGRPl and tlie Ras GTPase-activating protein CAPRI, Ca^  ^can regulate Ras in opposite 
directions on different subcellulai' compartments. The binary GTP/GDP switch that constitutes 
Ras as a signalling element cannot explain the vaiiety of outcomes of Ras activation. By 
expressing Ras on different sub-cellular compartments and by using distinct modes of regulation, 
the cell gains increased capacity to modulate its output [Bivona et a l, 2003]. A mechanism 
similai" to this, which allows regulation on different levels would permit each SIP receptor 
subtype to act at various stages of development of vessels, organs, etc., by sigialling multiple 
downstream pathways. A potential complex tliat reflects this behavioui" could occur between
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SlPs/Fyn or a similar kinase/PDGF. SIP3 forms a similar multiprotein complex which requires 
the presence of a tyi*osine kinase as findings from a study of PDGFp and SI Pi have shown that 
c-Src is involved in regulating signal transmission from PDGFP receptor-GPCR(s) complexes in 
mammalian cells [Waters et a l, 2004; Waters et a l, 2005]. Another study was the first to show 
that SIP3 mediates the crosstalk between SIP and PDGFR [Baudhuin et a l, 2004], and this 
provides a mechanism for tyrosine phosphorylation in SIP3 signalling.
Many G protein-coupled receptors activate growth factor receptors, although the 
mechanisms controlling this transactivation aie unclear. Comparative studies to those carried out 
in this reseai'ch were made when two proline-rich, SH3 binding sites (PXUP) in the carboxyl- 
terminal tail of die human P2 Y2 nucleotide receptor were identified that directly associated witii 
Src in protein binding assays [Liu et a l , 2004]. P2Y1, P2 Y2 , P2 Y4, and P2Ye receptors couple to 
Gq/11 and activate phospholipase C, resulting in increased inositol 3-phosphate formation and 
mobihzation of intracellular' Ca^  ^ [Lee et a l, 2003]. Src was found to co-precipitate with the 
P2 Y2 receptor in 1321N1 astrocytoma cells stimulated with the P2 Y2 receptor agonist uridine 
triphosphate (UTP). A mutant P2 Y2 receptor lacking the ŸXXP motifs was found to stimulate 
calcium mobilization and serine/threonine phosphoi-ylation of the Erkl/2 mitogen-activated 
protein kinases, like the wild-type receptor, but was defective in its abiUty to stimulate tyrosine 
phosphorylation of Src and Src-dependent tyrosine phosphoiylation of the proline-rich tyrosine 
kinase 2, epidermal gi'owth factor receptor (EGFR), and platelet-derived growth factor receptor 
[Liu et a l, 2004]. Dual immunofluorescence labeling of the P2 Y2 receptor and the EGFR 
indicated that UTP caused an increase in receptor co-localization in the plasma membrane that 
was prevented by the Src inhibitor, pyrazole pyrimidine-type 2 (PP2). Botli these results indicate 
that agonist-induced binding of Src to the SH3 binding sites in the P2 Y2 receptor may facilitate 
Src activation, which recruits the EGFR into a protein complex with the P2 Y2 receptor and 
allows Src to efficiently phosphorylate the EGFR [Liu et a l, 2004]. Although this research has 
shown througli GST-fusion constructs that Src does not interact with the C terminal domain of 
SIP3 (Figure 5.8), it is possible that another member of the Src family, possibly Fyn, could 
become activated tlirough agonist-induced binding of Fyn to the SH3 binding site in the SIP3 
receptor, in turn recruiting PDGF into a protein complex with the SIP3 receptor to allow Fyn to 
efficiently phosphoiylate PDGF.
Initially, the SI Pi and SIP3 C-tail exchange mutants were created to investigate whether 
altered Fyn interaction would be observed when the SIP3 C-tail was removed. These 
experiments have yet to be performed, however, tlie results fiom mutant phosphorylation studies
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have shown that SIP3CT1 has similai* levels of phosphorylation to WT SlPi and that this in itself 
is an indicator that the SIP3 C-tail hinders phosphorylation of tlie WT SIP3 receptor. Perhaps 
involvement of an intiacellulai* loop that encourages heightened phosphorylation in the SI Pi 
receptor can occur more readily with the addition of the SIP3 CT and this may have evolutionaiy 
consequences that support SI Pi as the dominant SIP receptor. If the SI Pi receptor is damaged 
at the C-terminal end, or agonist stimulation is not prevalent or there is interaction with a 
pathway whereby a downstream protein alters the conformation of SI Pi then possibly increased 
phosphoiylation of the receptor could be enabled by the involvement of an agonist-imitating 
region of an intracellular loop on the SlPi receptor. It has been reported that a KRX-725 peptide 
created from a region of the second intracellulai* loop of SIP3 can mimic the effects of SIP to 
cause receptor phosphorylation [Licht et a l,  2003].
In summary, through the results discovered by the investigations reported in this thesis, a 
tentative model for SIP3 receptor signalling has been proposed, (Figure 5.10). The model shows 
that SIP3 undergoes SIP-induced phosphorylation, and that this phosphorylation is most likely 
an agonist-activated non-GRK kinase. The model also shows that an SH3 containing protein, 
possibly Fyn, interacts with the SH3 domain binding motif of the C-terminal domain of the SIP3 
receptor. This interaction may alter correct complex formation, presumably for the cell types 
studied, tliis obstruction only occurs in CCL39 cells where internalisation is not achieved. This 
suggests that in certain cell-types, it may be a possibility that SIP3 receptor regulation could be 
orchestrated through interaction with a tyrosine kinase. This itself implies that the SIP3 
receptors involvement with PDGF could regulate SIP3 signalling in certain cell types.
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Figure 5.1; Alignment of the C-tails of SIP, ? highlighting the SH3-interaction motif on
SIP.
A schematic representation of the C-terminal tails of S IP  receptors SlPi,2,3 and SIP5 showing 
the differences of amino acid residues (numbered) between each receptor. SIP3 possesses an 
SH3  interaction motif unlike its fellow S IP  receptors. SIP2 possesses a PDZ interaction motif. 
Amino acids highlighted in yellow are homologous between receptors. * denotes potential 
palmitylation sites. Potential sites of phosphorylation in SIP3 are underlined.
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Figure 5.2: Schematic and immunoblot of Y2H bait protein
A: Schematic of the vector PGBKT7 showing the multiple cloning site (MCS) where the SIP3 
receptor C-terminal (SIP3CT) peptide was inserted for use as the Y2H bait protein, A the c-Myc 
epitope tag, kanamycin resistance and the GAL4 DNA binding domain.
B; The 76 amino acid peptide Lys^^ -^Asn^^ ,^ taken from the SIP3 cytoplasmic C-terminal 
(SIP3CT), which was used as the molecular bait that includes the SH3 domain binding motif, 
RASPIQP (red).
Ci Cell extracts of HEK293 cells transfected with either the vector PGBKT7 alone or the 
SIP3CT/PGBKT7  construct were solubilised, normalised for protein content and analysed by 
SDS-PAGE and immunoblotting with anti-myc monoclonal 9E10.
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Figure 5.3; Screening of tm e binding partnei^ using the X-aGal assay 
A selection plate of minimal medium without Tip, Leu, Ade, His. It shows the two 
SIP3/PGBKT7 constructs and several alternative yeast strain positive controls. X-gal expression 
appears blue.
Anticlockwise:
SIP3/PGBKT7 and PGADT7 
SIP3/PGBKT7 and PGADT7 
PGBKT7 and PGADT7 
pGM 2 0  and pGADT7 
pG M 2 0  and pG M 2 2  
pG M 4 7
pGADT7, pGM20, pGM22 and pGM47 were used as known positive controls for plasmid 
interaction and X-gal expression.
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Figure 5.4; Detection of Positive Clones of Interaction with the SlPi receptor SH3 Binding 
Domain Motif
Lanes 1-14 show seven positive colonies in duplicate which were rescued JBrom the PGBKT7 
plasmid and amplified with appropriate primers to allow identification of potential binding 
partner DNA.
M refers to a 1 Kbp ladder, ++ refer to positive controls pGAD Cl and PGAD + YSC84.
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Figure 5.5: Digestion of Positive Clones of Interaction with the SIP, receptor SH3 binding 
domain motif
Of the seven positive clones, the five clone PCR products most strongly amplified were purified 
and then digested with EcoRI and BamHI. Each digested clone was then run on a 1% agar gel 
with a 1 kbp DNA marker.
The symbols + and ++ refers to positive controls PGAD Cl and PGAD + YSC84.
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Figure 5.6: The Purification of GST-SHr^ Fusion Proteins from E.coli
Fyii, fodrin, Src and PI3K were expressed in BL21 E.coli and immobilised on glutathione beads. 
Samples were run on SDS-PAGE and transferred to nitrocellulose for analysis of protein purily. 
Lane 2 = GST alone. Gel has NOT been transferred to nitrocellulose and blotted with any Ab. 
The gel was run and stained with Coomasie Blue to ensure purity and integrity of the isolated 
fusion proteins.
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Figure 5.7: A Specific Pull-Down Assay of Fvn-SH^ with SlPi
A panel of GST fusion proteins containing the SH3 domains from Fyn, Src, fodrin and PI3K were 
assayed using a GST fusion protein assay, as described in section 2.7 to test the ability of SIP3 to 
bind to them in vitro.
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Figure 5.8: Effect of agonist treatment with Fvn-SH3/SlP^ interaction
Following treatment of CCL3 9 /mycSlP3 cells with 5 p,M SIP for 30 min, cells were solubilised 
and equalised for protein content prior to incubation for 1 hr with rotation with glutathione- 
Sepharose beads to which 10 p g o f the indicated GST-SH3 domain fusion proteins had been 
immobilised, as described in Section 2,7. Following isolation of GST-SH3-bound proteins by 
brief centrifugation and washing, the presence of SIP3 was determined by SDS-PAGE and 
immunoblotting with anti-myc antibody 9E10. This is one of four experiments, quantification 
from wliich is presented. There was no statistically significant difference in the recovery of 
SIP3 pulled down with GST-FynSH3 in control versus agonist-treated cells.
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Figure 5.9: C-tail exchange mutations, mvcSlPiCT^  and mvcSlP^CTi undergo agonist- 
stimulated phosphoiTlation
A: Two constructs were created by double PCR that possessed the WT full-length receptor of 
either SI Pi or SIP3, from the N-terminal through to the last transmembrane region and with the 
construct exchanging the C-terminal for that of the opposite receptor. ^^P-labelled serum starved 
stably transfected CCL-39/mycSlPi or CCL-3 9 /mycSlP3 or transiently transfected CCL- 
3 9 /mycSlPiCT3 or CCL-39/mycS 1P3CTi cells were treated with either vehicle or 5pM of SIP at 
37°C for 30 min. The cells were then solubilised for analysis of phosphorylation by 
immunoprécipitation followed by SDS-PAGE and visualised by autoradiography.
B: CCL-39 cells expressing each receptor were solubilised and then analysed by SDS-PAGE and 
immunoblotting with the anti-myc monoclonal antibody 9E10.
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Figure 5.10: Tentative Model of Human SIP^ Receptor Regulation
A potential signalling model for the human SIP3 receptor. This model incorporates the possibility 
of phosphorylation of the SIP3 receptor by a kinase similar to GRK2, involvement of arrestin and 
protein interaction at the SH3 interaction motif which may be Fyn or a related protein.
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Summary
Regulation of receptor phosphorylation, internalisation and desensitisation is critical to 
GPCR transduction. The classical model of GPCR phoshorylation and internalisation is the 
P2AR which provided the basic model to begin this research [Bouvier et a l, 1989; Freedman et 
a l, 1995; Januaiy cr a/., 1997; Bouvier eraZ., 1998; Mayor Jr. et a l, 1998; Seachiist era/., 2000]. 
Over the course of the last thi ee chapters, it has been demonsti ated tliat upon agonist exposure the 
SIP receptor SIP3 is phosphoiylated and that SIP3 phosphorylation cannot be duplicated by 
activation of second messenger-activated kinases. A number of chai'acteristics of SIP3 regulation 
were identified as distinct from previously described regulation of the related receptor SI Pi, 
which has been the subject of indepth characterisation [Liu et a l, 1999; Lee et a l, 2001; 
Watterson et a l, 2002]. Initially, SIP3 phosphorylation is solely agonist-dependent, whereas 
SI Pi is also phosphorylated upon activation of second messenger-activated kinases PKB and 
PKC [Lee et a l, 2001; Watterson et a l, 2002]. Currently, the effects of PKC phosphorylation are 
unknown, however, sensitivity of SlPi to phosphorylation by PKB is considered to be a pre­
requisite for activation of Rac and subsequent SIP-mediated chemotaxis [Lee et a l, 2001]. 
Seemingly, SI Pi sensitivity to multiple kinases activated by different receptor systems enables it 
to act as a signal integration point for angiogenic stimuli in endothelial cells, while SIP3 function 
is controlled entirely by SIP, its physiological activator. Additionally, though GRK2 
phosphorylates both SlPi and SIP3 in vitro, it is improbable that SIP3 regulation by tliis kinase 
exists in intact cells since a mutant SIP3 construct, with appaient resistance to phosphorylation in 
intact cells, displays the equivalent GRK2-mediated phosphorylation as the WT receptor in vitro, 
and GRK2 or GRK3 overexpression fails to potentiate SIP3 phosphorylation in intact cells. 
Furthermore, SIP3 desensitisation of Ca^  ^mobihsation does not appear to be affected by receptor 
phosphorylation as both WT and phosphorylation-resistant SIP3 responses desensitise at 
indistinguishable rates, which opposes the mechanism of the majority of GPCRs. As a final 
point, in HEK293 cells the receptor can internalise upon agonist exposure under conditions where 
mutant SIP3 receptor phosphorylation is undetectable.
This research poses a number of questions concerning SIP3 regulation, beginning 
with what is the kinase responsible for receptor phosphorylation in intact cells? Albeit 
improbable that GRK2 and the closely related kinase GRK3 control SIP3 phosphorylation in 
intact cells, mutagenesis studies elucidate a region of the carboxyl-terminal domain spanning 
Leu^^  ^and Vaf^^ as most probably containing the sites of receptor phosphorylation. Deleting this 
region does not reduce the ability of the SIP3 receptor to stimulate [Ca^^i mobilisation, denoting
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that the resistance to phosphorylation does not reflect a gross detrimental change in receptor 
conformation produced be the truncation. Furthermore, this region is almost bereft in acidic 
residues, which is a common hallmark of GRK2/3 substrates including SI Pi [Onorato et a l, 
1991; Prossnitz et a l, 1995]. Implausible too is the concept that SIP3 is a substrate for the 
GRK4-6 subfamily, as GRK5, a prototypical member of this group cannot reconstitute SIP3 
phosphorylation in vitro. Hence, it is plausible that SIP3 is phosphorylated in an agonist- 
dependent manner by a kinase distinct from the GRK family. Reports are increasing which 
describe agonist-dependent, GRK-independent regulation of GPCR phosphoiylation, [Budd et a l , 
2000; Blaukat et a l, 2001; Hanyaloglu et a l, 2001]. However, an acidotropic kinase that 
typically phosphoiylate clusters of Ser and/or Tin residues in a sequential fashion similar to 
GRK2 or GKR3 would be an unlikely candidate for agonist-activated SIP3 phosphorylation 
[Tobin, 2002].
A compelling aspect of this research is the evidence supporting a role for the SIP3 
receptor’s extreme caihoxyl-terminus in regulating the inhibition of SIP3 phosphoiylation. Initial 
removal of the last 27 residues of the carboxyl-terminal results in a receptor markedly 
phosphoiylated with the absence of agonist and receptor phosphoiylation in the presence of SIP 
is some five-fold greater than observed in the WT receptor. Accordingly, the extreme carbo)Q/l- 
terminus (or any receptor-bound protein) could sterically hinder interaction of a SIP3 kinase with 
the receptor, such that when removed significant agonist-independent receptor phosphoiylation 
can occur. Endorsement for this model is given by the observation that agonist-stimulated 
phosphoiylation of both SIP3 receptor tiuncation mutants by GRK2 in vitt*o is increased in 
comparison to the WT receptor. Although GRK2 is most probably not the kinj^e responsible for 
SIP3 phosphoiylation in intact cells, the observations discussed advocate a model for WT SIP3 
receptor having reduced kinase accessibility as a result of its extreme 27 residue component.
The uniqueness of SIP3 regulation is also exemplified by its ability to internalise in 
HEK293 cells despite the loss of agonist-stimulated phosphoiylation upon deletion of the region 
between Leu^^  ^and Val^^ ,^ although SIP3 receptor internalisation is not apparent in CCL-39 cells 
intimating a cell-tj'pe specific role for SI P  receptors where subcellular distribution of S IP  
receptors is dependent on the pathways required for activation by the cell [Hedemann et a l,
2004]. An ability to internalise regardless of loss of phosphoacceptor sites in the carboxyl- 
terminal domain is characteristically associated with family 2 GPCRs, like the secretin receptor 
[Holtmann et a l, 1996; Walker et a l, 1999], instead of family 1 receptors like SIP3 although p- 
opioid receptor internalisation in response to etorphine treatment occurs independently of
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receptor phosphorylation [Qiu et a i, 2003]. Together with evidence against a role for GRK2 in 
mediating SIP3 phosphorylation, it may be predicted that SIP3 phosphorylation could have 
consequences for receptor function which aie not seen in classical internalisation and functional 
desensitisation pathways. The observation that a phosphoiylation-resistant SIP3 truncation 
mutant desensitises at a rate indistinguishable from the WT receptor, indicates that 
phosphorylation is not required for this aspect of SIP3 receptor regulation wliich is consistent 
with the hypothesis. A potential role for the C-terminal domain of SIP3 was put fomaid by the 
presence of a RxxPxxP class I SH3 domain interaction motif as a scaffold for the 
phosphorylation-regulated assembly of signalling complexes. Motifs akin to die SH3 binding 
motif are found in several GPCRs, including the Ai adenosine, dopamine D4 and ps-adrenergic 
receptors [Oldenhof et a l, 1998; Cao et a l, 2000a]. For P3-adrenergic receptors, its motifs 
mediate receptor interaction with Src, which is essential to observe receptor activation of the 
ERK signalling cascade [Cao et a l, 2000a]. A panel of GST fusion proteins encoding SH3 
domains from multiple sources have been compared by their ability to interact and precipitate 
SIP3 from cell extracts. The function of the SH3 binding motif within SIP3 is currently 
unknown, but in this study it has been shown that it is functional and displays a high degree of 
specificity, as evidenced by the ability of a recombinant SH3 domain from Fyn, but not those 
from PI3K, fodrin or Src to bind to SIP3 in vitro. However, Fyn is probably not a bona fide 
SlPs-interacting protein as it was not possible to detect any association between mycSlPs and 
endogenous Fyn by co-immunoprecipitation in either vehicle- or agonist-treated CCL39 cells 
(W.A. Sands & T.M. Palmer, unpublished observations).
Although only conjecture at this point, it would be interesting to discover how celltype 
influences the interaction of fyn with SIP3 and whether there is potential for it to assist in 
mediating TcR/CD3 signalling. However, it has been proposed that the required kinase specific 
regulatory mechanisms necessary for interaction with fyn reside witliin lipid rafts, and subcellular 
localisation of SIP3, identified in tliis thesis presents the receptor within the PM, and not uniquely 
or abundantly within the areas of lipid rafts. Yet, if one reverses this hypothesis, the role of fyn 
in T cell signalling is well-known, hi the resting T cell 98% of Fyn is localized in lipid rafts. 
Following TCR activation, Lck-associated CD4 is activated and then translocates to lipid rafts. 
Evidence has shown that raft-associated Lck activates Fyn, inferring that Fyn functions 
downstream of Lck in TCR signalling. Recently, it was shown that Fyn is required for tyrosine 
phosphorylation of Wiskott-Aldrich syndrome protein (WASp), a critical regulator of the Arp2/3 
complex and actin polarization in T cells, which is regulated by activated Cdc42-GTP. Mutation
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of the Fyn phosphorylation site on WASp, severely inhibited TCR-induced actin
polymerization and prevented the rescue of WASp deficient cells, suggesting that Fyn contributes 
to the regulation of cytoskeletal remodelling. Phosphoiylation of this site was still observed in a 
mutant WASp that lacked a Cdc42 binding site [Cannons and Schwartzberg, 2004]. Although 
somewhat tenuous, it is possible to perceive that a complex of SIP3 and arrestin recruits to where 
Fyn localises and this provides a platform where cytoskeletal remodelling can be regulated, tliis 
may have benefits in diseases such as atherosclerosis and COPD. And if fyn is not the specific 
kinase, tliis putative extension of the proposed model of SIP3 regulation goes someway to 
encouraging new explanations of its roles in various celltypes and physiological processes.
Although SIP3 and SI Pi shaie similai homology they employ markedly different 
molecular mechanisms to govern signal output compared to other GPCRs. These differences can 
be exploited to specifically inliibit angiogenic signalling pathways in disease states. The unique 
regulation of SIP3 phosphorylation may be useful in designing selective drugs. If selective drugs 
were designed to inhibit or promote phosphorylation, then downstream signalling could be 
regulated enabling the processes of angiogenesis, cell gi'owth, differentiation to be accelerated or 
decelerated accordingly. For example the SIP agonist FYT720 is in trials for use as drug in 
transplant rejection [Rosen and Liao, 2003], and more recently a novel immunomodulator, 
KRP203, similar to FTY720 is being developed for use in organ transplantation [Sliimizu et a l,
2005].
Amongst the SIP family, the presence of an SH3 domain binding motif is unique to SIP3 . 
The ability of SIP3 to avoid sequestration under certain conditions can be compared to the 
apolipoprotein E receptor 2 (apoER2), which comprises, among others, an SH3 domain binding 
motif. ApoER2 is expressed mainly in the brain, and the first evidence for its physiological role 
came from genetically modified mice [Sun and Soutai, 2003]. The human brain expresses two 
major splice variants of apoER2 mRNA, one of which includes an additional exon that encodes 
59 residues in the cytoplasmic domain. The LDL receptor does not contain the exon containing 
the three proline-rich (PYYP) motifs that may allow apoER2 to function as a signal transducer. 
LDL, VLDL and apoER2 all have an amino-terminal region composed of multiple cysteine-rich 
repeats that mediates ligand binding in tlie LDL receptor. Adjacent to this is a region with 
homolo^ to the EGF precursor followed by a serine- and tlireonine-rich region that is heavily 
glycosylated in the LDL receptor. This is followed by a single TM segment and finally followed 
by a carboxyl-terminal cytoplasmic domain containing an NPVY motif that comprises the 
internalization signal of the LDL receptor [Sun and Soutai*, 2003]. Investigations with chimeras
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comprising the ectodomain and TM domain of the LDL receptor fused to the cytoplasmic domain 
of apoER2 lacking the PXW-containing residues have shown chimeras are capable of mediating 
clatMn-dependent endocytosis of LDL as effectively as cells expressing the LDL receptor but not 
if the VXXP insert is present in the protein [Sun and Soutar, 2003], Although expressed on the cell 
surface, the PXYP-containing chimeric receptor is excluded from clathiin vesicles as judged by its 
failure to co-localize with AP-2 possibly due to interaction with intracellulai* adaptors or 
scaffolding proteins. Chimeras with the TM domain of apoER2, predicted to be longer than that 
of the LDL receptor by several residues, failed to mediate endocytosis of LDL or to co-localize 
with AP-2 regardless of the presence or absence of the PX¥P insert. Features that render apoER2 
a signalling receptor rather than an endocytosis receptor, such as the LDL receptor, reside in or 
near the TM domain and in the PXXP motifs. The VLDLR and apoER2 can bind lipoproteins 
containing apoE, but their primary role in vivo does not appeal* to involve lipoprotein catabolism, 
and their pattern of expression differs from that of the LDL receptor.
ApoE has proved to be an important factor in the repair of neural injuiy, and it also 
appeal's to interact with p-amyloid proteins. The PX¥P insert in apoER2 has also been shown to 
bind to scaffolding proteins, for example, the c-Jun amino-terminal kinase-interacting proteins 
JIP-1 and JIP-2, also known to be involved in cell signalling It has previously been shown that 
apoER2 cannot bind LDL and is unable to internalize and degrade even apoE-containing 
lipoproteins, wliich is consistent with the view that the main function of apoER2 is not 
endocytosis of lipoproteins. While tlie LDL receptor localizes with clathrin-containing membrane 
fragments apoERZ tends to associate with lighter, caveolin-containing membranes' It appears that 
both the TM domain and the cytoplasmic domain of apoERZ influence the propei*ties of the 
protein probably because they determine its ability to localize in different regions of the cell 
membrane [Sun and Soutar, 2003].
Another study of apoE isoforms demonstrated that inhibition of apoptosis by lipoproteins 
depends partly on the apoE genotype, with lipoproteins from tlie apoE4/4 genotype inhibiting 
apoptosis less than diose from other apoE genotypes. Also, the antiapoptotic activity of HDL was 
suppressed by VLDL comprising the apoE4 isoform. These observations may help explain how 
apoE modifies disease expression, and may assist in new therapeutic strategies.[DeKroon et a i, 
2003].
In recent studies myogenic differentiation was found to be accompanied by a profound 
variation of SIP2 and SIP3 receptor expression levels and the progressive uncoupling of SIP 
from PLD activation [Meacci et a l, 2003b]. This could explain the vai’iation in internalisation
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characteristics of SIP3 between cell types. Depending on the requirement of the receptor to assist 
in proliferation of a cell, the SIP3 receptor may be expressed differentially at the cell surface of 
different cell-types, and thus internalisation may not be easily observed in certain cell types, if it 
occurs at all.
As there is an abundance of potential phosphorylation sites within the C-terminal domain 
of SIP3 (including Ser^ ^  ^ witliin the SH3  binding motif), it is important to determine whether 
phosphoiylation blocks or primes receptor interaction with associated or alternative adapter 
proteins. Tliis study can be made once two-hybrid screening and affinity puiification using 
mutant SIP3 C-terminal domain constructs in which phosphoiylation sites can be mutated to 
either Asp or Glu to mimic the acquisition of negative charge and conformation changes occuiing 
in phosphorylation.
A novel association of SIP receptors could come horn its role in survival of T cells. A 
key initiating event in T-cell activation by antigen is the increased phosphorylation of 
immunoreceptor tyrosine-based activation motif (ITAM) tyrosines in T cell receptor (TCR) 
subunits by the Src family kinases Lck and Fyn. Exactly how the TCR couples antigen 
recognition to this phosphorylation remains to be determined [Cannons and Schwartzberg, 2004]. 
Proposed models include juxtaposition of Lck to the TCR mediated by CD4 or CDS, increased 
local concentrations of kinases and their substrates following receptor oligomerization and lipid 
raft coalescence and the active exclusion of Csk and PTPases. These mechanisms are not 
mutually exclusive, and probably operate in concert.
In vitro, both Lck and Fyn can phosphorylate IT AM tyrosines of the Ç chain. Fyn seems 
to phosphorylate only one site with higli affinity, while Lck readily phosphorylates four or five 
oilier sites. It seems that Lck is the kinase responsible for much, if not all, of tlie IT AM 
phosphoiylation tliat follows TCR tiiggering in T-cells. Fyn may catalyse some ITAM 
phosphorylation in the absence of Lck, but is largely unable to compensate for the loss of Lck 
[Cannons and Schwartzberg, 2004]. Based on this discrepancy of regulation between Lck and 
Fyn, it would imply that those receptors requiring interaction with fyn for transduction may be 
less significant than those interacting with Lck, and this would hold true for SIP receptors, where 
SI Pi is the major interactor with T cells in lymphocyte recirculation. And this would reinforce 
the supporting role of SIP3, or help explain a distinct celltype specific function for SIP3 , witii 
regard to the immune system, which has been discovered by its expression in dendritic cells and 
macrophages
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To r e i t e r a t e ,  t h e  c h a r a c t e r i s a t i o n  o f  r e c e p t o r  s e n s i t i v i t y  t o  p h o s p h o r y l a t i o n  a n d  c h a n g e s  i n  
s u b c e l l u l a i -  d i s t i i b u t i o n  t h a t  r e g u l a t e  t h e  a n g i o g e n i c  S I P  r e c e p t o r  S I P 3  h a s  b e e n  r e p o r t e d .  S i m i l a r  
t o  t h e  r e l a t e d  r e c e p t o r  S l P i ,  S I P 3  p h o s p h o i y l a t i o n  i s  r a p i d  a n d  r e v e r s i b l e  i n  i n t a c t  c e l l s  w i t h i n  a n  
18 r e s i d u e  r e g i o n  i n  i t s  C - t e r m i n a l  d o m a i n  i n  r e s p o n s e  t o  i n c r e a s i n g  c o n c e n t r a t i o n s  o f  a g o n i s t .  
Y e t  SI ? 3  i s  d i s s i m i l a r  t o  S I  Pi a n d  m a n y  o t h e r  G P C R s  i n  t h a t  t h e r e  a p p e a r s  t o  b e  n o  r e q u i r e m e n t  
f o r  r e c e p t o r  p h o s p h o r y l a t i o n  t o  t r i g g e r  t h e  s e q u e s t r a t i o n  o f  S I P 3  a w a y  f r o m  t h e  p l a s m a  
m e m b r a n e .  In a d d i t i o n ,  G R K 2  s e l e c t i v e l y  p h o s p h o i y l a t e s  S I P 3  in vitro. W h e n  in vitro a n d  i n t a c t  
c e l l  p h o s p h o r y l a t i o n  a s s a y s  a r e  c o m p a r e d  via m u t a t e d  r e c e p t o r s ,  r e s u l t s  i n d i c a t e  t h a t  i t  i s  
i m p r o b a b l y  t h a t  G R K 2  i s  t h e  a g o n i s t - r e g u l a t e d  S I P 3  k i n a s e  p r e s e n t  i n  i n t a c t  c e l l s .  F u r t h e r m o r e ,  
f i i n c t i o n a l  a n a l y s i s  o f  WT a n d  p h o s p h o r y l a t i o n - r e s i s t a n t  m u t a n t  S l P s - s t i m u l a t e d  c a l c i u m  
m o b i l i s a t i o n  i n d i c a t e d  t h a t  s e n s i t i v i t y  t o  a g o n i s t - i n d u c e d  p h o s p h o i y l a t i o n  w a s  u n a b l e  t o  i n f l u e n c e  
S I P 3  r e c e p t o r  d e s e n s i t i s a t i o n  k i n e t i c s .  W h i l s t  S I P 3  h a s  t h e  p o t e n t i a l  t o  i n i t i a t e  G - p r o t e i n -  
i n d e p e n d e n t  s i g n a l l i n g ,  s u g g e s t e d  b y  a n  a b i l i t y  t o  i n t e r a c t  in vitro w i t h  t h e  F y n S H 3 d o m a i n ,  t h e  
i n s e n s i t i v i t y  t o  r e c e p t o r  p h o s p h o i y l a t i o n  o f  t h i s  e v e n t  i m p l i e s  t h a t  a n y  i n t e r a c t i o n  in vivo w i t h  t h e  
S I P 3 - S H 3  d o m a i n  w o u l d  b e  c o n s t i t u t i v e .
As described in Chapter 1 the apoER2 has novel internalisation characteristics. The 
FDNPVY motif within tlie apoER2 c-terminal has been predicted to foim a reverse turn 
conformation, and it is believed that this conformation is important for directing the receptor to 
clathrin-coated pits [Sun and Soutar, 2003]. The 59 amino acids in the cytoplasmic domain of the 
chimeric LDLR-TM/apoER2+, wliich are located 26 amino acids downstream from FDNPVY, 
appeared to disrupt the function of this motif [Sun and Soutar, 2003]. Although the FDNPVY 
motif is not present in the C-terminal of the SIP3 receptor, a similar acting motif could be 
inhibited by the presence of the SH3 domain binding motif that SIP3 possesses.
The direction of future work should be in identifying SIP3 binding partners whose 
receptor interaction is regulated by phosphoiylation within the SH3 domain, and also defining the 
kinase responsible for SIP3 phosphorylation. Viable p-arrestin knockout cell lines would be 
useful tools to delineate the sequestration pathways utilised by SIP3 receptors. Furthermore, 
assessment of the intracellular localisation would provide gieater insight into the mechanisms 
involved in the resensitisation of the full-length receptor and the carboxyl tail chimeras. Further 
understanding of SIP3 receptor regulation could also be achieved by investigations of C- 
terminally GFP-tagged forms of chimeric SIP3 receptors which would provide the opportunity to 
directly monitor the localisation, and trafficking of receptors in response to extracellular stimuli.
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In a recent study, a stable knock-down of SIPi was generated in human endothelial cell 
lines derived from human pulmonary micro vascular endothelial cells (HPMEC-ST1.6R) and 
human angiosarcoma (AS-M.5 and ISO-HAS. 1) to show the influences of SlPi on an array of 
functions in endothelial cells [Krump-Konvalinkova et a l, 2005]. The research establishes for 
the first time a reliable system that allows long-term functional consequences of SI Pi silencing to 
be studied in detail [Krump-Konvalinkova et a l, 2005]. Similai' investigations could be 
perfoimed using the SIP3 receptor as a knock-down. This is achieved by generating SlPs-specific 
small interfering RNA (siRNA) vectors, by cloning the sequences encoding the hairpin siRNA 
targeted to SIP3 into the siRNA expression vector, and introducing plasmids encoding the SIP3 
targeted siRNA into endothelial cells. This would help to assertain how SIP3 exerts its influence 
in endothelial cells, which would augment the findings made from SIP3 overexpressed in 
fibroblasts in this thesis.
From the proposed model that tliis thesis puts forward for the characterisation of the SIP3 
receptor it is clear that the mechanisms involved in SIP3 signal transduction are not as simple as 
originally perceived. It appears that S I P  receptor signalling is intertwinned with various growth 
factor signalling mechanisms, and is associated with transactivation of a number of tyrosine 
kinases, not merely G-protein interactions. SIP3 is an enigmatic receptor, and the discrete nature 
of its distribution in various physiological systems lends itself to dynamic regulation for a 
multitude of important processes wliich require further investigation to provide therapeutic tools 
for the treatment and control of many pathological diseases.
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